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 The presence of thiols in living systems is critical for the maintenance of cellular 
redox homeostasis, the maintenance of protein thiol-disulfide ratios and the protection of 
cells from reactive oxygen species.  In addition to the well studied tripeptide glutathione  
(γ-Glu-Cys-Gly), a number of compounds have been identified that contribute to these 
essential cellular roles.  Many of these molecules are of great clinical interest due to their 
essential role in the biochemistry of a number of deadly pathogens, as well as their possible 
role as therapeutic agents in the treatment of a number of diseases.  A series of studies were 
undertaken using theoretical, chemical and biochemical approaches on a selection of thiols, 
ergothioneine, the ovothiols and mycothiol, to further our understanding of these necessary 
biological components. 
 Ergothioneine is present at significant physiological levels in humans and other 
mammals; however, a definitive role for this thiol has yet to be determined.  It has been 
implicated in radical scavenging in vivo and shows promise as a therapeutic agent against 
disease states caused by oxidative damage.  Given the clinical importance of this intracellular 
thiol, further investigation into the behaviour of ergothioneine appeared warranted.  A high 
level theoretical study was performed to determine the thermodynamic driving force behind 
the instability of the ergothioneine disulfide, as well as the thermodynamics of the reactions 
of ergothioneine with a selection of biologically relevant reactive oxygen species.  These 
results were compared to those determined for a glutathione model compound, as well as the 
related ovothiols.  The latter are believed to act as hydrogen peroxide scavengers in vivo and 
are currently under review as possible therapeutics against oxidative damage.  The structural 
differences between the ovothiols and ergothioneine dramatically affect their reactivity and 
this study investigates the thermodynamic driving forces behind these differences.    
 Mycothiol is the major thiol found in the Actinomycetales bacteria, which include the 
causative agent of tuberculosis, and the enzymes which use mycothiol have been identified as 
important targets for the development of novel antimicrobials.  To better understand the in 
vivo behaviour of mycothiol, a thorough conformational search was performed to determine 
what, if any, trends exist among the low energy conformers expected to be present in 
solution.  Knowledge of the conformations preferred by mycothiol may aid in the design of 
substrate-based inhibitors targeted at mycothiol-dependent enzymes.  In addition, the efforts 
towards the identification of a mycothiol-dependent glyoxalase system are described.  The 
glyoxalase system is essential for the detoxification of methylglyoxal, a toxic by-product of 
glycolysis, and this system would serve as a target for the design of new therapeutics against 
tuberculosis and other pathogenic Actinomycetales bacteria. 
 In addition to the study of intracellular thiols, this work details a preliminary 
theoretical study of the thermodynamics of the phosphorylation of proteinaceous serine 
residues by inositol pyrophosphates in eukaryotic cell-free extracts.  It has been postulated 
that this observed activity may represent a novel signalling pathway in eukaryotes.  This 
study focused on the effect of inositol pyrophosphate structure and overall charge on the 
thermodynamics of these reactions.  This information should contribute to our understanding 
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Chapter 1: Introduction to Intracellular Thiols 
 
The presence of thiols in living systems is critical for the maintenance of cellular 
redox potentials and protein-disulfide ratios, as well as for the protection against reactive 
oxygen species (ROS).  In addition to the well-studied tripeptide γ-L-glutamyl-L-cysteinyl-
glycine (glutathione, GSH 1-1), a number of compounds have been identified that 
contribute to these essential cellular roles.  Our research focused on the properties of 
several critically important and naturally occurring thiols (Figure 1.1): ergothioneine (ESH, 
1-2), the ovothiols (OSHs, 1-3A-C) and mycothiol (MSH, 1-4).  ESH, although only 
biosynthesized by fungi and the Actinomycetales bacteria, is present at significant levels in 
humans and may contribute to single electron redox reactions in human cells.  The OSHs 
appear to function as important modulators of reactive oxygen toxicity and act as small 
molecule mimics of GSH peroxidase, a key enzyme in the detoxification of ROS.  MSH is 
essential to the biochemistry of a number of human pathogens, including Mycobacterium 
tuberculosis, and the enzymes utilizing this thiol have been recognized as important novel 









































R1 = R2 = H (OSHA, 1-3A)
 R1 = H, R2 = CH3 (OSHB, 1-3B)









Figure 1.1: Glutathione, ergothioneine, the ovothiols and mycothiol 
Despite the involvement of these intracellular thiols in essential biological 
processes and their possible therapeutic applications, very little is known regarding their 
fundamental behaviour.  To gain insight into the detoxification reactions of ESH and the 
OSHs, we performed a series of calculations to determine the thermodynamics of these 
reactions.  We also applied theoretical techniques to determine the preferred conformations 
of MSH, which may aid in the design of substrate based inhibitors. In addition, we sought 
to identify a new MSH-utilizing enzyme system in Actinomycetales bacteria, which could 
serve as a novel drug target against the pathogenic members of this class.  Due to their 
critical involvement in cellular biochemistry, any information gained regarding these thiols, 
should increase our understanding of intracellular thiol behaviour. 
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1.1.   Ergothioneine 
ESH has been identified in a diverse group of organisms including humans and the 
pathogenic Mycobacteria, and may be of great clinical importance, not only due to its role 
in pathogenic species, but also due to its possible therapeutic applications.  ESH may assist 
in the treatment of chronic lung inflammations such as asthma1 and may have a role in the 
protection against Alzheimer’s disease.2  While many possible roles have been suggested 
for ESH, much remains to be determined regarding the definitive role that ESH plays in the 
cell. 
1.1.1. Distribution 
 ESH was first isolated from ergot (Claviceps purpurea), the fungal infection of rye 
grain, by Tanret in 19093 and its structure was determined to be a novel betaine of 2-thiol-
L-histidine.4  ESH has since been detected in plants,5-8 fungi,9-11 bacteria,11-13 humans14,15 
and other animals16-19 at millimolar concentrations.  To date, evidence for the biosynthesis 
of ESH has only been noted in certain fungi9,11,20 and the Actinomycetales bacteria.12,13  It 
has been shown that Bacillus, Clostridium, Corynebacterium, Escherichia, Lactobacillus, 
Propionibacterium, Proteus, Pseudomonas, Staphylococcus, Streptococcus and Vibrio 
bacteria do not biosynthesize ESH.12  The presence of an ESH derivative,  
β-hydroxyergothioneine, has recently been identified in the mushroom Lyophyllum 











Figure 1.2: β-Hydroxyergothioneine 
 It is believed that organisms that do not biosynthesize ESH obtain it from their 
environment.  Plants are thought to obtain ESH from the soil,6 as oat seedlings have been 
shown to incorporate ESH via their root system.22  Animals are believed to obtain ESH 
from dietary sources,18 since it has been observed that diet can affect an organism’s ESH 
content.5,8  ESH levels are found to vary between species16 and tissue type,23 but it is 
mainly found in tissues exposed to oxidative stress including red blood cells (RBCs),17,24-26 
seminal fluid,27,28 kidneys,29 liver,29,30 the ocular lens15,16 and the brain.19  RBCs sequester 
ESH at concentrations two to nine times greater than that of blood plasma.  It was 
originally believed that ESH was incorporated into RBCs during cell formation,31 but 
recent work indicates that RBCs gradually take up ESH32 and maintain ESH levels against 
a concentration gradient.  The uptake of ESH is believed to be transporter dependent; 
however, a specific ESH transporter in RBCs has not yet been identified.32  An ESH 
transporter has recently been identified in human kidney cells and cells expressing this 
transporter were found to accumulate ESH to high levels and avidly retain it.  Cells without 
this transporter were found to lack ESH as ESH cannot pass through the plasma 
membrane.33   
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1.1.2. Biosynthesis 
 Initial studies of the biosynthetis of ESH (Figure 1.3) in fungi have shown that the 
pathway begins with the enzymatic methylation of the α-amino group of L-histidine three 
times by S-adenosyl-L-methionine to yield hercynine (1-6).20,22,34  The sulfur group is then 
added by the coupling of cysteine to hercynine to form an S-(β-amino-β-carboxyethyl)-
ergothioneine sulfoxide intermediate (1-7) through an undetermined pathway requiring 
oxygen and iron (II).20,35  This intermediate is then converted to ESH and pyruvate via an 
unknown pyridoxal-requiring enzyme.35  Detailed studies of the biosynthesis of ESH in 
bacteria have not yet been performed; however, the use of radioactive precursors has 























Figure 1.3: The biosynthetic pathway of ergothioneine.  AdoMet = S-adenosyl-L-methionine. 
1.1.3. Chemical Properties 
 ESH can exist as three different tautomers (Figure 1.4) with the thione being 
favoured under physiological conditions.36  The C-S bond length has been determined by 
X-ray crystallography to be intermediate to the C-S single and double bond lengths, 
confirming the contribution of the thione.37  The thione/thiol tautomerism of ESH causes 
the reactivity of ESH to differ from that of other thiols.  ESH will react with certain thiol 
reactive agents including iodoacetamide,38 the bromobimanes,10 and 2,2-diphenyl-1-
picrylhydrazyl (DPPH),39 a stable free radical known to react with sulfhydryl groups to 
form thiyl radicals.40  Unlike standard aliphatic thiols, ESH will not react with N-methyl-
N′-nitro-N-nitroguanidine,41 metmyoglobin (metMb),42 nor carbon centered or aliphatic 
peroxy radicals.43  At a pH greater than 7, ESH will ionize to the thiolate, which is a better 





























Figure 1.4:  The three different tautomeric states of ergothioneine. 
 
The most significant difference between ESH and other thiols is the instability of 
the ESH disulfide (ESSE) under physiological conditions.  Most low molecular weight 
thiols are known to form disulfides upon exposure to aerated aqueous solutions; their 
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cognant organisms produce disulfide reductases to maintain these thiols in their 
biologically useful free thiol form.44  ESSE does not form under conditions known to 
oxidize GSH and has only been shown to be stable under strongly acidic conditions, where 
the free and oxidized forms exist simultaneously.45  Even if ESSE was formed in vivo, the 
large concentrations of GSH or MSH in these organisms would likely maintain ESH in its 
reduced state. 
1.1.4.  Biological Function 
 Despite the large amount of literature related to ESH, its definitive role in the cell 
has yet to be determined.  ESH has been implicated as a possible antioxidant and recent 
studies have shown that ESH may have superior scavenging ability for oxygen centered 
radicals as compared to the well-known antioxidant GSH.  ESH may therefore be involved 
in, or be a useful treatment for, diseases known to involve oxidative stress.  Susceptibility 
to the chronic inflammatory diseases Crohn’s disease and rheumatoid arthritis have been 
associated with variants in the gene coding for the ESH transporter.33,46,47  In addition, ESH 
has been shown to inhibit the release of certain mediators of inflammation in the lung, 
which may indicate a possible therapy to inhibit the chronic immune response known to 
occur in airway inflammations such as asthma and adult respiratory distress syndrome.48   
 ESH may also be a useful therapeutic agent for disease states caused by oxidative 
stress such as Alzheimer’s disease.  Alzheimer’s patients show neuronal degradation and 
increased levels of nitrosotyrosine caused by peroxynitrite (ONOO¯ ).49-51  ESH has been 
shown to attenuate intracellular formation of ONOO¯ through ONOO¯ scavenging,2 which 
is consistent with the observation that ESH can inhibit the nitration of tyrosine.52  ESH may 
therefore decrease the neuronal apoptosis caused by Alzheimer’s disease.2 
In addition to its possible therapeutic applications, ESH may be important for the 
cellular response to oxidative stress caused by ROS and reactive nitrogen species (RNS).  
The hydroxide radical (HO•), for example, is one of the most reactive biologically relevant 
free radicals, attacking a number of essential cellular components.53  Studies have shown 
that ESH can scavenge HO• in a biologically relevant manner,54 through the formation of a 
putative radical cation intermediate,55 which is believed to decay into ESSE.54  ESH has 
also been shown to inhibit the copper and iron catalyzed production of HO•54 and 2-thiol-
imidazoles, such as ESH, have been shown to protect ascorbic acid from copper (II) 
catalyzed oxidation.56  It has been suggested that this protection indicates that a cooperative 
interaction may exist between ESH and ascorbic acid in the protection of biological 
systems from ROS.55   
Most thiols, including GSH, are oxidized to form disulfides and peroxides in the 
presence of heavy metals, such as copper or iron.57,58  ESH however, has been shown to 
chelate divalent metals including cadmium (II), cobalt (II), copper (II), mercury (II),  
nickel (II) and zinc (II), and is not auto-oxidized in the presence of these metals to ESSE.59  
At physiological pH, ESH-copper (II) complexes are stable and, unlike GSH, do not 
decompose to give radicals.60,61 The chelation of copper into redox inactive forms may be a 
major function of ESH.54  
 Hydrogen peroxide (H2O2) is not as reactive as HO•; however it is membrane 
permeable and once in the cell, it can react with thiols, inactivating thiol-containing 
enzymes.62  H2O2 can interact with iron (II) and copper (I) to form HO•, which is highly 
toxic to the cell.62  H2O2 can also oxidize metMb very quickly to ferrylmyoglobin 
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(ferMb),54 which has peroxidase activity against many cellular components such as 
membrane lipids and fatty acids.63  The addition of ESH to ferMb has been shown to 
quickly recover myoglobin (Mb) and its addition to mixtures of Mb or hemoglobin (Hb) 
and H2O2 has been shown to inhibit the peroxidation of fatty acids through the transient 
formation of the ergothioneine radical (ES•) and ESSE.54  The reactivity of ESH with 
ferMb is greater than that of GSH and is closer to that of ascorbate,63 a known radical 
scavenger.62,64  In addition, the formation of methemoglobin (metHb) from oxyhemoglobin 
(oxyHb) is also inhibited by 2-thiol-imidazoles such as ESH,56,65 which would aid in 
maintaining the useful Hb concentration in biological systems.   
 Hypochlorous acid (HOCl) is a potent oxidizing and chlorinating agent that can 
react with primary amines to form cytotoxic N-chloroamines.66  HOCl can induce cell lysis 
at low concentrations and can oxidize plasma membrane thiol groups causing the 
inactivation of glucose and amino acid transporters and a loss in potassium ion pumping 
activity.67  An important biological target of HOCl is α1-antiproteinase (α1-AP), the major 
inhibitor of serine proteinases in bodily fluids.  Few compounds can protect α1-AP against 
HOCl inactivation; however, ESH was shown to scavenge HOCl in a biologically relevant 
manner at concentrations as low as 500 µM.54   
To date, the role of ESH appears to be as an antioxidant, active in the prevention of 
damage caused by ROS and RNS.  Further investigation into the antioxidant behaviour of 
ESH may elucidate the true role of ESH in biological systems and any information gained 
may be applicable to the development of therapeutics against disease states caused by 
oxidative damage.  The role of ESH in the pathogenic Mycobacteria has yet to be explored, 
and studies in this area may provide novel targets for the development of antimycobacterial 
agents.   
1.2. Ovothiols 
The OSHs are not as widely found as ESH; however, they too may be of medical 
significance.  In sea urchin eggs, the OSHs have been shown to be scavengers of H2O2,68 
which has led to the development of medicinally useful antioxidants based upon the 
OSHs.69-71  The OSHs have also been identified in the pathogenic Trypanosoma,72 and 
therefore may serve as useful drug targets against diseases such as African sleeping 
sickness,73 Chagas disease74 and visceral leishmaniasis.75 
1.2.1. Distribution 
 The disulfide of OSHA* (OSSOA) has been identified in a number of echinoderms, 
including the sea urchins Paracentrotus lividus, Sphaerechinus granularis and Arabacia 
lixula, the holothuroid Holothuria tubulosa, and the asteroids Astropecten auratiacus and 
Marthasterias glacialis,76 as well as in the marine invertebrate Platynereis dumerili,77 and 
the mottle sea star Evasterias troschelli.78  OSHA (1-3A) and 4-thiol-L-histidine have been 
identified in the common octopus Octopus vulgaris, the European squid Loligo vulgaris79 
and in all insect stages of the pathogenic Kinetoplastida,80 such as Crithidia fasciculata81 
and Leishmania donovani.72  OSHB (1-3B) and OSHC (1-3C) have been identified in the 
spiny scallop Chlamys hastata and the purple sea urchin Strongylocentrotus purpuratus 
                                                 
* Initial work by Palumbo et al. (1984) identified the OSHs as 1-methyl-5-thiol-L-histidine due to confusion 
surrounding the nomenclature and numbering of substituted histidine rings.  The corrected numbering system 
assigns OSHs as 1-methyl-4-thiol-L-histidine (Turner et al., 1987). 
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respectively.78  OSHs have also been identified in the eggs of rainbow trout and Coho 
salmon68 and in the halo-tolerant green alga Dunaliella salina.82   
 The OSHs are also components of the adenochromines and imbricatine.  The 
adenochromines are found in O. vulgaris and consist of two OSHA moieties attached at 
various locations to a substituted phenyl ring: in adenochromine A (Figure 1.5, 1-8), the 
attachment points are positions 2 and 6 while in B and C the attachment points are 
positions 5 and 6 and positions 2 and 6 respectively.83  Imbricatine is produced by the 
starfish Dermasterias imbricata and, like the adenochromines, has OSHA attached to a 

































Figure 1.5:  The adenochromines are found in adenochrome, the purple iron (III) sequestering pigment of 
Octopus vulgaris, and differ in the position of the ovothiols on the phenyl ring.  Imbricatine (1-8) is found in 
Dermasteria imbricata, a starfish. 
1.2.2. Biosynthesis 
 The exact biosynthetic pathway of the OSHs is unknown.  Preliminary studies in 
Crithidia fasciculata (Figure 1.6) indicate that cysteine is first coupled to intact histidine to 
form a S-4-(L-histidyl)-L-cysteine sulfoxide intermediate (1-10) via a sulfoxide synthase 
enzyme which requires iron (II) and oxygen.  The cysteine is then cleaved by an enzyme 
requiring a pyridoxal phosphate cofactor to yield 4-thiol-L-histidine (1-11) and a side 
product which can be reduced with dithiothreitol to pyruvate and cysteine.  The 
methylation of 4-thiol-L-histidine by S-adenosyl-L-methionine is catalyzed by a 
methyltransferase to form OSHA.85  




































Figure 1.6: The proposed biosynthetic pathway of OSH in Crithidia fasciculata, where X is an unknown 
product that can be reduced with dithiothreitol to yield pyruvate and cysteine. 
1.2.3. Chemical Properties 
 Unlike ESH, the OSHs are unable to form a thione due to the location of the sulfur 
atom on the imidazole ring.  The thiol group is instead expected to exist as a thiolate at 
physiological pH: the pKa of OSHA model compound 4-thiol-N1-methyl-5-methyl-
imidazole (TMMI, Figure 1.7, 1-12) is only 2.3 for the thiol moiety.86  In contrast, GSH has 








Figure 1.7: 4-Thiol-N1-methyl-5-methyl-imidazole is often used as a model to study the properties of the 
OSHs. 
The presence of the thiolate may explain the superior nucleophilicity of TMMI as 
compared to GSH: iodoacetamide has been shown to react faster with TMMI than with 
GSH.86  In addition, TMMI is a superior radical scavenger to GSH as it reacts faster than 
GSH with several radicals,86,89 including tyrosyl radicals.89  The increased reactivity of 
TMMI with radicals is likely related to the aromatic nature of TMMI, which allows for 
delocalization of the thiyl radical onto the imidazole ring, increasing the stability of the 
TMMI radical.89  Semi-empirical calculations of the TMMI radical indicate that the free 
radical density is not localized on the sulfur atom, but is shared between the sulfur atom 
and carbon atoms 4 and 5 (see Figure 1.1 for numbering).71 
1.2.4. Biological Function 
 The OSHs have been linked to a number of diverse activities in marine 
invertebrates.  They can act as a pheromone in P. dumerilii,77 as a component of the 
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adenochromines which sequester iron in adenochrome of O. vulgaris,79 and as a component 
of imbricatine in D. imbricata which elicits a swimming response from Stomphia 
coccinea.84  OSHC has been shown to act as an H2O2 scavenger in sea urchin eggs.68    
During fertilization, the sea urchin S. purpuratus uses H2O2 to crosslink tyrosine 
residues in its egg’s fertilization envelope.90,91  The concentration of H2O2 must be tightly 
controlled to protect the embryo from oxidative damage and this goal is accomplished 
through the non-enzymatic reaction of OSHC with H2O268 to form OSSOC and water 
(Figure 1.8, 1-13).68,92  OSSOC is believed to be reduced back to its free thiol form by 
GSH, as there have been no reports of an OSSO reductase in any OSH containing 
organism.  The OSHC system accounts for 73% of the metabolism of H2O2 in unfertilized 
and fertilized sea urchin eggs, while catalase, an enzyme used to convert H2O2 to water, 
accounts for only 27%.68  OSHC may therefore play a critical role in the prevention of 



























Figure 1.8: The redox cycle for the detoxification by ovothiol C of peroxides formed during the fertilization 
of sea urchin eggs.  The disulfide of ovothiol C (1-13) is formed, which is believed to be reduced by 
glutathione back to the free thiol form. 
The role of OSH in the Trypanosoma parasites is not clear.  These organisms utilize 
a trypanothione-based peroxidase system to scavenge H2O2, relegating the non-enzymatic 
scavenging of H2O2 by OSH to a relatively minor role.80  OSHA has been shown to 
decompose the S-nitroso groups of S-nitrosoglutathione and di-S-nitrosotrypanothione,93 
the intermediate products of nitric oxide detoxification.  Reactive nitrogen species (RNS) 
such as nitric oxide are produced by the parasite’s host organisms as a defence94 and the 
protection of the parasite from RNS may prove to be an essential role for OSHs in these 
organisms.   
 OSHs and their derivatives may be of therapeutic importance as GSH peroxidase 
mimics.  GSH peroxidase catalyzes the reduction of peroxides by GSH, thereby protecting 
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the cell from oxidative damage.95  Peroxides have been implicated in a number of disease 
states, including inflammation and cancer.53,96,97  Recently, there has been intense interest 
in the development of small-molecule mimetics of GSH peroxidase, as these compounds 
could aid in the control of peroxide levels in the cell and possibly act as a treatment in 
prevention of oxidative damage.98-100  The 4-thiol-imidazoles are of interest as therapeutic 
antioxidants, as they can reduce oxygen-centered radicals,89 many of which have been 
implicated in a variety of disease processes.53,96  Analogues of OSH have been successfully 
synthesized in hopes of finding pharmaceutically relevant antioxidants.69  Some of these 
derivatives are potent scavengers of HOCl, HO•, and H2O2 and are able to inhibit copper 
induced low density lipoprotein peroxidation.70  Due to their apparent non-toxic properties, 
these compounds might contribute to the medicinal control of ROS.68  Further research in 
this area may result in the development of useful therapeutic agents to defend against 
oxidative damage. 
1.3. Glutathione 
GSH (Figure 1.9, 1-1) is the best characterized of the intracellular thiols.  Much is 
known about GSH and its relationship to cellular reduction-oxidation (redox) processes, its 
activity as an enzyme cofactor, and its biosynthesis and degradation.  Once considered 
ubiquitous, it has been determined that not all organisms produce GSH; the pathogenic 
Mycobacteria for example produce MSH in the place of GSH.  The functions of MSH are 
believed to parallel that of GSH; therefore, GSH and its enzymes may serve as a template 
for the discovery of new MSH functionalities.  Consequently, before discussing MSH, one 
of our thiols of interest, GSH will be briefly discussed to give context to the studies of 












Glutathione (GSH, 1-1)  
Figure 1.9: Glutathione is composed of γ-L-glutamyl-L-cysteinyl-glycine. 
1.3.1. Distribution 
 GSH is the predominant thiol in eukaryotic organisms including humans, animals, 
plants, and fungi.101  All mammalian cells synthesize GSH102 and it is maintained at an 
intracellular concentration between 0.5 to 10 mM.103  Approximately 98% of GSH is found 
in its free thiol form.  The remaining is present as the GSH disulfide (GSSG), mixed 
disulfides or as thioethers.102   
 Most Gram-negative bacteria,104 including Escherichia coli, the cyanobacteria and 
the purple bacteria use GSH as their major thiol,101 as do certain Gram-positive bacteria 
including Streptococcus agalactiae and Streptococcus lactis.104 The pathogenic 
Trypanosoma and the Leishmania also produce GSH; however, it is mostly bound as 
trypanothione (N1-N8-bis(glutathionyl)spermidine), the major thiol in these 
organisms.105,106   
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1.3.2. Biosynthesis 
 The well characterized biosynthesis  of GSH (Figure 1.10) begins with the coupling 
of L-glutamate with L-cysteine catalyzed by glutamate-cysteine ligase followed by the 



























Figure 1.10: The biosynthetic pathway of glutathione. A: γ-glutamyl-cysteine synthase; B: glutathione 
synthase 
1.3.3. Chemical Properties 
 Unlike ESH, GSH has no structural features that lead to unusual bond lengths, 
angles or energies.87  The pKa values for GSH have been determined (Table 1.1) and at 
physiological pH it is found as a thiol rather than a thiolate, with an overall charge of -1.87  
GSH is highly soluble in water as is its disulfide.  Also, unlike ESH, GSSG is stable and 
found under physiological conditions.  
Table 1.1:  The pKa values of glutathione.87 
Ionizable Group  
SH NH3+ CO2H CO2H 
pKa 9.2 8.9-9.6 2.6 3.4 
 
GSH can act as a nucleophile and a scavenger of free radicals.  Once oxidized to the 
thiyl radical, GSH is not further oxidized to the thiol cation and often dimerizes to form the 
disulfide.87  GSH is not as easily oxidized as cysteine, which is attributed to the blocking of 
the carboxyl and amino groups of cysteine by peptide bonds, which slows autooxidation in 
the presence of trace metals such as copper (II) and iron (II).108,109   
1.3.4. Biological Function 
 Since its discovery in 1888,110 GSH has been implicated in a wide variety of 
processes, including the metabolism of aromatic carbon sources, the maintenance of 
cellular redox potentials, and the removal of toxic substances from the cell.  It is a co-factor 
for a number of vital enzymes including many enzymes essential in detoxification 
pathways.  An encompassing description of the role that GSH plays in the cell is not 
feasible within the confines of this introduction† and therefore this discussion will be 
limited to the details which pertain to the work detailed herein.  The reader is referred to 
the extensive review literature available for GSH.102,103,111-115 
                                                 
† A search of the PubMed database, a service of the National Library of Medicine and the National Institute 
of Health, for glutathione returned 73 334 references, 4 022 of which are review articles (accessed November 
13, 2006). 
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The metabolism of aromatic compounds by microorganisms is important for the 
removal of toxic compounds from the environment.116 Gentisate and its derivatives are key 
intermediates in the metabolism of a large number of aromatic compounds, including  
3-hydroxybenzoate,117 substituted phenols,118-120 salicylate,116 and naphthalene.121,122  The 
cleavage of the aromatic ring of gentisate is catalyzed by gentisate 1,2-dioxygenase to form 
maleylpyruvate.  In Salmonella typhimurim,117,123 Pseudomonas acidovorans,124 Klebsiella 
pneumoniae,125 Ralstonia sp. Strain U2126 and Moraxella OA3,127,128 maleylpyruvate is 
converted to fumarylpyruvate by maleylpyruvate isomerase, using GSH as an essential 
cofactor (Figure 1.11),129 followed by the hydrolysis of fumarylpyruvate to pyruvate and 
fumarate.  Maleylpyruvate isomerase activity was first identified by Lack in 1959;129 
however, very little research has been reported regarding the further characterization of this 
enzyme despite the confirmation of this pathway in a number of organisms and its 























Figure 1.11: The gentisate pathway.  A: gentisate dioxygenase; B: maleylpyruvate isomerase; C: 
fumarylpyruvate hydrolase. 
 The removal of ROS is essential to the viability of the cell as they can react with 
carbohydrates, DNA, lipids, and proteins, inactivating cellular components.62  GSH can 
react with many ROS, detoxifying them, and in the process forming its disulfide, GSSG.  
The reaction of GSH with free radicals goes through a glutathionyl radical (GS•) which is 
less reactive than most ROS species, before ultimately forming GSSG and superoxide 
(O2•¯) (Eqs. 1.1 to 1.4).  The latter is removed by superoxide dismutase.62   
 
 HO•, RO•, or RO2• + GSH → H2O, ROH, or RO2H + GS• Eq. 1.1 
 GS• + GS¯ → GSSG•¯ Eq. 1.2 
 GSSG•¯ + O2 → GSSG + O2•¯ Eq. 1.3 
 2 GS• → GSSG Eq. 1.4 
 
GSH will also react with H2O2 to form GSSG.  H2O2 is less reactive than free radicals such 
as HO•; however, it is known to inactivate thiol-containing enzymes and can generate HO• 
upon interaction with iron (II) and copper (I).62   The intracellular concentration of H2O2 is 
therefore tightly controlled by several peroxidases,62 including GSH peroxidase (Eq. 
1.5)130,131 and catalase (Eq. 1.6).62 
 
 H2O2 + 2 GSH → GSSG + 2 H2O  Eq. 1.5 
 2 H2O2 → 2 H2O + O2 Eq. 1.6 
 
In addition, GSH has been implicated in the repair of vitamin E (Figure 1.12),62 an 
essential lipid soluble antioxidant responsible for the protection of the cellular membrane 
against ROS.132-134  Cell membranes contain polyunsaturated fatty acids, which are readily 
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auto-oxidized, and if left unchecked, can cause a loss in the structural integrity of the 
membrane.134  Vitamin E reacts with lipid peroxy radicals, preventing lipid peroxidation62 
by breaking the free radical chain reaction (Eq. 1.7).134  The resulting fatty acyl 
hydroperoxide is presumed to be reduced to a hydroxyl acid by GSH peroxidase135 and the 
vitamin E radical must then be reduced back to its active form for continued protection of 
the membrane.  The membrane-bound vitamin E radical can react with cytosolic 
antioxidants, such as GSH, to regenerate vitamin E (Eq. 1.8).62  As detailed above, 








α: R1 = R2 = CH3
β: R1 = CH3, R2 = H
γ: R1 =  H, R2 = CH3
δ: R1 = R2 = H
Tocopherols Tocotrienols
 
Figure 1.12: The naturally occurring forms of vitamin E. 
 
 Vit-E + RO2• → Vit-E• + RO2H Eq. 1.7 
 Vit-E• + GSH → Vit-E + GS•136 Eq. 1.8 
 
Once formed by these reactions, GSSG must be reduced back to its biologically 
useful free thiol form.102,137   GSSG reductase (GR), which reduces GSSG to GSH, has 
been identified in bacteria, fungi, plants, protozoa and animals.138  GR is a dimer of 
identical subunits138 and belongs to the family of flavin adenine dinucleotide (FAD)-
containing pyridine nucleotide:disulfide oxidoreductases.137  GR reduces GSSG to GSH 
using one equivalent of nicotinamide adenine dinucleotide phosphate (NADPH) (Eq. 1.9). 
 
 GSSG + H+ + NADPH → 2 GSH + NADP+ Eq. 1.9 
 
The enzyme binds NADPH, which reduces the FAD and NADP+ is released.  The active 
site contains a redox active disulfide, which is reduced by the reduced FAD and GSSG 
binds.  The newly formed active site sulfur attacks GSSG, forming a mixed disulfide and 
one GSH molecule is released.  The other active site sulfur attacks the mixed disulfide, 
reforming the active site disulfide and releasing the second GSH molecule.139  Without this 
enzyme, the concentration of biologically active GSH would be depleted, hampering the 
organism’s ability to maintain redox homeostasis and protect the cell from ROS.   
Cells must also be protected from electrophilic species which can modify 
nucleophilic cellular components such as DNA and proteins.  These compounds can often 
be linked to GSH to form GSH-S-conjugates which are further metabolized by the cell for 
excretion; these conjugation reactions are catalyzed by GSH-S-transferases (GSTs),140-144 
whose active site environment lowers the pKa of GSH to ~6.2, which increases the thiol 
group nucleophilicity and facilitates the reaction.142  The most common GST reactions 
involve attack on an electrophilic carbon atom,102 such as those shown in Figure 1.13.  
Once a GSH-S-conjugate is formed, it is further metabolized with the exact pathway and 
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ultimate mode of excretion varying with species and xenobiotic (an example pathway is 
































Figure 1.13: Examples of known physiological substrates of glutathione-S-transferases.  The arrows indicate 





































Figure 1.14: Selected pathways for the metabolism of glutathione-S-conjugates.  I: γ-glutamyl transpeptidase; 
II: cysteinyl glycine dipeptidase; III: cysteine conjugate β-lyase; IV: UDP-glucuronyl transferase; V: S-
methyltransferase; VI: N-acetyltransferase catalyzes the forward reaction while a deacetylase catalyzes the 
reverse reaction.  Adapted from Pickett and Lu (1989).141 
 
GSTs have been noted in mammals, certain insects, plants, squid and bacteria.142  
These enzymes can be divided into multiple classes140 and each organism can have more 
than one isoform from each class.  All known GSTs are dimeric with one active site per 
monomer.142  The dimers need not be homodimeric but the monomers must be of the same 
class, as the features of subunit recognition differ between classes.144  In addition to the 
removal of xenobiotics, GSTs are also involved in the formation of biological mediators 
and a number of physiological substrates have been identified.146,147   
Cells must also be protected from toxic electrophilic substances produced as by-
products of cellular processes.  Formaldehyde for example, is produced during a number of 
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metabolic and detoxification processes,148-151 but it must be removed due to its non-specific 
reactivity with proteins and nucleic acids.  One of the most widespread methods of 
formaldehyde detoxification involves the oxidation of formaldehyde to formate via a two 
enzyme system.  The first enzyme in this pathway, formaldehyde dehydrogenase (FD), has 
been identified in all animal tissues, pea and corn seeds, Baker’s yeast, E. coli, all 
methanol-utilizing yeasts, and many methanol-utilizing methylotrophic bacteria.  FD has 
been shown to be GSH dependent (GD) in these organisms152 with the true substrate for 
GD-FD being the non-enzymatically formed hemithioketal adduct of formaldehyde and 
GSH, S-hydroxymethylglutathione (S-HM-GSH Eq. 1.10, Figure 1.15, 1-14).  S-HM-GSH 
is reversibly converted to S-formylglutathione (Eq. 1.11, Figure 1.15, 1-15), whose 
hydrolysis is catalyzed by S-formylglutathione hydrolase to formate and GSH (Eq. 1.12). 
 
 Formaldehyde + GSH → S-HM-GSH Eq. 1.10 
 S-HM-GSH + NAD+ → S-Formylglutathione + NADH + H+ Eq. 1.11 






























Figure 1.15: The reaction catalyzed by glutathione dependent formaldehyde dehydrogenase. 
 GD-FD is highly specific for GSH and will not accept oxidized GSH, or other thiols 
such as cysteinylglycine, ESH, cysteine, or N-acetylcysteine.153  The specificity for the 
cofactor is less rigorous and GD-FD can accept both NAD+ and NADP+ as cofactors.153  
Based upon structural studies, GD-FD belongs to the family of alcohol dehydrogenases and 
is homologous to the class III alcohol dehydrogenases.154  In agreement with this 
observation, GD-FD has been shown to catalyze the oxidation of long chain aliphatic 
alcohols independent of GSH; however, this activity is low at physiological pH.154   
 Unexpectedly, GD-FD has also been implicated in the metabolism of  
S-nitrosoglutathione (GSNO, Figure 1.16, 1-16).155,156  GSNO is formed by the nitrosation 
of GSH by nitric oxide (NO) in the presence of oxygen.  NO performs a number of 
essential roles in the cell, including the control of blood pressure and the destruction of 
pathogens.62  However, it can also damage metalloproteins and DNA,62 and can react with 
O2•¯ to form ONOO¯, which can attack many biologically important molecules.62  The 
formation of GSNO has been suggested to be a mechanism for the storage and transport of 
NO, as well as a protective method against NO toxicity.  The structural similarity between 
GSNO and S-formylglutathione is visibly apparent (Figure 1.16), which may account for 
this activity of GD-FD.   
 


























S-nitrosoglutathione (GSNO, 1-16)  
Figure 1.16: Structural comparison of the two substrates of glutathione dependent formaldehyde 
dehydrogenase. 
The main products of the GSNO metabolism by E. coli GD-FD, ammonia (NH3) and 
GSSG, are consistent with Eqs. 1.13-1.15.156   
 
 GSNO + NADH + H+ → GSNHOH + NAD+ Eq. 1.13 
 GSNHOH + NADH + H+ → GSNH2 + NAD+ + H2O Eq. 1.14 
 GSNH2 + GSH → GSSG + NH3 Eq. 1.15 
 
GD-FD has been identified in E. coli,156 mammals,155-158 Arabidopsis thaliana,157 and 
yeasts.156,157  It has been determined that GD-FD is essential for cellular protection against 
nitrosative stress in yeast and it regulates and protects against the S-nitrosylation of 
proteins.156,158   
 Formaldehyde is not the only toxic by-product produced during metabolism. 
Methylglyoxal (MG, Figure 1.17, 1-18) is produced by a number of pathways and is known 
to modify proteins and nucleic acids, resulting in cell death if its concentration is not 
controlled.  A major source of MG is its spontaneous production by triose phosphate 
isomerase (TIM) during the conversion of dihydroxyacetone phosphate (DHAP, Figure 
1.17, 1-17) to D-glyceraldehyde-3-phosphate (DGAP, Figure 1.17, 1-19) during 
glycolysis.159  MG is formed when phosphate elimination occurs rather than 
reprotonation.160  While reprotonation occurs 106 times more frequently than phosphate 
release, the high concentration of TIM in the cells allows for a significant accumulation of 
MG in the cells: the rate of MG accumulation due to TIM has been postulated to be as high 
as 0.4 mM/day.159,160   











































Figure 1.17: The isomerization catalyzed by triose phosphate isomerase: dihydroxyacetone phosphate 
(DHAP, 1-17) is converted to D-glyceraldehyde-3-phosphate (DGAP, 1-19) via a deprotonation and 
reprotonation mechanism.  When inorganic phosphate (Pi) is eliminated (pathway A) methylglyoxal (MG,  
1-18) is formed.160 
Microorganisms can also produce MG directly from DHAP by MG synthase in a 
postulated bypass to phosphorylating glycolysis.161,162  DHAP can accumulate when cells 
have limited sources of phosphate and MG synthase, combined with other enzymes in the 
bypass, this may serve as a pathway for the formation of pyruvate, with the release of 
phosphate.  This enzyme is tightly controlled through feedback inhibition by phosphate and 
activation by DHAP.163  The concentration of MG must be tightly controlled by the cell as 
it, and other α-ketoaldehydes, can form adducts with RNA and proteins and can inhibit 
protein biosynthesis.164   
Many organisms control the intracellular concentration of MG by converting it to 
D-lactate (Figure 1.18, 1-22) using the two-enzyme glyoxalase (Glx) system composed of 
GlxI and GlxII (Figure 1.18).  The Glx system requires GSH and is believed to be present 
in all GSH-utilizing organisms.165 GlxI sequences have been identified in humans,166 
mice,167 yeasts,168,169 plants,170-177 insects,165 protozoa,178 fungi179 and at least 42 species of 
bacteria,165,180 including E. coli.181  The true substrate for GlxI is the non-enzymatically 
formed hemithioacetal (Figure 1.18, 1-20) of MG and GSH.  The product of the GlxI 
catalyzed reaction, S-D-lactoylglutathione (Figure 1.18, 1-21), is the substrate for GlxII, 
which hydrolyzes the thioester to GSH to form D-lactate (1-22).  The mechanism is 
believed to proceed via the deprotonation of 1-20 to form the endiolate intermediate, 
followed by reprotonation to yield S-D-lactoylglutathione (1-21).182  GlxI will accept either 
of the two possible stereoisomers of the hemithioacetal as substrates,183  and will accept 
hemithioacetals formed from the condensation of GSH with other α-ketoaldehydes, thereby 
protecting the cell against modification by α-ketoaldehydes other than MG. 
 



















































Figure 1.18: The glyoxalase system: a two enzyme system which converts cytotoxic methylglyoxal (MG,  
1-17) to D-lactate (1-19) using glutathione (GSH, 1-1) as an essential cofactor. 
 The human, bacterial, and plant GlxI enzymes are known to be dimeric, while the 
yeast enzyme has been shown to be a monomer165 containing two copies of a segment 
which is equivalent to two copies of the human enzyme.165  Crystal structures have been 
solved for the human184 and E. coli181 GlxI enzymes and both structures indicate that there 
are two active sites, each of which is located at the interface of the dimers and contains a 
metal ion which interacts with amino acid residues from both subunits.  The human 
enzyme has been shown to be most active with zinc (II)185 which is coordinated by 
glutamine-33A,‡ glutamate-99A, histidine-126B, glutamate-172B and two water 
molecules.184  In contrast, the E. coli enzyme is maximally activated by nickel (II)186 which 
is bound by histidine-5A,‡ glutatmate-56A, histidine-74B, glutatamte-122B and two water 
molecules.181  Both the human166 and E. coli181 enzymes have an octahedral coordination 
state for their preferred metal ion.  When E. coli binds zinc (II), the coordination sphere is 
trigonal bipyramidal, which may account for the difference in activity.181    
While GlxI enzymes have been thoroughly characterized from a number of 
organisms, much less is known regarding GlxII.  GlxII has been identified in the tissues of 
humans,187,188 rat liver,189,190 yeasts (Sacchromyces cerevisiae,191 and Hansenula markii192), 
a limited number of plants,193-196 and Candida albicans.197 Also, the cloning of GlxII from 
humans,198   A. thaliana199, S. cerevisiae200, and Neisseria meningitidis201 has been 
reported.  While S-D-lactoylglutathione is the major substrate for this enzyme, it will accept 
other S-D-lactoylthiols, as well as non-GSH thioesters, though it has a high specificity for 
GSH.202 Interestingly, while GlxI has only been identified in the cytosol, the presence of 
GlxII in both the cytosol and mitochondria189,190,195,196,203 of various organisms has been 
reported.   The definitive role of mitochondrial GlxII has yet to be identified; however, S-D-
lactoylglutathione of unknown origin has been isolated from mitochondria.  Multiple 
isozymes of GlxII have been reported in A. thalinana,203 S. cerevisiae200,204 and humans,205 
which differ in localization within the cell: mitochondrial or cytosolic.    
                                                 
‡ Where A and B indicate different subunits. 
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In all cases, GlxII is a monomeric enzyme with no sequence similarity to GlxI.  
GlxII requires metal ions for activity206 and the crystal structure of the human enzyme 
indicates that the enzyme has two metal binding sites.207  Initial evidence indicated that 
GlxII is a zinc metalloenzyme; however, further studies have indicated that GlxII from  
A.thaliana demonstrates flexibility in its metal binding and can incorporate iron, 
managanese and zinc in vivo.208  A variety of metal ion combinations were detected 
observed in the active site including iron (III)§-iron (II), iron (III)-zinc (II) and  
manganese (II)-manganese (II) centers, and similar catalytic efficiencies (kcat/KM) were 
observed with the different ions.208  The crystal structure indicates that the two metals are 
bridged by a water or hydroxide molecule and an oxygen from an aspartate residue.207  The 
first ion is also coordinated by the nitrogen atoms of histidine-54, histidine-56, and 
histidine-110, while the second ion is coordinated by an oxygen atom from aspartate-58 
and nitrogen atoms from histidine-59 and histidine-173.207  All of the coordinating residues 
are stabilized by direct or indirect hydrogen bonding interactions with other residues in a 
second coordination sphere.207  The bound water/hydroxide molecule is suspected to attack 
the carbonyl of the substrate to form a tetrahedral intermediate that collapses to release 
GSH and the corresponding carboxylic acid.207 
A GSH-independent Glx system has been reported in E. coli which accepts MG as a 
substrate and yields D-lactate as a product.  This monomeric enzyme, termed glyoxalase III 
(GlxIII), does not catalyze the formation or breakdown of the GlxI product S-D-
lactoylglutathione.  GlxIII was found to have a greater substrate specificity then the Glx 
system as it will only accept MG and phenylglyoxal as substrates, activity with 
phenylglyoxal being only 15 % of that seen with MG.209  To date, this enzyme has not been 
further characterized.   
As mentioned, GSH is the best characterized of the intracellular thiols.  It is 
involved in a diverse range of cellular activities, only a small sampling of which was 
presented here.  Not all organisms use GSH, and instead use other low molecular weight 
thiols in its place.  It may be true that what is known about GSH can act as a guide for the 
discovery of enzymes that use these other thiols. 
1.4. Mycothiol 
The Actinomycetales bacteria, such as the pathogenic Mycobacteria, do not produce 
GSH and instead use a unique thiol termed MSH (1-D-myo-inosityl-2-(N-acetyl-L-
cysteinyl)amido-2-deoxy-α-D-glucopyranoside, Figure 1.19, 1-4).  The most well known 
disease associated with Mycobacteria is tuberculosis (TB), caused by M. tuberculosis in 
humans210 and Mycobacterium bovis in bovines.211  The emergence of antibiotic resistant 
strains of M. tuberculosis has brought this disease back to the forefront of clinical research: 
strains resistant to single drugs have been reported in every country surveyed and strains 
that are resistant to all of the major TB drugs have been documented.210  According to the 
World Health Organization (WHO), a third of the world’s population is currently infected 
with TB.210  Mycobacteria are linked to a number of other clinically and agriculturally 
important diseases including human leprosy and Johne’s disease which affects cattle and 
causes losses to the dairy industry in excess of $1.5 billion (US) per year.212  Despite the 
medical importance of the organisms that utilize MSH, very little is known concerning its 
                                                 
§ The presence of a ferric ion is consistent with the oxidative experimental condition and likely does not 
reflect the in vivo oxidation state (Schilling et al. 2003).  
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behaviour and reactions.  The role of MSH appears to parallel that of GSH, indicating that 
the function of GSH and its enzymes may serve as a template for the discovery of new 
MSH functionalities.  MSH and its enzymes act as a novel target for the development of 














Figure 1.19: Mycothiol. 
1.4.1. Distribution  
MSH was first identified as a disulfide (MSSM) in Streptomyces sp. AJ9463213 and 
as a free thiol214 in M. bovis72 and Streptomyces clavuligerus.215  Further studies identified 
MSH in species of Micrococcus, Nocardia, Rhodococcus, Mycobacterium, 
Micromonospora, Actinomadura and Nocardiopsis,216 but not in representatives of the 
Arthrobacter, Agromyces or Actinomyces genera (Table 1.2).216  MSH was not detected in a 
selection of Gram-positive bacteria including representative species of Listeria, 
Staphylococcus, Enterococcus, Bacillus and Clostridium.216  MSH was also absent from  
E. coli and Psuedomonas aeruginosa.216  Tests of rat liver, bonito muscle, Candida 
albicans, Neurospora crassa, and spinach leaves were also negative.216  Based upon these 
results it was assumed that MSH production is restricted to the Actinomycetales bacteria 
and that it is the major thiol in most Actinomycetales bacteria.101,216   
1.4.2. Biosynthesis 
 The steps in the biosynthetic pathway of MSH in Mycobacteria have recently been 
fully elucidated (Figure 1.20).  The pathway begins with the coupling of D-myo-inositol-3-
phosphate (Ins(3)P1, (1-23)) and UDP-N-acetylglucosamine (UDP-GlcNAc, (1-24))217,218 
to form 3-phospho-1-D-myo-inosityl-2-acetamido-2-deoxy-α-D-glucopyranoside (GlcNAc-
Ins(3)P1 (1-25)) which is catalyzed by a glycosyltransferase termed MshA.217  GlcNAc-
Ins(3)P1 is then dephosphorylated by an inositol kinase MshA2 to yield GlcNAc-Ins  
(1-26).217  GlcNAc-Ins is deacetylated by MshB to yield GlcN-Ins (1-27).219  The coupling 
of GlcN-Ins to cysteine is catalyzed by the ligase MshC which activates cysteine using 
ATP to form a cysteine-AMP derivative.  This derivative is attacked by the amino group of 
GlcN-Ins to form Cys-GlcN-Ins (1-28); AMP and pyrophosphate are also released.220  The 
final step of MSH biosynthesis is the acylation of the cysteinyl amino group of Cys-GlcN-
Ins by acetylCoA, catalyzed by MshD.221   
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Table 1.2: Thiols produced by Actinomycetales.a 
 Thiol(μmol/g [residual dry weight] 
Strains (sorted by subclass) MSH Cys GSH H2S CoA Other 
Actinomycineae       
Actinomyces israelii <0.02 0.22 <0.02 0.04 0.17  
       
Corynebacterineae       
Corynebacterium diphtheriae 0.18 0.015 <0.01 0.04 0.19 0.14b 











Mycobacterium chelonae 6.60 <0.05 <0.02 0.8 5  
Mycobacterium fortunitum 9.40 <0.03 <0.02 0.9 3  
Mycobacterium smegmatis 19.00 0.09 <0.02 0.9 3  











Nocardia asteroids 3.50 <0.06 <0.05 0.35 0.66 0.01b 
Nocardia brasiliensis 2.80 <0.03 <0.03 0.47 1.0 0.03e 
Rhodococcus roseus 3.00 0.2 <0.03 0.3 0.15  
       
Micrococcineae       
Arthrobacter globiformis <0.01 0.11 <0.01 0.4 0.34 0.28b 
Micrococcus agilis 0.90 <0.01 <0.01 0.4 0.47  












Micrococcus kristinae 0.60 <0.01 <0.01 0.10 0.50  
Agromyces ramosus <003 <0.04 <0.03 0.15 0.38  
       
Micromonosporineae       
Micromonospora carbonacea 1.50 0.20 <0.01 3.8 0.3 2.4h 
Micromonospora floridensis 14.00 0.90 <0.01 2.5 0.91 4.2h 
Micromonospora fulvopurpurea 2.40 0.60 <0.01 2.3 0.58 1.9h 
       
Propionibacterineae       
Propionibacterium acnes <0.03 0.08 <0.02 0.28 0.4  
       
Pseudonocardineae       
Nocardiopsis flava 2.70 1.10 0.22 0.74 0.39 0.69i 
Nocardiopsis mutabilis 0.44 0.06 <0.02 0.29 0.9 0.85j 
       
Streptomycineae       
Streptomyces clavuligerus 5.40 0.78 <001 1.3 0.8 1.55k 
Streptomyces coelicolor A3(2) 2.80 0.56 <0.02 0.75 0.5 <0.02l 
Streptomyces jumonjinensis 6.70 1.30 <0.09 0.83 1.9 1.1k 
Streptomyces lactamdurans 5.90 1.30 <0.08 1.3 1.1 23.05m 
Streptomyces lividans 6.60 0.58 <0.06 1.3 1.0 0.51k 
       
Streptosporangineae       
Actinomadura hibisca 1.50 0.43 <0.01 1.0 0.17 2.41n 
aMSH: mycothiol, Cys: cysteine, GSH: glutathione, H2S: hydrogen sulfide, CoA: coenzyme A, Adapted from 
Newton et al. (1996).216  bUnknown thiol.  cTwo strains of M. avium were tests NJH9151 and NJH1854-4.  
dTwo strains of M. tuberculsosis were tested: ATCC 25618 and PZA UCSD 100.  e4’-phosphopantetheine.  
fTwo strains of M. luteus were tested: UCSD 22 and ATCC 4698.  gN-acetylcysteine; hthiosulfate and  
N-acetylcysteine.  iN-acetylcysteine, thiosulfate and an unknown thiol.  junknown thiols.  kδ-(L-α-amino-
adipyl)-L-cysteinyl-D-valine (ACV) and an unknown thiol.  lACV.  mACV and ergothioneine.   
nN-acetylcysteine and an unknown thiol. 














































































Cys-GlcN-Ins (1-28)  
Figure 1.20: The biosynthetic pathway of mycothiol. 
Studies of M. tuberculosis and Mycobacterium smegmatis mutants deficient in the 
various biosynthetic enzymes have been performed.  Inactivation of the gene for MshB 
does not fully block the biosynthesis of MSH as an alternative deacetylase activity exists in 
these organisms which produces a modest amount of GlcN-Ins and ultimately a limited 
amount of MSH.222,223  Mutants of M. tuberculosis and M. smegmatis deficient in MshD 
were able to produce low levels of MSH as well as another thiol, N-formyl-Cys-GlcN-Ins, 
which can act as a poor substitute for MSH is some biochemical reactions.224  The removal 
of MshA218 or MshC225 results in a complete halt in the biosynthesis of MSH in  
M. smegmatis, and in the case of M. tuberculosis, no cellular growth.217  The biosynthetic 
enzymes involved in the production of MSH are therefore excellent targets for the 
development of antituberculins and the development of inhibitors to these enzymes is 
ongoing.226 
Homologues of the M. tuberculosis MshC sequence have been identified in 
Streptomyces coelicolor and Corynebacterium striatum and orthologues of MshC were 
found in M. bovis, Mycobacterium leprae, the causative agent of leprosy, Corynebacterium 
diphtheriae,220 the causative agent of diphtheria, and in Mycobacterium avium.220  
Homology studies of the S. coelicolor genome have identified the msha, b, c and d genes 
and the identity of their gene products were proven experimentally.227  These genes have 
also been identified in Corynebacterium glutamicum, Corynebacterium efficiens, and 
Corynebacterium jeikeium.228  It is therefore believed that the biosynthetic pathway of 
MSH is conserved throughout all MSH biosynthesizing organisms. 
1.4.3. Chemical Properties 
 Despite the intense interest in MSH as a possible target for antimycobacterial 
agents, there is little data available regarding the chemical properties of MSH.  Most of the 
research published is related to the elucidation of the biosynthetic pathway of MSH and the 
identification of MSH-utilizing enzymes as possible targets for the development of novel 
pharmaceuticals.  It is known that MSH will react with monobromobimanes,215,216 
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electrophiles often used to tag intracellular thiols229 in cell extracts for purification and 
identification.10  The pKa of MSH has been estimated to be close to that of cysteine (pKa = 
8.33) and GSH (pKa = 9.2), which would suggest that the nucleophilicity of MSH would 
decrease at physiological pH72 and would be similar to that of GSH.  GSH does not react 
with most electrophiles under normal physiological conditions and conjugation reactions 
proceed with the assistance of GSTs.140-144  It is therefore likely that MSH does have some 
nucleophilic character; however, at physiological pH, it is not enough to react unassisted 
with most electrophiles.  
 Thiols are known to auto-oxidize in the presence of oxygen and heavy metals such 
as copper.  GSH is known to auto-oxidize much slower than cysteine which is attributed to 
the blockage of the amino and carboxyl groups of cysteine by amide bonds with glutamate 
and glycine.  MSH, in turn has been shown to auto-oxidize at a rate seven-fold slower than 
that of GSH and 30-fold slower than that of cysteine.215  This decreased rate of oxidation 
cannot be accounted for by the blockage of the amino and carboxyl groups of cysteine 
alone.  It is suspected that the GlcN-Ins scaffold may be an important factor in the 
resistance of MSH to autooxidation.215 
1.4.4. Biological Function 
 Current research indicates that the function of MSH in Actinomycetales bacteria 
parallels that of GSH in other organisms.  MSH is produced in a similar pattern to GSH 
during cellular growth and the MSH-utilizing enzymes identified to date, parallel GSH-
utilizing enzymes in function.  These enzymes are involved in the metabolism of the 
aromatic carbon sources and the protection of the cell from ROS and RNS, xenobiotics and 
endogenous electrophiles, and may serve as novel drug targets for the development of 
novel antimycobacterials.  
 Recently, MSH producing C. glutamicum has been noted to robustly metabolize 
aromatic compounds, and mutants deficient in the production of MSH were unable to use 
gentisate as a carbon source.  An MSH-dependent (MD) gentisate pathway was 
subsequently identified which, similar to the GSH pathway, involves 1,2-dioxygenase, 
maleyl pyruvate isomerase and fumaryl pyruvate hydrolase, with maleyl pyruvate 
isomerase requiring MSH as an essential cofactor.  The gene encoding MD maleyl 
pyruvate isomerase was not homologous to GSH-dependent enzyme found in  
K. pneumoniae or Ralstonia U2.  Genomic mining of other Actinomycetales bacteria found 
sequences homologous to the MD maleyl pyruvate isomerase in C. efficiens, Streptomyces 
strain WA46, S. coelicolor, Streptomyces avermitilis, and Nocardia farcinica.228  While 
this enzyme may not be a viable drug target against tuberculosis, it does illustrate the 
parallel evolution of GSH and MSH dependent enzymes. 
The removal of ROS is essential for cellular viability.  While there have been no 
reported studies of the direct reaction of MSH with ROS, studies of mutants of 
Mycobateria deficient in the biosynthesis of MSH have shown that MSH is important for 
the modulation of oxidative stress in these bacteria.230,231  Mutants of M. tuberculosis 
deficient in MSH biosynthesis are not viable, as MSH contributes to the protection of this 
organism from oxidative stress.223  MSH is also important for the growth of M. smegmatis, 
as mutants deficient in MSH have a much slower growth rate.232  The difference in viability 
is believed to be related to the longer doubling time of M. tuberculosis, which is six times 
that of M. smegmatis.  This longer growth time may allow for the accumulation of lethal 
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levels of oxidative damage to M. tuberculosis, while the faster doubling time of  
M. smegmatis results in less damage and therefore some growth is observed.225   Mutants of 
M. smegmatis deficient in MSH production have increased sensitivity to H2O2,232 as well as 
redox-cycling agents which increase the concentration of the O2•¯ in the cell.230  The 
reactions of the thiols, such as GSH with peroxides and free radicals, usually lead to the 
formation of disulfides which must be reduced back to their biologically useful free thiol 
form.  In keeping with this observation, an MSH disulfide (MSSM) reductase (MR)** has 
been identified which converts MSSM to MSH233 using NADPH as a reducing agent.234,235  
Similar to GR, MR is homodimeric, binds FAD, and has a redox active disulfide in the 
active site.  MR is 31% homologous to the GR from E. coli and belongs to the same family 
of FAD-containing pyridine nucleotide:disulfide oxidoreductases.  The chemical 
mechanism of MR parallels that of GR, using NADPH to reduce FAD followed by 
reduction of the active site disulfide.  One of the active site thiols can then attack bound 
MSSM to form a mixed disulfide,  releasing one molecule of MSH.  The mixed disulfide is 
attacked by the other active site thiol, reforming the disulfide and releasing the second 
molecule of MSH.  MR will not accept GSSG as a substrate.  The reduction of MSSM to 
free MSH is essential for the protection of the cell from oxidative stress and the unique 
structure of MSSM makes MR an attractive drug for the development of novel 
antituberculins.235 
The emergence of antibiotic resistant strains of TB represents a major challenge to 
the medical community.  The presence of MSH has been shown to influence the sensitivity 
of M. tuberculosis to rifampin, an important electrophilic antituberculin.223  In GSH-
utilizing organisms, GSTs catalyze the coupling of electrophilic xenobiotics to GSH and 
these S-conjugates are then metabolized for excretion from the cell, often as mercapturic 
acids.  Similarly, MSH is believed to form S-conjugates with rifampin223 and other 
electrophilic xenobiotics, which are then cleaved to release mercapturic acids and GlcN-
Ins.236  An MSH-S-transferase has yet to be identified in these organisms but the resultant 
MSH-S-conjugates are known to be cleaved by MSH-S-conjugate amidase (MCA).236  
MCA is a monomeric236 zinc metalloenzyme,237  with high specificity for S-conjugates of 
MSH and little selectivity for the structure of the conjugate.237  A sampling of known MCA 
substrates are shown in Figure 1.21.  MCA is believed to be common to most MSH-
utilizing organisms, especially those known to produce antibiotics.  Mercapturic acids have 
been found in the fermentation broths of the Streptomycetes bacteria which are known to 
produce a large number of antibiotics.238  In addition, genomic searches have returned 
homologous sequences in M. tuberculosis, M. avium, M. leprae, M. bovis,236  
C. glutamicum, Thermobifida fusca,237 S. coelicolor,237 238 Amycolatopsis mediterranei, 
Saccharoplyspora erythraea, Streptomyces lincolnensis, and Streptomyces rochei.238  
Mutants of  M. smegmatis deficient in MCA have been shown to be more susceptible to 
electrophilic toxins including the antibiotic streptomycin.239  Because MCA are not found 
in GSH-producing mammals, drugs inhibiting MCA may be less toxic than those for other 
drug targets.237  MCA may therefore be an important target for the development of novel 
drugs to combat drug resistant tuberculosis237 and the search of inhibitors of MCA is 
ongoing.240-245 
                                                 
** Also known as mycothione reductase 
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Figure 1.21: Selected substrates for mycothiol-S-conjugate amidase.  Structures 1-27 through 1-32 are 
mycothiol-S-conjugates of monobromobimane (1-27), cerulenin (1-28), acetophenone (1-29),  
N-ethylmaleimide (1-30), 7-(diethyl-amino)-3-(4′-maleimidylphenyl)-4-methylcoumarin (1-31), and   
3-(N-maleimidopropionyl)biocytin (1-32). 
   In addition to the removal of xenobiotics, the detoxification of toxic electrophiles 
produced as by-products of cellular processes is essential to cellular viability.  A number of 
metabolic and detoxification processes produce formaldehyde as a by-product, which must 
be removed due to its reactivity with proteins and nucleic acids.  Many GSH-utilizing 
organisms oxidize formaldehyde to formic acid using GD-FD and S-formylglutathione 
hydrolase.  In keeping with the parallel functions of MSH to GSH, an MD-formaldehyde 
dehydrogenase (MD-FD) has been identified in Amycolaptopsis methanolica, Rhodococcus 
erythropolis246 and M. smegmatis,247 which is the first step in the oxidation of 
formaldehyde to formic acid.  MD-FD is similar to GD-FD in that it requires NADH and 
appears to belong to the class III alchohol dehydrogenases as it has a similar subunit 
molecular mass,  is zinc dependent, and can oxidize higher aliphatic alcohols;246  MD-FD 
differs from GD-FD in that it appears to be a trimer.246  The residues typical of GSH 
binding are not present, which is consistent with the differences in structure between GSH 
and MSH,248 and MD-FD does not bind GSH, cysteine, or their derivatives.249  The 
conjugate of MSH and formaldehyde, S-hydroxymethylmycothiol, is likely the true 
substrate of MD-FD, forming S-formylmycothiol as the product.246  In GSH-utilizing 
organisms, the conversion of S-formylglutathione to formic acid is catalyzed by S-
formylmycothiol; however an S-formylmycothiol hydrolase has not been identified to date.   
 Further studies have shown that similar to GD-FD, MD-FD may be involved in the 
defence of Actinomycetales bacteria against nitrosative stress.247  RNS are an essential part 
of the defense of a host organism against pathogenic species.250  Therefore, the control of 
nitrosative stress is vital for the viability of pathogens like Mycobacteria.  Upon exposure 
to NO, or NO donors, long lived S-nitrosothiols form which can nitrosate proteinaceous 
thiol residues, disturbing their cellular function.247,251,252  Mycobacteria must therefore have 
a method for handling RNS and preventing nitrosative damage in order to survive the 
stresses placed upon it by the host organism’s defence response.  Studies of M. smegmatis 
have demonstrated that GSNO is metabolized to form GSSG and nitrate, with the 
involvement of MSH and MD-FD.247  MSH is believed to react with GSNO to form  
S-nitrosomycothiol (MSNO), a substrate for MD-FD.  MSNO is then reduced to an  
N-hydroxysulfenamide (MSNHOH) by MD-FD using NADH as a cofactor.  The remaining 
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steps in this pathway have not yet been fully elucidated; however, this new MD-FD activity 
presents a possible route for the detoxification of RNS in Mycobacteria.247  All of the 
MSH-utilizing enzymes thus far identified directly parallel GSH-utilizing enzymes in 
function.  It is therefore expected that many known GSH-utilizing enzymes have MSH 
counterparts in the Actinomycetales bacteria.  Because of the large differences in the 
structure of MSH and GSH, it is likely that these enzymes have very different criteria for 
substrate and cofactor binding and therefore are orthogonal in terms of selectivity.  This 
relationship may allow for the design and development of novel antimicrobials against the 
pathogenic Mycobacteria. 
1.5. Objectives 
 Intracellular thiols are essential components of biological systems as they are 
responsible for the control of redox homeostasis and can act as cofactors for a number of 
vital enzymes.  ESH and the OSHs have been shown to scavenge ROS in a biologically 
relevant manner and this behaviour has led to investigations into their use as novel 
therapeutics against disease states caused by oxidative stress.  We performed a detailed 
theoretical study, as described in Chapter 2, of the thermodynamics of several important 
reactions that ESH and the OSHs may undergo in the cell and determined the 
thermodynamic driving force of the instability of the ESSE disulfide, which, unlike other 
known thiols, is unstable under physiological conditions.  Our results should contribute to 
the further understanding of the fundamental chemistry and biochemistry of these 
important intracellular thiols 
 In addition to ESH and the OSHs, we investigated the behaviour of MSH, the major 
intracellular thiol of the Actinomycetales bacteria such as pathogenic M. tuberculosis.  Our 
investigations commenced with a theoretical study of the conformational preferences of 
MSH both in vacuo and with implicit water solvation as described in Chapter 3.  This 
information may aid in the design of substrate-based inhibitors aimed at MSH-utilizing 
enzymes.  The functions of known MSH-utilizing enzymes parallel those of the GSH-
utilizing enzymes in function.  With this in mind, we sought to determine if a MSH 
requiring glyoxalase system exists in the Actinomycetales bacteria (Chapter 4).  The 
identification of this enzyme system would increase the fundamental knowledge of MSH 
and would provide another target for the development of novel targets for the development 
of antimicrobials aimed at the pathogenic Mycobacteria. 
1.6. Other Interesting myo-Inositol Derivatives 
In addition to our studies of ESH, the OSHs, and MSH, we investigated the 
thermodynamics of phosphorylation reactions involving inositol pyrophosphates.  These 
myo-inositol-based species are believed to phosphorylate serine residues in eukaryotes 
without enzymatic assistance.  Because these compounds differ greatly from the main 
focus of this work, we have restricted all discussion of the inositol pyrophosphates to 
Chapter 5. 
1.7. Publications 
The research detailed in this thesis has resulted in four publications and one crystal 
structure deposition to the Cambridge Crystallographic Database:  
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Hand, C. E.; Taylor, N. J.; Honek, J. F. Ab initio studies of the properties of intracellular 
thiols ergothioneine and ovothiol. Bioorg. Med. Chem. Lett. 2005, 15, 1357-1360 
 
Hand, C. E.; Honek, J. F. Biological chemistry of naturally occurring thiols of microbial 
and marine origin. J. Nat. Prod. 2005, 68, 293-308 
 
Hand, C. E.; Auzanneau, F.-I.; Honek, J. F. Conformational analyses of mycothiol, a 
critical intracellular glycothiol in Mycobacteria. Carbohydr. Res. 2006, 341, 1164-1173 
 
Hand, C. E.; Honek, J. F. Phosphate transfer from inositol pyrophosphates InsP5PP and 
InsP4PP2: A semi-empirical investigation, Bioorg. Med. Chem. Lett. 2007, 7, 183-188 
 
Hand, C. E.; Taylor, N. J.; Honek, J. F. L-Ergothioneine, Cambridge Crystallographic 
Database. 2004, Deposition No. FOLRII. 
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Chapter 2: Modelling of Ergothioneine and Ovothiol 
 
 Unlike other biological thiols, the ergothioneine disulfide (ESSE) is not stable under 
physiological conditions and it has not been detected under conditions that are known to 
oxidize glutathione (GSH) to its disulfide (GSSG).1  It is likely that even if formed in vivo, 
ESSE would be quickly reduced to its free thiol form (ESH, Figure 2.1, 2-1) by the large 
concentrations of GSH and mycothiol (MSH) found in ESH-containing organisms.  ESH has 
been implicated in radical scavenging activities in vivo, and shows promise as a therapeutic 
agent against disease states caused by radical damage such as is found in Alzheimer’s 
disease.2  Studies have shown that during the scavenging of hydroxide radicals (HO•), ESSE 
may be formed transiently before being reduced to ESH.3  Despite the possible importance of 
the formation of ESSE, very little thermodynamic information exists regarding its instability.  
In addition, very little data is available regarding the thermodynamics of the known reactions 
of ESH with HO•3 and hydrogen peroxide (H2O2),3,4 as well as the possible cooperative 
relationship believed to exist between ESH and ascorbic acid in the protection of the cell 
from reactive oxygen species (ROS).5 With this in mind, we performed a detailed 
computational study of ESH and its possible reactions to determine the driving force behind 
the ESSE instability and the thermodynamic nature of some important detoxification events.   
In addition, we performed a detailed study of the related ovothiols (OSHs, Figure 2.1, 
2-2A-C) to determine if there is a thermodynamic basis for the differences in the reactivity 
between ESH and the OSHs.  These thiols differ in the placement of the sulfur atom on the 
imidazole ring and this difference alters the reactivity of OSH as compared to ESH, such that 
the OSH disulfide (OSSO) is stable under physiological conditions.6,7  The OSHs are 
currently under review as possible therapeutic agents in the prevention of oxidative damage6,8 
as their proposed role in sea urchin eggs is to scavenge the H2O2 produced during 














R1 = R2 = H (OSHA, 2-2A)
R1 = H, R2 = CH3 (OSHB, 2-2B)




Figure 2.1: Ergothioneine and the ovothiols.  
2.1. Computational Chemistry 
 Computational chemistry uses the results of theoretical chemistry to determine the 
structures and properties of molecules and molecular systems.9  A wide variety of properties 
can be described using these techniques including minimum energy and transition state 
structures, enthalpies, vibrational frequencies and spectroscopic properties.10  The results 
obtained from computational studies cannot be defined as exact values as even the use of 
quantum mechanics cannot give an exact result for a system more complicated than a 
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hydrogen atom.11  As such, all computational chemistry methods use approximations and the 
number and sophistication of the approximations determines the accuracy of the results.  
While these techniques do not give exact values, they can give useful information regarding 
trends and insight into systems which are difficult to study experimentally.   
 There are a variety of molecular modelling techniques available.  The ab initio 
molecular orbital calculations for example, are derived directly from quantum mechanical 
theory11 and include approximations that are usually mathematical in nature and do not 
incorporate experimental data.11  One of the most well-known ab initio techniques is the 
Hartree-Fock (HF) method, which builds the many-electron Schrödinger equation from 
many, simpler, one-electron equations.  Though computationally expensive, ab initio 
techniques give very good qualitative results.11  An alternative to the HF method is density 
functional theory (DFT) which uses the electron density, as opposed to the Schrödinger 
equation, to determine the energetics of the molecule.11  This method can give results for a 
wide variety of properties that are comparable or superior to ab initio calculations.9   
 While the HF and DFT methods are known to give very good results, they are 
computationally demanding with respect memory and time.  Other less rigorous methods 
have been developed, including the semi-empirical (see Chapter 5) and molecular mechanics 
(see Chapter 3) methods.  Semi-empirical methods take the same form as an HF calculation; 
however, they simplify the calculation by approximating or eliminating certain integrals.  
They do so by incorporating experimental data or values obtained from ab initio calculations 
as parameters to fit their data to model compounds.  While these approximations hasten the 
calculation, they reduce the accuracy as these results are dependent upon the system used to 
develop the parameter set.  Compared to the ab initio techniques, fewer properties can be 
predicted reliably using semi-empirical methods.11  The molecular mechanics methods use 
classical mechanics calculations to determine the properties of a system.  These calculations 
are parameterized and are more sensitive than semi-empirical methods to the system used to 
develop the parameter set.  While the semi-empirical and molecular mechanics methods are 
much less time consuming and are computationally less expensive than HF and DFT 
techniques, they are often less accurate.  These methods are very useful in the modelling of 
large or difficult systems where time and resource constraints are issues.11 
 Based upon the above considerations, we chose HF and DFT techniques for our study 
of ESH and OSH.  These molecules are relatively small and therefore the time and 
computational resource demands of the geometry optimizations would not be prohibitive and 
we desired the increased accuracy that these techniques would provide.   
2.1.1.  Hartree-Fock Methods 
The HF method is the most commonly used, purely ab initio technique and is based 
on quantum mechanical theory. One of the fundamental postulates of quantum mechanics 
describes electrons as waves whose behaviour can be defined by a wave function.  This wave 
function can describe the probability of the electrons’ locations but not their exact position.  
The HF method builds the wave function of a system from many simpler one-electron 
equations which can be solved to give one-electron wave functions.11  These one-electron 
equations are commonly called basis functions and a complete set of basis functions is called 
a basis set.  The accuracy of the basis set scales with the number of functions used to 
describe the system (see 2.1.2. Basis Functions and Sets). 
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The HF method is an approximate quantum mechanical method with the primary 
approximation being the omission of an explicit definition of electron-electron repulsion, also 
known as electron correlation.  This approximation is called the central field approximation 
and describes the behaviour of the electron in a net field of electrons giving an average effect 
of the electron-electron repulsion.  As a result, all energies calculated using the HF method 
will be greater than the actual energy of the system; the limit to how close the calculated 
energies can approach the actual energy of the system is termed the HF limit11  There are a 
number of methods available to correct for the lack of electron correlation, as in general, its 
inclusion improves the accuracy of the calculated energies and molecular geometries.  One 
popular method is the Møller-Plesset perturbation theory (MPn, where n indicates the level of 
theory), which uses perturbation theory to improve the results.  The MP method is attractive 
in that it is size-independent; however, it can give energies lower than the “true” energy of 
the system.9  The inclusion of electron correlation is not always necessary; in the case of 
organic molecules correlation is not generally required to obtain quantitative results.11  
Despite the HF limit, the energies calculated using HF methods can be very useful in 
calculating overall reaction thermodynamics.  If the bond types in the products and reactants 
of a reaction are essentially identical, it is expected that the bond-by-bond electron 
correlation energy errors would mostly cancel in the computed heat of reaction resulting in 
relatively accurate results.10  If comparing structures with similar bond types, the errors 
caused by a lack of electron correlation energy would also likely be reduced and the trends 
noted would therefore be valid.    
2.1.2. Basis Functions and Sets 
The choice of basis set is one of the largest determinants in the results obtained by HF 
and DFT calculations.  A minimal basis set uses only the number of functions required to 
account for all of the atomic orbitals in the system.  For example, in the case of hydrogen and 
helium, the basis set would include a single function to describe the 1s orbital, while the 
second row of the periodic table, lithium to neon would require five functions (the 1s, 2s, and 
three 2p orbitals) and third row, sodium to argon, would require nine functions.12  Minimal 
basis sets unfortunately have several failings, especially when dealing with atoms at the end 
of a period.  Atoms such as oxygen and fluorine are described using the same number of 
functions as atoms at the beginning of the period, even though they have more electrons.  
One solution to address the deficiencies of the minimal basis set is to increase the number of 
functions used to describe each orbital.9  The double-zeta (DZ) basis sets replace each basis 
function in the minimal basis set with two, while in the triple-zeta set (TZ) three basis 
functions are used to describe each of the orbitals.  Unfortunately, doubling or tripling the 
number of basis functions increases the computational demands of the calculations. As an 
alternative, the split valence method doubles the number of functions used to describe the 
valence electrons but uses a single function to describe the inner orbitals.  These core orbitals 
do not have a large effect on chemical properties and vary only slightly between molecules.9  
Split valence methods include the 6-31G and 6-311G basis sets.   
The split valence method does not solve all of the problems related to basis set 
accuracy.  The basis sets often use functions that are centered on the nucleus and therefore do 
not take into account the change in the shape of the electron cloud when an atom is part of a 
molecule.9  The performance of a basis set can be improved by the addition of polarization 
functions, which give more flexibility to the shape of the orbitals, often yielding more 
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accurate geometries and vibrational frequencies.11  The application of polarization functions 
to heavy atoms is indicated by “*”, and the further addition to helium and hydrogen atoms is 
indicated by “**”.  Even with the addition of polarization functions, these basis sets have 
difficulty describing atoms with lone pairs and anions, because both have a large amount of 
electron density distal from the nucleus.  The addition of diffuse functions aids in the 
description of the orbital far from the nucleus.9  These functions describe van der Waals and 
other long distance interactions,11 as well as account for the effects of lone pairs and anions.  
The addition of diffuse functions is denoted by “+” for heavy atoms and “++” for hydrogen. 
The accuracy of the calculation is dependent upon the basis set in use.  The better a 
basis set can describe the system, the closer the calculated energy will approach the HF limit 
for that system.  As can be seen in Table 2.1, as the basis sets becomes more complete, the 
calculated energy approaches the HF limit.12 
Table 2.1: As a basis set becomes more complete, the computed energies approach the HF limita,b 
Basis Set H2 N2 CH4 NH3 H2O 
4-31G -1.127 -108.754 -40.140 -56.102 -75.907 
6-31G* -1.127 -108.942 -40.195 -56.184 -76.011 
6-31G** -1.131 -108.942 -40.202 -56.195 -76.023 
HF limit -1.134 -108.997 -40.225 -56.225 -76.065 
aThe energies are expressed and were calculated using HF methods as multiples of the hartree, 
Eh=4.360 x 10-18J; bAdapted from Atkins and Friedman (2005).12 
2.1.3.  Density Functional Theory 
A popular alternative to HF methods is DFT which uses the electron density of a 
molecule to determine its energy.  The electron density is expressed as a linear combination 
of basis functions, similar to the HF calculations.11  A functional is a mathematical function 
applied to another function.12  Density functionals can be broken down into several classes 
and the functional used can affect the accuracy of the calculation.  In general, the two most 
accurate methods are the gradient-corrected functionals, which use the electron density and 
its gradient, and the hybrid method which combines functionals from other methods with 
aspects of the HF method to determine the energy of a system.11  A commonly used 
functional is the B3LYP13-15 hybrid functional which has been shown to yield accurate results 
for a wide range of molecules, particularly organic molecules.11 
The accuracy of the DFT methods has been shown to depend on the basis set and 
density functional chosen.  The results obtained from DFT calculations can match and even 
surpass the accuracy of HF calculations in some cases.  In addition, DFT techniques are often 
less time consuming and require less computational resources.11  These factors, combined 
with the inclusion of electron correlation, make DFT techniques an attractive alternative to 
HF methods for determining the energy of a system. 
2.1.4.  Energy Minimization or Geometry Optimization 
The potential energy of a molecule is a function of the coordinates of its atoms.  The 
way in which this energy changes with respect to changes in the molecular geometry defines 
a potential energy surface.  These surfaces are multi-dimensional for all but the simplest of 
molecules; therefore, they are impossible to visualize except in cases where the changes in 
energy are a result of modifications to only one or two coordinates, such as a rotation around 
one or two torsional angles, as seen in Figure 2.2. The peaks of a potential energy surface 
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indicate transition structures while the valleys correspond to minimum energy structures.  
Multiple minima can exist on a surface with the very lowest energy point being the global 
energy minimum.  All other minimum energy points are termed local energy minima.  Any 












Figure 2.2: Potential energy surface for o-methoxy-phenol observed  for the simultaneous rotation of the 
torsional angles of the hydroxyl and methoxy groups.16 
To identify minimum energy structures, and therefore optimize a molecule’s 
geometry, the coordinates of the atoms are gradually changed to produce configurations with 
lower and lower energies until a minimum is reached.  Most minimization methods move 
down the potential energy surface and therefore find minima that are nearest to the starting 
structure (Figure 2.3).9  To find multiple local minima, or to ensure that the global minimum 
energy structure was found, multiple starting structures must be generated and minimized.  
There are a variety of methods available to generate these starting structures and they are 
more thoroughly discussed in Chapter 3.  These methods include molecular dynamics, which 
follows the time dependent behaviour of a system, dihedral angle driving, which rotates one 
or more torsional angles through a defined rotation, and the Monte Carlo methods, which 
randomly alter torsional angles within a molecule to generate new structures.  
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Figure 2.3: A schematic one-dimensional energy surface.   Most minimization algorithms move downhill in 
energy towards the lowest energy structure.  “A” would move towards the global energy minimum while “B” 
and “C” move towards a local energy minimum.  Adapted from Leach.9 
2.1.5. Gas Phase versus Solvation Modelling 
The geometries and energies obtained during minimization will be more accurate if 
the structures are optimized in the phase in which they are normally found and studied.  For 
example, to determine the behaviour of a molecule under physiological conditions, it is 
important to include water solvation.  Calculations performed in vacuo treat the molecule as 
an isolated system and may not yield an accurate representation of the molecule’s behaviour 
in solution.  This discrepancy is especially great when the molecule of interest contains 
highly polar or charged functional groups.  The omission of solvation can exaggerate the 
importance of intramolecular interactions, resulting in a closed, folded structure that may not 
exist in solution.  Water and other polar solvents can provide electrostatic shielding and 
competing hydrogen bonding interactions, resulting in a very different conformation than that 
observed in the gas phase.17   
Solvation can also have a dramatic effect on reaction thermodynamics as it can 
change the stability of the reactants and products, altering equilibria.  For example, the 
equilibrium of the tautomers of 4-hydroxypyridine and 4-pyridone (Figure 2.4) is 
dramatically affected by solvation as the pyridone is stabilized by high polarity solvents.  
Experimental data indicates that the equilibrium is dramatically shifted towards the pyridone 
in water as compared to the gas phase (Kvapour = <1/10 vs. Kaq. = 2000/1).10,18  As 
demonstrated by this example, it is essential to perform thermodynamic calculations in the 
phase in which the reactions would occur to account for increased stabilization that the 







Figure 2.4: The equilibrium between 4-hydroxypyridine and 4-pyridone. 
Multiple methods are available for the inclusion of solvation in molecular modelling.  
The most accurate method, explicit solvation, defines all of the solvent molecules involved in 
each solvation sphere individually to account for all possible hydrogen bonding and 
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intermolecular interactions which may affect the solute.  The number of solvent molecules 
that must be defined increases exponentially with each solvation sphere included.  The 
biggest disadvantage to this method is the large amount of computational resources and time 
required to complete such a calculation.  Few researchers have access to the resources 
required to model such a system in a reasonable amount of time.10    
To reduce the computational demands of solvation modelling implicit solvation 
methods were developed which treat the solvent as a continuum which surrounds the solute 
with a given dielectric (Figure 2.5). The main assumption of implicit solvation is that it is 
reasonable to remove the individual water molecules from the model as long as the space 
around the solute is modified to have properties consistent with those of the solvent.10  While 
implicit solvation cannot account for specific hydrogen bonding interactions, it can provide 
electrostatic shielding to minimize the over-emphasis on certain intramolecular interactions.    
Due to the savings in computational resources and time involved, as well as the complexity 
of predicting the location of any explicitly defined solvent molecules, implicit methods are 




Figure 2.5: Schematic of the treatment of a solute in a liquid by the implicit water solvation Polarized 
Continuum Model (PCM).  The solute cavity is defined as the union of a series of interlocking atomic spheres 
within a continuum of a uniform dielectric constant (ε).  Adapted from Foresman and Frisch.19  
2.1.6.  Zero Point Energy Correction 
The energy determined during a geometry optimization is a minimum on the potential 
energy curve; however, it does not include the inherent vibrational energy of the system.  
Even at absolute 0 K, a molecule will have some vibrational energy, otherwise both its 
kinetic and potential energies would equal zero and the particle would always be at the 
origin, violating the Heisenberg uncertainty principle.*  The lowest vibrational mode a 
system can have, V = 0, is a non-zero value (Figure 2.6) termed the zero-point energy (ZPE).  
Many modelling programs calculate a ZPE correction which is then added to the total energy 
of the optimized structure.  The ZPE for a single vibrational mode is quite small; however 
medium or large sized molecules can have multiple vibrational modes resulting in a 
substantial overall ZPE.  In the case of 1,3-butadiene, there are 24 vibrational modes yielding 
a ZPE of ~ 50 kcal/mol, a significant contribution to the overall energy of the molecule.  This 
                                                 
* ΔxΔpx ≥ ½ (h/2π), where x is a particle’s x coordinate, Δpx is the measure of the uncertainty of x and h is 
Planck’s constant (= 6.62608 x 10-34 J s). 
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correction is therefore essential for the accurate comparison of the energetics of 










Figure 2.6: Vibrational modes of a system, where PE is the potential energy and x is the average distance 
between the nuclei involved in the vibration.  The difference between the minimum energy and the V = 0 level 
is the zero-point energy correction. 
2.1.7. Vibrational Frequencies 
To determine the legitimacy of a structure obtained through geometry optimization, 
the various vibrational frequencies of the resultant conformation are often calculated.  If all 
of the vibrational frequencies are positive, the structure is likely a minimum energy 
conformation.  This conformation may not be the global minimum structure, but rather a 
local minimum between two or more low energy structures.  If there are negative or 
imaginary frequencies returned, the structure is possibly a transition structure and is not a 
minimum structure.10   
2.1.8. Plan of Action 
With the above considerations in mind, we undertook a detailed study of the 
thermodynamics of select biologically relevant reactions involving ESH and the OSHs.  We 
wished to determine which combination of modelling method (HF or DFT) and basis set was 
best suited for studying ESH; therefore, we obtained a crystal structure of ESH to use both as 
a starting structure and as a benchmark for the accuracy of the modelling methods.  We then 
performed geometry optimizations on ESH using either HF or DFT methods with a wide 
variety of basis sets either in vacuo or with implicit water solvation.  The resultant minimum 
energy structures were compared to the crystal structure to determine which method and 
basis set combination gave the most accurate results.  This combination was then used for all 
other calculations performed in this study.  The calculated heats of formation were then used 
to determine the thermodynamics of a selection of the possible detoxification reactions of 
ESH and the OSHs. 
2.2. Materials and Methods 
ESH dihydrate was used as obtained from Sigma-Aldrich. For crystallization, Milli-Q 
quality water and HPLC grade ethanol (Fisher Scientific, Ottawa, ON) were used.  
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Preliminary calculations were performed using Jaguar 5.0 R.22 with structures drawn and 
visualized using Maestro 5.1, both of Schrödinger Inc. (Portland, OR).  Detailed electronic 
structure calculations were performed using Gaussian 03, Revision B.0521 (Gaussian Inc. 
Wallingford, CT) with structures drawn and visualized in GaussView 3.09 (Gaussian Inc.).  
All calculations were run on either a Silicon Graphics Inc. (SGI, Mountain View, CA) O2 
workstation (Violin) or Flexor, the University of Waterloo’s multi-CPU SGI Origin 3800 
system.  Violin uses a MIPS R10000 processor chip, a MIPS R10010 floating point chip and 
a 195 MHz IP32 processor and has 750 MB of RAM.  Violin runs the IRIX 3.5X operating 
system.  Flexor consists of forty 400 MHz MIPS R12000 CPUs and twelve 500 MHz MIPS 
R14000 CPUs with 52 GB of RAM.  The home and scratch directories reside on nine 36 GB 
fibre-channel disks in a RAID-5 configuration which is controlled by a TP9100 disk array 
with a 1 Gb hardware RAID controller.  Third party software resides on a 36 GB fibre-
channel disk outside of the RAID-5.  Network connections include a 10/100 MB interface 
and a fibre-optic Gigabit Ethernet interface.  Flexor runs the 64-bit IRIX 6.5.27f operating 
system. 
2.2.1. Crystal Structure of Ergothioneine 
 ESH dihydrate was dissolved in a minimal amount of water and ethanol was added 
drop-wise until the solution became cloudy.  This was allowed to sit at room temperature 
until crystals formed.  The crystal was coated with a perfluoropolyether oil and frozen onto a 
glass fibre.  The X-ray diffraction data was collected, and the structure solved by  
Dr. Nicholas J. Taylor of the University of Waterloo Chemistry Department.  Data was 
collected on a Bruker Apex diffractometer at 150(1) K from a crystal with a size of 
0.30{100} x 0.15{011} mm; from 9536 reflections with 2.19 < θ < 35.48 collected and 4649 
unmerged Friedels were used for structure analysis.  The radiation source was a fine focus 
sealed tube, λ = 0.71073 Å and the radiation type was MoKα.  Data was collected using 
SMART, the integration was performed using SAINT and the structure refinement was 
performed by and the graphics were prepared using SHELXTL, all of Bruker AXS 
(Karlsruhe, Germany) and all run on an NT4 system.  Final R indices for all data were R1 = 
0.0438 and wR2 = 0.0731, the refinement was based on the wR(F2) and the goodness of fit 
was 1.792.  The absorption correction used face-indexed analytical integration with  
0.928 < T < 0.962.  The protons were found and freely refined isotropically.  The absolute 
configuration was determined by refinement of the Flack parameter.22  The coordinates were 
deposited in the Cambridge Crystallographic Database, deposition FOLRII. 
2.2.2. Determination of Appropriate Basis Set 
 A series of geometry optimizations of ESH were performed using the crystal structure 
as a starting conformation.  The coordinates were imported into Maestro as a pdb file and the 
geometry was optimized by Jaguar using HF and DFT methods with the 3-21G,23-25 6-31G,26-
31 6-311G,32-35 cc-pVDZ36-38 and cc-pVTZ(-f)36-38 basis sets with the presence and absence of 
additional diffuse and polarization functions.†  The DFT calculations used the B3LYP 
functional,13-15,39-42 These calculations were performed both in vacuo and with the implicit 
water solvation model developed by Schrödinger Inc. for use with Jaguar.  Vibrational 
                                                 
† In the case of 3-21G, polarization is only applied to the sulfur atom, in all other cases it is applied to all atoms 
of ESH.  The cc-PVDZ and cc-PVTZ(-f) basis sets incorporate polarization and therefore calculations cannot be 
performed in the absence of polarization.   
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frequencies were calculated for all optimized structures; those that returned imaginary 
frequencies were discarded.  In some cases, a minimum energy structure could not be 
obtained for a particular method and basis set combination.  An optimized structure obtained 
using the same method but a simpler basis set was therefore used as a starting structure for 
the calculation.  An optimization was also performed using DFT with the  B3PW9113,39,43,44 
functional at the cc-PVTZ(-f) level both in vacuo and with implicit solvation to compare to 
the results of B3LYP.  The bond distances and internal angles of the imidazole ring were 
used to compare the geometry optimized structures to the ESH crystal structure to determine 
the minimum basis set required for accurate geometry prediction. 
2.2.3. Detailed Electronic Structural Calculations 
All structures were drawn and visualized in GaussView and all optimizations were 
performed in vacuo and with the IEF-PCM implicit solvation model45-47 at the 
B3LYP14,15,40,42/6-311G34,35,48-54 level with the addition of polarization and diffuse functions‡ 
as implemented by Gaussian 03 (Gaussian Inc.).  ESH was modelled using 2-thiol-4-methyl-
imidazole (TMI, see Results and Discussion) in the various protonation states available to its 
thione, thiol, thiolate, thiyl radical and disulfide (TMI-S)2 (Figure 2.7, (2-3) through (2-13)).  

















































































Figure 2.7: Structures of ergothioneine and 2-thiol-4-methyl-imidazole and its disulfide. 
The OSHs were modelled by 4-thiol-N1-methyl-5-methyl-imidazole (TMMI, see 
Results and Discussion) as a thiol, thiolate, zwitterion, thiyl radical and disulfide (TMMI-S)2 
(Figure 2.8, (2-14) through (2-18)).  Calculations were also performed on OSHA as a 
comparison (Figure 2.1, (2-2A)).  
                                                 
‡ Denoted by 6-311++G(d,p) in Gaussian 03 notation (Frisch et al. (2003))  
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Figure 2.8: Structures of OSHA and 4-thiol-N1-methyl-5-methyl-imidazole used for modelling the OSH. 
Certain biologically relevant molecules, such as H2O2 and HO•, were studied to 
examine the thermodynamics of possible detoxification reactions involving ESH and the 
OSHs.  GSH and its disulfide (GSSG) were modelled as methyl mercaptan and dimethyl 
disulfide (Figure 2.9, (2-19) through (2-22)), and ascorbic acid was modelled as 2-23 and  
2-24 (Figure 2.9).  To compare TMI and TMMI to standard aromatic thiols, thiophenol and 
diphenyl disulfide (Figure 2.9, (2-25) and (2-26)) were also modelled.   
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Figure 2.9: Miscellaneous compounds used to model biologically relevant reactions. 
2.2.4. Free Energy of Reaction Calculations 
 To determine the thermodynamics of a number of biologically relevant oxidation and 
reduction reactions, the sum of the thermal and electronic energies (ZPE corrected) were 
taken as ΔG° for each compound.  
2.3. Results and Discussion 
 ESH is an important molecule in biological systems; however, there is very little 
known regarding the thermodynamics of the instability of its disulfide and the detoxification 
actions it is believed to perform.  The placement of the sulfur atom on the imidazole ring of 
ESH differs from that of the OSHs, which is believed to lead to the difference in the stability 
of the two disulfides under physiological conditions.  Both ESH and the OSHs have been 
suggested as therapeutic agents against the damage caused by oxidative stress.  Our 
theoretical study into the thermodynamics of these compounds gives insight into the driving 
forces behind the differences in reactivity and the ability of these thiols to scavenge reactive 
oxygen species. 
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2.3.1. The Use of a Crystal Structure as a Starting Point for Optimization and a Potential 
Benchmark for Accuracy 
 Geometry optimizations usually move down the potential energy surface towards a 
minimum; therefore, the minimum energy structure determined somewhat resembles the 
starting structure.9  The choice of the starting structure determines which local minimum 
energy structure is found by the minimization algorithm.  As a starting point for our 
optimizations, we felt that the use of a crystal structure of ESH would be most appropriate as 
it would act as a pre-minimization, and might give a better orientation for the less rigid 
amino acid portion of ESH.  In addition, we felt that using the crystal structure as a starting 
point might result in more accurate final geometries. 
 To evaluate the quality of the calculated geometries we used the crystal structure as a 
comparison point for the bond lengths, bond angles and torsional angles determined.  This is 
a commonly used practice in the literature for determining the accuracy of the minimization 
method.55-59  While a crystal structure of ESH had been previously determined by Sugihara et 
al.,60 it included water molecules which, because of our use of implicit solvation, could not 
be included in our calculations.  In addition, this crystal structure did not determine the 
absolute configuration of ESH.  We therefore obtained a crystal structure which excluded 
water molecules and used this as our starting geometry and as a comparison for the accuracy 
of our calculated geometries. 
2.3.2. Crystal Structure Determination of Ergothioneine 
 The crystals were grown optimally in water/ethanol and were orthorhombic and 
colourless and belong to the space group P212121.  The unit cell had the dimensions of           
a = 6.0885(2) Å, b = 12.4212(5) Å and c = 13.9867(6) Å, a volume of 1057.76(7) Å3 and      
Z = 4.  The C2-S bond length was determined to be 1.69 Å, intermediate to the C2-S single 
and double bond lengths of 1.82 and 1.56 Å respectively, which is consistent with a 
substantial contribution of the thione form to the tautomeric equilibrium (Table 2.2).  This 
result is in agreement with the Raman and 13C-NMR spectral data which indicate that ESH 
exists predominantly as the thione under physiological conditions.61  In addition, our crystal 
structure is in very good agreement with a previously published structure obtained for ESH 
crystals grown from water60 (Table 2.2 through Table 2.7).  All other crystallographic data 
can be found in Appendix 1 
Table 2.2: Bond lengths (in Å) observed in the crystal structures of ESH, part A. 
Conditions C2-S N1-C2 C2-N3 N1-C5 N3-C4 C4-C5 C4-C6 C6-C7 
Water/Ethanola 1.69 1.35 1.35 1.38 1.39 1.35 1.50 1.52 
Water onlyb 1.69 1.35 1.35 1.38 1.38 1.35 1.49 1.53 
athis work; bSugihara et al.60 
 
Table 2.3: Bond lengths (in Å) observed in the crystal structures of ESH, part B. 
Conditions C7-N11 C7-C8 C8-C10 C8-O9 N11-C12 N11-C13 N11-C14 
Water/Ethanola 1.54 1.55 1.25 1.25 1.50 1.50 1.51 
Water onlyb 1.54 1.56 1.23 1.26 1.51 1.49 1.50 
athis work; bSugihara et al.60 
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Water/Ethanola 126.6 127.9 110.4 110.3 105.6 106.5 123.7 107.2 123.7 129.8 112.4 
Water onlyb 128.0 126.6 110.3 110.8 105.4 107.1 121.9 106.4 121.9  109.7 
athis work; bSugihara et al.60 
 





















Water/Ethanola 111.4 110.8 115.5 116.3 109.7 108.6 113.4 108.0 108.4 108.7 
Water onlyb 109.9 112.2 115.9 118.0 108.9 109.5 111.5 109.6 108.8 108.4 
athis work; bSugihara et al.60 
 























Water/Ethanola -177.9  178.3 -0.9 0.5 0.1 84.6  176.5 -176.7 -98.7 55.9  179.9 
Water onlyb -179.7 -179.7 -1.0 0.8 0.1 79.7 -179.0  178.5 -97.7 67.4 -168.6 
athis work; bSugihara et al.60 
 





















Water/Ethanola 50.1 -128.6 70.4 -171.0 -50.9 -165.3 -46.7 73.4 107.5 -73.8 
Water onlyb 46.4 -132.4 69.3 -172.3 -50.8 -167.3 -48.9 72.6 102.9 -78.3 
athis work; bSugihara et al.60 
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A packing diagram of the ESH crystal (Figure 2.10) indicates that each oxygen atom 
of the carboxylate moiety forms a hydrogen bond to the N-H of the imidazole ring of an 
adjacent ESH.  Each ESH molecule is therefore involved in four hydrogen bonds: one for 
each N-H and one for each carboxylate oxygen.  The sulfur atom is found packed in close 
proximity to the methyl groups of the quaternary ammonium group and does not appear to 
interact in any hydrogen bonding arrangement.     
 
 
Figure 2.10: Crystal packing diagram of ergothioneine crystals grown from water/ethanol. The carboxyl 
oxygens (red) hydrogen bond to an adjacent N-H (blue) from the imidazole ring while the sulfur atom is packed 
in close proximity to the methyl groups of the quaternary ammonium group (orange). 
2.3.3. Determination of Appropriate Basis Set 
 As mentioned, the geometries produced by minimization methods are often compared 
to crystal structure data to confirm the accuracy of the computed structure.55-57,59  To 
determine which method and basis set combination was best suited for the modelling of ESH 
and the OSHs, the optimized structures of ESH obtained from the HF and DFT calculations 
were compared to the crystal structure.§  A comparison of the DFT and HF methods using 
implicit water solvation indicated that the DFT calculations yielded structures in better 
agreement to the crystal structure (see Appendix 1).  A comparison of the implicitly solvated 
structures found using the B3LYP and B3PW91 functionals were very similar, with the 
B3LYP functional yielding results that were slightly closer to the crystal structure (Table 2.8, 
                                                 
§ All comparisons were performed using the crystal structure determined in this work. 
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Table 2.9, and Appendix 1).  The B3LYP functional was therefore used for all further 
calculations.  The addition of polarization functions to the basis set was important to obtain 
the correct C-S bond length as the absence of polarization functions resulted in a longer 
bond.  The inclusion of diffuse functions did not have a large effect on the computed 
structures (see Table 2.8, Table 2.9 and Appendix 1).  Diffuse functions will be important for 
later modelling the thiolate moieties of ESH and the OSHs as they improve the description of 
the wavefunction of anionic species (see 2.1.2. Basis Sets and Functions for more details). 
   
Table 2.8: Bond lengths (in Å) returned after the geometry optimization of the ergothioneine crystal structure 
using DFT methods with implicit solvation.a 
Basis set ** ++ C2-S N1-C2 C2-N3 N1-C5 N3-C4 C4-C5 C4-C6 
B3LYP          
6-31G ** ++ 1.71 1.36 1.36 1.39 1.39 1.36 1.50 
 ** None 1.71 1.36 1.36 1.39 1.39 1.36 1.50 
 None None 1.75 1.36 1.36 1.40 1.40 1.37 1.50 
6-311G ** ++b 1.70 1.35 1.35 1.38 1.39 1.36 1.50 
 ** Nonec 1.71 1.35 1.35 1.40 1.40 1.37 1.50 
 None None 1.75 1.36 1.36 1.39 1.40 1.36 1.50 
cc-pVDZ Incl. ++ NDd ND ND ND ND ND ND 
 Incl. None 1.70 1.35 1.36 1.38 1.39 1.36 1.49 
cc-pVTZ(-f) Incl. ++ 1.70 1.35 1.35 1.38 1.39 1.35 1.49 
 Incl. None 1.71 1.35 1.35 1.38 1.40 1.36 1.49 
B3PW91          
cc-pVTZ(-f) Incl. ++ 1.70 1.35 1.35 1.38 1.39 1.35 1.49 
Crystala -- -- 1.69 1.35 1.35 1.38 1.39 1.35 1.50 
aThe crystal structure obtained in this work was used as the starting structure and the implicit solvation was 
applied as implemented by Jaguar; bThe optimized structure obtained using HF/6-311++G** methods and 
implicit water solvation was used as the starting structure; cThe optimized structure obtained using HF/6-
311G** methods and implicit water solvation was used as the starting structure; dNot determined due to 
difficulties in convergence. 
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Table 2.9: Bond angles (in degrees) returned after the geometry optimization of the ergothioneine crystal structure using DFT methods with implicit water 
solvation.a 
Basis set ** ++ S-C2-N1 S-C2-N3 C2-N3-C4 C2-N1-C5 N1-C2-N3 N3-C4-C5 N1-C5-C4 N3-C4-C6 
B3LYP           
6-31G ** ++ 127.57 127.18 111.06 110.61 105.24 105.88 107.20 123.14 
 ** None 127.68 127.30 111.24 110.77 105.02 105.80 107.18 122.50 
 None None 127.42 127.33 110.98 110.68 105.25 105..88 107.21 122.81 
6-311G ** ++b 127.15 127.46 110.96 110.57 105.36 105.86 107.23 123.04 
 ** Nonec 127.22 127.38 110.95 110.58 105.39 105.93 107.14 122.76 
 None None 127.22 127.29 110.77 110.55 105.49 106.02 107.17 123.13 
cc-pVDZ Incl. ++ NDd ND ND ND ND ND ND ND 
 Incl. None 127.62 127.39 111.21 110.76 104.99 105.74 107.30 122.87 
cc-pVTZ(-f) Incl. ++ 127.67 126.98 110.89 110.48 105.36 106.00 107.27 123.12 
 Incl. None 127.68 127.15 111.02 110.67 105.17 105.93 107.22 122.56 
B3PW91           
cc-pVTZ(-f) Incl. None 128.81 127.97 111.92 111.71 103.21 105.94 107.21 123.25 
Crystala -- -- 126.55 127.89 110.41 110.34 105.55 106.48 107.22 123.71 
aThe crystal structure obtained in this work was used as the starting structure and the implicit solvation was applied as implemented by Jaguar; bThe optimized 
structure obtained using HF/6-311++G** methods and implicit water solvation was used as the starting structure; cThe optimized structure obtained using HF/6-
311G** methods and implicit water solvation was used as the starting structure.; dOptimization using this basis set was not successful. 
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Once polarization and diffuse functions were included, all four basis sets produced 
results in fairly good agreement with the crystal structure for the bond lengths and angles of 
ESH.  When the examination was expanded to include the dihedral angles of ESH found with 
implicit solvation, it was noted that the cc-pVTZ(-f) and 6-311++G** basis sets returned 
geometries which were in better agreement with the ESH crystal structure (Table 2.10). 
Table 2.10: Selected dihedral angles (in degrees) returned after the geometry optimization of the ergothioneine 
crystal structure using DFT methods with implicit water solvation.a 
Basis set ** ++ C5-C4-C6-C7 C4-C6-C7-N11 
B3LYP     
6-31G ** ++ -101.0 178.0 
 ** None -80.3 -174.9 
 None None -83.7 -176.6 
6-311G ** ++b -85.0 179.8 
 ** Nonec -79.5 -177.0 
 None None -101.5 175.4 
cc-pVDZ Incl. ++ NDd ND 
 Incl. None -93.8 -179.6 
cc-pVTZ(-f) Incl. ++ -101.0 176.2 
 Incl None -92.6 -173.3 
Crystala -- -- -98.7 179.9 
aThe crystal structure obtained in this work was used as the starting structure and implicit solvation was applied 
as implemented by Jaguar; bThe optimized structure obtained using HF/6-311++G** methods and implicit 
water solvation was used as the starting structure; cThe optimized structure obtained using HF/6-311G** 
methods and implicit water solvation was used as the starting structure; dOptimization using this basis set was 
not successful. 
While the cc-PVTZ(-f) basis set gave results which were closer to the crystal 
structure than the 6-311++G** basis set, it uses more basis functions in its calculations 
(Table 2.11).  An increase in the number of basis functions exponentially increases the time 
and computational resources required for the calculations.11  These effects are clearly 
demonstrated by the time required to complete a geometry optimization of phenol (Table 
2.12).  It was felt that the slight increase in accuracy obtained by the use of the cc-pVTZ(-f) 
basis set did not warrent the increased time and computational demands caused by the larger 
number of basis functions.  It was concluded that given the large number of calculations to be 
performed, the B3LYP/6-311++G** combination gave adequate accuracy with an acceptable 
use of time and computational resources and hence was used for all subsequent calculations. 
The reactions in which we are interested occur under physiological conditions and are 
therefore in an aqueous environment.  As demonstrated by the equilibrium of  
4-hydroxypyridine and 4-pyridone (see Section 2.1.5. Gas Phase versus Solvation 
Modelling), the effect of solvation on polar compounds can alter the stability of reactants and 
products, affecting the overall thermodynamics of reactions and equilibria.  To exclude 
solvation in our study would likely invalidate our results due to the polarity of the 
compounds involved.  All further discussion therefore focuses on the results obtained using 
implicit solvation, as implemented by Jaguar.  Gas phase results can be found in Appendix 1. 
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Table 2.11: The number of functions in each basis set for the geometry optimization of ergothioneine using the 
crystal structure as the starting conformation. 
Number of Functions Basis Set 
Alonea **b **++b,c 
3-21Gd 169 175 250 
6-31G 169 304 379 
6-311G 248 368 443 
cc-pVDZ --e 289 484 
cc-pVTZ(-f) --e 484 679 
aNo polarization or diffuse functions; bwith polarization; cwith diffuse functions; dpolarization is only applied to 
the sulfur atom; epolarization is included in these basis sets. 
 
Table 2.12: The number of functions in each basis set and time required for the geometry optimization of 
phenol.a 
Basis Set Time Required 
6-311++G** 1790 s 
cc-pVTZ(-f)++ 6196 s 
aPerformed using DFT methods and the B3LYP functional with implicit solvation as implemented by Jaguar. 
2.3.4. Use of Truncated Analogues 
 The structures of ESH and the OSHs can be divided into the amino acid backbone 
and the thioimidazole side chain.  Studies have shown that the amino acid portion of ESH 
does not affect its biological activity as 2-thiol-imidazole behaves in the same manner.5  
Similarly, the OSHs are often studied using truncated analogues.8,62-64  Based upon this 
precedence, we used truncated versions of ESH and the OSHs in our studies.  ESH was 
represented by TMI and the OSHs by TMMI.  The use of these simpler structures decreases 
the number of degrees of freedom available to these compounds, simplifying the calculation, 
and ensures that the energies determined are related to the reactive portion of the molecule 
and not to the rather floppy backbone. In addition, the use of TMMI eliminates any confusion 
caused by the variation in methylation of the amino group of the OSHs (see Figure 2.1). 
2.3.5. Modelling 2-Thiol-4-Methyl-Imidazole and its Disulfide 
ESH and by extension, TMI, can exist in multiple protonation states, with the 
ESHthione being observed under physiological conditions. To obtain a complete picture of the 
stability of ESH, four structures of TMI (Figure 2.11) were modelled.  TMIthione (2-3) and its 
charge separated resonance structure (2-6) were found to be the most thermodynamically 
stable forms of TMI, and were closer in structure to the crystal and geometry optimized 
structures of ESH (Table 2.13).  The results found for 2-3 and 2-6 were essentially identical, 
which is expected as ab initio calculations would treat them as the same structure.  During an 
ab initio calculation, the overall charge is not localized to a specific atom but is applied to the 
whole molecule.  The tautomeric forms 2-4 and 2-5 do not yield identical results due to the 
difference in protonation which slightly alters the calculated bond angles and bond lengths.   
 
  
























2-3                    2-4 2-5 2-6  
Figure 2.11: To simplify the calculations of ergothioneine, the amino acid portion was omitted leaving the ESH 
analogue 2-thiol-4-methyl-imidazole.  Structures 2-3 and 2-6 are resonance structures, which would be in 
equilibrium with their tautomers 2-4 and 2-5. 
Table 2.13: Calculated energies, bond lengths and angles of 2-thiol-4-methyl-imidazole, its tautomers and 
ergothioneine. 
Tautomer Energy (kcal/mol) ΔE (kcal/mol)a N1-C2-N3b N1-C2 C2-N3 C2-S 
ESH crystalc -- -- 105.5 1.38 1.39 1.69 
ESHd -668261.72 -- 104.7 1.36 1.40 1.68 
2-3 -416545.39 + 00.02 104.7 1.35 1.36 1.71 
2-4 -416532.12 + 13.27 111.8 1.36 1.32 1.77 
2-5 -416531.86 + 13.27 110.0 1.32 1.37 1.77 
2-6 -416545.41 0 104.7 1.35 1.36 1.71 
aEnergy difference between the lowest energy structure (2-6) and the other form studied; bthe angles in °, bond 
lengths in Å;  cCrystal structure determined in this work; dGeometry optimized structure. 
 
 The disulfide of ESH, and by extension TMI, can exist in multiple protonation states 
(Figure 2.12).  Regardless of the protonation state, ESSE is unstable under physiological 
conditions1 and ESH is not oxidized by conditions that readily oxidize GSH.1  ESSE has been 
observed as a transient intermediate in redox reactions in vitro and may occur in vivo but is 
decomposed too quickly to be seen.3  This decomposition may be caused by endogenous 
levels of GSH or mycothiol, which are found in ESH containing organisms.  GSH is more 
easily oxidized than ESH and may act as a reducing agent for ESSE.  To determine the 
thermodynamic driving force behind this instability the thermodynamics of the three  
(TMI-S)2 tautomers (Figure 2.12, (2-11 through 2-13)) and their reduction by 
























2-11                                                2-12                                                  2-13  
Figure 2.12: The tautomers.of the disulfide of 2-thiol-4-methyl-imidazole 
The optimized structures of TMI disulfides 2-11 and 2-12 differed in free energy by 
only 0.05 kcal/mol (Table 2.14).  The bond lengths and angles of these disulfides were closer 
to those determined for the thiol form of TMI rather than that of the thione (see Appendix 1).  
Unfortunately, the optimization of the goemtery of the TMI disulfide 2-13 was not successful 
and this structure is omitted from any further discussion. 
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Table 2.14: Energies and selected bond lengths and angles for the tautomers of the disulfide of 2-thiol-4-
methyl-imidazole. 
Ring A/Ring B 
Form Energya N1-C2-N3b N1-C2c C2-N3 C2-S S-S 
CA2-SA- 
SB-CB2 
2-11 -832299.34 111.8/110.9 1.36/1.36 1.32/1.76 1.77/1.76 2.15 83.8 
2-12 NDd ND ND ND ND ND ND 
2-13 -832299.29 111.7/110.9 1.36/1.33 1.32/1.36 1.77/1.76 2.15 -84.0 
aEnergy in kcal/mol; bAngles in °; cBond lengths in Å; dND = not determined. 
 
The reduction of ESSE by GSH is predicted to be favourable based upon the 
oxidation potentials of both compounds: ESH: Eo' = -0.06V65 and GSH: Eo' = -0.25 V.66  The 
thermodynamics of the reduction to ESHthione were estimated using (TMI-S)2 and methyl 
mercaptan, as shown in Eq. 2.1. 
 
 (TMI-S)2  + 2 CH3SH → 2 TMIthione + H3CSSCH3 Eq. 2.1 
 
This reaction was favourable (Table 2.15), indicating that the reduction of ESSE by GSH is 
likely thermodynamically favourable.  Interestingly, the free energy released by the reduction 
of (TMI-S)2 to TMIthione is much greater than the energy released by the reduction of diphenyl 
disulfide (Table 2.15), indicating that TMIthione differs from a regular sulfhydryl and perhaps 
the thione character of the C-S bond plays a role in the thermodynamics. 
Table 2.15: (TMI-S)2 + 2 CH3SH → 2 TMIthione + H3CSSCH3 (Eq. 2.1). 
Reactant Product ΔG° (kcal/mol) 
2-11 2 2-3 -30.32 
2-12 2 2-3 NDa 
2-13 2 2-3 -30.37 
Diphenyldisulfide Thiophenol -3.60 
aNot determined 
To determine the influence of the tautomerization of TMIthiol to TMIthione on free 
energy, Eq. 2.1 was broken down into its component steps: the reduction of the disulfide to 
the thiol followed by tautomerization (Eq. 2.2 and 2.3). 
 
 (TMI-S)2 + 2 CH3SH → 2 TMIthiol + H3CSSCH3 Eq. 2.2 
 
 2 TMIthiol → 2 TMIthione Eq. 2.3 
 
The free energy values for the reduction of (TMI-S)2 to TMIthiol were found to be comparable 
to the reduction of diphenyldisulfide, which was used as a model aromatic thiol (Table 2.16) 
The tautomerization to TMIthione must therefore be a large contributor to the overall 
thermodynamics of the reaction. 
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Table 2.16: (TMI-S)2 + 2 CH3SH → 2 TMIthiol + H3CSSCH3 (Eq. 2.2) 
Reactant Product ΔG° (kcal/mol) 
2-11 2 2-4 -3.78 
2-12 2 2-5 NDa 
2-13 2-4 + 2-5 3.47 
Diphenyldisulfide Thiophenol -3.60 
aNot determined 
 
The conversion of the TMIthiol to TMIthione was found to be extremely favourable 
(Table 2.17) and accounts for over 85% of the energy released in Eq. 2.1 (Table 2.15).  The 
free energy release found with implicit solvation was almost double that released in the gas 
phase (see Appendix 1), indicating that solvation may play a role in the stabilization of the 
thione.   
Table 2.17: 2 TMIthiol → 2 TMIthione (Eq. 2.3). 
Reactant Product ΔG° (kcal/mol) 
2 2-4 2 2-3 -26.53 
2 2-5 2 2-3 -27.06 
2-4 + 2-5 2 2-3 -26.80 
 
The use of tautomerization as a driving force for a reaction in biological systems is 
not isolated to the reduction of ESSE.  In the hydrolysis of phosphoenolpyruvate to the keto 
form of pyruvate, the tautomerization of enol pyruvate contributes almost 75 % of the overall 










ΔGo' = -16 kJ/mol














Figure 2.13: The hydrolysis of phosphoenolpyruvate.  The reaction is broken down into two steps, hydrolysis 
and tautomerization.  The tautomerization of enol pyruvate to pyruvate is the major contributor to the overall 
ΔG°′ of hydrolysis.67   
 The thermodynamics of the reduction of (TMI-S)2 indicate that the thermodynamic 
instability of ESSE may be due to the free energy released by the tautomerization of ESHthiol 
to ESHthione.  Should ESSE be formed by redox reactions in the cell, it would likely be 
reduced by endogenous GSH or mycothiol.  This reduction could account for the inability to 
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detect ESSE under physiological conditions and the absence of an ESSE reductase in the 
ESSE containing organisms.   
2.3.6. Modelling 4-Thiol-N1-Methyl-5-Methyl-Imidazole and its Disulfide 
The OSHs differ from ESH by the placement of a sulfur atom.  This variation 
dramatically alters the properties of the OSHs in comparison to ESH.  The OSHs exist 
mainly in the zwitterionic state, as pKaNH = 10.3 and pKaSH = 2.6, with no reported presence 
of a thione moiety.62  Geometry optimizations were performed on the model compound 
TMMI in the uncharged, anionic and zwitterionic forms (Figure 2.14).  The fully protonated 
cationic form would only be present at very acidic pH and therefore was not included in this 
study.  The zwitterionic form was found to be the most stable thermodynamically, in 
agreement with the pKa values of the OSHs.  The calculation C-S bond length was consistent 
with the calculated C-S bond length of thiophenol, indicating the presence of a thiol rather 































Figure 2.14: 4-Thiol-N1-methyl-5-methyl-imidazole and its various forms and disulfide. 
Table 2.18: A comparison of the C-S bond lengths of the various ionic states of 4-thiol-N1-methyl-5-methyl-
imidazole to thiophenol determined with implicit water solvation using the B3LYP/6-311++G** combination 




Thiophenol  1.80 
 
Also unlike ESH, the OSH disulfide has been detected in vivo,68-70 suggesting that it 
may be more stable than ESSE.  In sea urchin eggs OSSO is formed during the detoxification 
of H2O2;6,71 however, there have been no reports of an OSSO reductase to reduce OSSO to its 
biologically useful free thiol form.  In lieu of an OSSO reductase, it has been proposed that 
GSH may act as an endogenous reducing agent.  To assess the thermodynamics of OSSO 
reduction by GSH, the disulfide of TMMI, (TMMI-S)2 was modelled and the 
thermodynamics of its reaction with methyl mercaptan determined (Eq. 2.4).  There are 
multiple protonation states possible for (TMMI-S)2; however, the methylation of TMMI to S-
methyl-TMMI decreases the pKa of N3H to ~6, similar to that of imidazole.62  It is likely that 
the formation of (TMMI-S)2 would have the same effect on N3H and therefore (TMMI-S)2 
was modelled as a neutral molecule (Figure 2.14).   
 
 (TMMI-S)2 + 2 CH3SH → 2 TMMI + H3CSSCH3 Eq. 2.4 
  
The reduction of (TMMI-S)2 by methyl mercaptan to the zwitterion was determined 
to be favourable (ΔG° = -6.40 kcal/mol).  These results predict that GSH is able to act as a 
reducing agent for OSSO under physiological conditions.  It is clear that under identical 
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conditions, the reduction of ESSE is much more favourable than the reduction of OSSO.  
This result is consistent with the detection of OSSO in vivo. 
2.3.7. Biologically Relevant Reactions 
ESH is known to react with a number of toxic ROS3 including HO• and H2O2, and it 
has been suggested that ESH may work in concert with ascorbic acid to protect the cell 
against oxidative damage.5  Similarly, OSHs act as peroxidase mimics, protecting sea urchin 
eggs from cytotoxic H2O2.6,71  To further our understanding of these important reactions, the 
thermodynamics of the interactions of TMI and TMMI with H2O2 and HO•, as well as the 
interaction of TMI• with an ascorbic acid analogue, were determined.  These results were 
compared to the reactions of methyl mercaptan as a model for known ROS scavenger GSH.  
 The reduction of H2O2 (Eq. 2.5) to water was favourable for all three thiols (Table 
2.19).  However, the protonation state of TMI and TMMI modulates the thermodynamics of 
these reactions.  In the case of TMI, the thiol form is a thermodynamically superior reducing 
agent compared to the thione form.  The difference between the two tautomers corresponds 
to the energy required to convert the thione to the thiol form.  It is therefore likely that ESH 
is thermodynamically a good scavenger of H2O2.   
 
 2 RSH + H2O2 → RSSR + 2 H2O Eq. 2.5 
  
 2 TMIthione → 2 TMIthiol Eq. 2.6  
 ~ 27 kcal/mol** 
 
 2 TMIthiol + H2O2 → (TMI-S)2 + 2H2O Eq. 2.7 
 ~ - 63 kcal/mol** 
 
In the case of TMMI, the effect of protonation state on the thermodynamics of Eq. 2.5 
is even more striking.  Reduction by the anion is thermodynamically 2.5 times more likely 
than by the zwitterion.  This result is consistent with experimental evidence which suggests 
that the OSH anion is the primary reducing agent,62 even though it accounts for only 0.002% 
of the OSH population at physiological pH.††  The use of the anionic form of TMMI as a 
reducing agent for H2O2 was more than twice as thermodynamically favoured over reduction 
by methyl mercaptan, in agreement with the role that OSHs act as H2O2 scavengers in sea 
urchin eggs, in the presence of GSH.6,71   
                                                 
** See Tables 2.13 and 2.14 for exact values. 
†† As calculated from pKa data. 
 - 58 -
Table 2.19: 2 RSH + H2O2 → RSSR + 2 H2O (Eq. 2.5) 
Reactant Product ΔG° (kcal/mol) 
TMI   
2 2-3 2-11 -36.63 
 2-12 NDa 
 2-13 -36.58 
2 2-4 2-11 -63.17 
2 2-5 2-12 ND 
2-4 + 2-5 2-13 -63.38 
   
TMMI   
2 2-14 2-18 -69.13 
2 2-15b 2-18 -152.41 
2 2-17 2-18 -60.55 
   
Methyl Mercaptan   
2 2-19 2-22 -75.97 
aNot determined; bBalanced equation becomes 2 TMMI- + 2 H3O+ + H2O2 → (TMMI-S)2 + 4 H2O 
 
The scavenging of HO• was studied using three different possible reaction schemes 
(Equations 2.8 to 2.10).  All pathways were favourable for the three thiol analogues (Table 
2.20, Table 2.21, and Table 2.22).  Similar to the H2O2 results, the anionic form of TMMI 
was the most thermodynamically favourable reducing agent.  These results are consistent 
with experimental observations that ESH, the OSHs and GSH are potent scavengers of 
HO•.3,8,62,64,72,73  
 RSH + HO• → RS• + H2O Eq. 2.8 
 
 RS- + HO• + H3O+ → RS• + 2 H2O  Eq. 2.9 
 
 2 RSH + 2 HO• → RSSR + 2 H2O  Eq. 2.10 
 
Table 2.20: RSH + HO• → RS• + H2O (Eq. 2.8) 
Reactant Product ΔG° (kcal/mol) 
TMI   
2-3 2-9 -33.83 
2-3 2-10 -34.05 
2-4 2-9 -47.10 
2-5 2-10 -47.58 
   
TMMI   
2-14 2-16 -45.88 
   
Methyl Mercaptan   
2-19 2-21 -31.04 
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Table 2.21: RS- + HO• + H3O+ → RS• + 2 H2O (Eq. 2.9). 
Reactant Product ΔG° (kcal/mol) 
TMI   
2-7 2-9 -83.12 
2-8 2-10 -83.57 
   
TMMI   
2-15 2-16 -87.52 
   
Methyl Mercaptan   
2-20 2-21 -78.97 
 
Table 2.22: 2 RSH + 2 HO• → RSSR + 2 H2O (Eq. 2.10). 
Reactant Product ΔG° (kcal/mol) 
TMI   
2 2-3 2-11 -69.27 
 2-12 ND 
 2-13 -69.21 
2 2-4 2-11 -95.80 
2 2-5 2-12 ND 
2-4 + 2-5 2-13 -72.85 
   
TMMI   
2-14 2-18 -101.77 
2-15a 2-18 -185.04 
2-17 2-18 -93.19 
   
Methyl Mercaptan   
2-19 2-22 -99.58 
aBalanced equation becomes 2 OS- + 2 HO• +2 H3O+ → OSSO + 4 H2O 
To further understand the behaviour of the ESH and OSH radicals the spin density of 
the TMI and TMMI radicals were modeled in vacuo and with implicit water solvation to 
determine the localization of the unpaired electron.  In TMI, the spin density was found on 
multiple atoms: the S, C5 and N3 atoms of 2-9 and the S, C4 and N1 atoms of 2-10 in vacuo 
(see Figure 2.15 and Figure 2.16).  When modeled with implicit solvation, the spin density 
on the nitrogen atom of each tautomer decreased, leaving most of the density on the S and C4 
or C5 atoms (Figure 2.15 and Figure 2.16, see Appendix 1 for a detailed listing of the spin 
densities of each atom).  In contrast, the spin density of TMMI is localized on the S and C4 
atoms regardless of solvation (Figure 2.17 and Appendix 1), which is in quantitative 
agreement with published AM1 calculations for OSH derivatives.64  The delocalization of the 
radical into the imidazole ring may aid in the stabilization of the ESH and OSH radicals.  
This increased stability may explain why the formation of the TMI and TMMI radicals was 
thermodynamically favoured over the formation of the methyl mercaptan radical.  The 
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increased stability may also account for the superior ability of the OSHs to scavenge radicals 














Figure 2.15: Spin density localization (Isovalue for isosurface: 0.0004 electrons/au3) for 2-thiol-4-methyl-














Figure 2.16: Spin density localization (Isovalue for isosurface: 0.0004 electrons/au3) for 2-thiol-4-methyl-













Figure 2.17: Spin density localization (Isovalue for isosurface: 0.0004 electrons/au3) for 4-thiol-N1-methyl-5-
methyl-imidazole (2-16) in gas (left) and water (right) 
The scavenging of radicals by thiols often creates a thiyl radical which, though less 
reactive than ROS such as HO•, can still cause oxidative cellular damage.  Ascorbic acid is 
an effective scavenger of a number of ROS and of thiyl radicals.  The ascorbate radical 
formed by these reactions is much less reactive than most of the radicals scavenged, making 
it a powerful antioxidant.  It has been suggested that a cooperative interaction may exist 
between ESH and ascorbic acid as the exposure of ESH/ascorbic acid solutions to azide 
radicals results in the formation of the ESH radical, which decays while the ascorbate radical 
forms, indicating the ascorbate repairs ESH.5  Ascorbate has also been implicated in the 
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repair of vitamin E, an essential lipid soluble antioxidant that protects the cell membrane 
against ROS.72  Vitamin E reduces lipid peroxy radicals, breaking the free radical 
propagation chain reaction, and in the process, vitamin E is oxidized to its radical form.74,75  
Continued membrane protection requires the reduction of the vitamin E radical; this is 
accomplished by a number of cytosolic antioxidants, including ascorbate.72  In a similar 
fashion, ascorbate may be involved in the reduction of ES• to ESH.5 
To study the thermodynamics of this interaction, we modeled the reactions of TMI, 
TMMI and methylmercaptan radicals with an ascorbic acid analogue (Figure 2.18, 2-23, Eq. 
2.11) to form 2-24.  These truncated analogues of ascorbic acid were used to reduce the 
number of degrees of freedom involved in the geometry optimization.  Based upon the pKa 
values of ascorbic acid (pKa1 = 4.2, pKa2 = 11.6), 2-23 is expected to exist in the anionic 
form, as shown in Figure 2.18).  It is expected that hydroxyl group B is more acidic than A, 
as the resulting anion is resonance stabilized as seen in Figure 2.19.  Hydroxyl A remains 
protonated at physiological pH, and therefore can act as a hydrogen donor to harmful radical 








Figure 2.18: Model compounds used to study the reactions of ascorbic acid. 





HO OBA  
Figure 2.19: Tautomerization of the ascorbate model  2-23. 
The reduction of the thiyl radicals of all three thiols by 2-23 was favourable 
indicating that ascorbate could play a role in returning ESH, the OSHs and GSH to their 
biologically useful thiol form (see Appendix 1).     
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Table 2.23: RS• + 2-23 → RSH + 2-24 (Eq. 2.11) 
Reactant Product ΔG° (kcal/mol) 
TMI   
2-9 2-3 -16.39 
 2-4 -3.12 
2-10 2-3 -16.17 
 2-5 -2.64 
   
TMMI   
2-16 2-14 -4.34 
 2-15a 37.3 
 2-17 -8.63 
   
Methyl Mercaptan   
2-21 2-20 -19.18 
aBalanced equation modified to TMMI• + 2-23 + H2O → TMMI- + 2-24 + H3O+ 
2.4. Conclusions and Future Work 
 This computational approach explored the theoretical aspects of the thermodynamics 
of several of the important reactions that ESH and the OSHs may undergo in the cell.  A key 
result from this work is the indication that the instability of ESSE may be driven by the 
energy released by the tautomerization of the thiol form of ESH to the thione.   
 Further computational studies of ESH and OSH could involve the determination of 
the thermodynamics of the reactions of TMI and TMMI with reactive nitrogen species (RNS) 
such as peroxynitrate (ONOO-), and with S-nitroso-glutathione and di-S-nitroso-
trypanothione.  ESH is believed to scavenge cytotoxic ONOO- in a biologically relevant 
manner2,76,77 and both ESH and OSH have been shown to decompose S-nitrosothiols, 
intermediates in the detoxification of RNS.78,79  
The calculations and results presented herein should contribute to our further 
understanding of the fundamental chemistry and biochemistry of these important intracellular 
thiols.  
2.5. References  
 
1. Heath, H.; Toennies, G. Biochem. J. 1958, 68, 204-210. 
2. Jang, J.-H.; Aruoma, O. I.; Jen, L.-S.; Chung, H. Y.; Surh, Y.-J. Free Radic. Biol. Med. 
2004, 36, 288-299. 
3. Akanmu, D.; Cecchini, R.; Aruoma, O. I.; Halliwell, B. Arch. Biochem. Biophys. 1991, 
288, 10-16. 
4. Arduini, A.; Eddy, L.; Hochstein, P. Arch. Biochem. Biophys. 1990, 281, 41-43. 
5. Asmus, K.-D.; Bensasson, R. V.; Bernier, J.-L.; Houssin, R.; Land, E. J. Biochem. J. 1996, 
315, 625-629. 
6. Turner, E.; Hager, L. J.; Shapiro, B. M. Science 1988, 242, 939-941. 
7. Pathirana, C.; Andersen, R. J. J. Am. Chem. Soc. 1986, 108, 8288-8289. 
8. Holler, T. P.; Hopkins, P. B. Biochemistry 1990, 29, 1953-1961. 
 - 63 -
9. Leach, A. R. Molecular Modelling: Principles and Applications; Second ed.; Prentice 
Hall: Harlow, Essex, England, 2001. 
10. Cramer, C. J. Essentials of Computational Chemistry; Second ed.; John Wiley and Sons 
Ltd.: West Sussex, 2004. 
11. Young, D. C. Computational Chemistry: A Practical Guide for Applying Techniques for 
Real World Problems; Wiley Interscience: New York, 2001. 
12. Atkins, P.; Friedman, R. Molecular Quantum Mechanics; Fourth ed.; Oxford University 
Press: New York, 2005. 
13. Becke, A. D. Phys. Rev. A 1988, 38, 3098-3100. 
14. Becke, A. D. J. Chem. Phys. 1993, 98, 1372-1377. 
15. Lee, C.; Yang, W.; Parr, R. G. Phys. Rev. B 1988, 37, 785-789. 
16. Agache, C.; Popa, V. I. Monatshefte für Chemie 2006, 137, 55-68. 
17. Boström, J.; Norrby, P.-O.; Liljefors, T. J. Comput. Aided Des. 1998, 12, 383-396. 
18. Beak, P. Acc. Chem. Res. 1977, 10, 186-192. 
19. Foresman, J. B.; Frisch, Æ. Exploring Chemistry with Electronic Structure Methods; 
Second ed.; Gaussian Inc.: Pittsburgh, PA, USA, 1996. 
20. Levine, I. N. Quantum Chemistry; Fifth ed.; Prentice Hall: Upper Saddle River, NJ, USA, 
2000. 
21. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, 
J. R.; Montgomery, J. A., Jr.; Vreven, T.; Kudin, K. N.; Burant, J. C.; Millam, J. M.; Iyengar, 
S. S.; Tomasi, J.; Barone, V.; Mennucci, B.; Cossi, M.; Scalmani, G.; Rega, N.; Petersson, G. 
A.; Nakatsuji, H.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; 
Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Klene, M.; Li, X.; Knox, J. E.; Hratchian, H. 
P.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; 
Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Ayala, P. Y.; 
Morokuma, K.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Zakrzewski, V. G.; Dapprich, 
S.; Daniels, A. D.; Strain, M. C.; Farkas, O.; Malick, D. K.; Rabuck, A. D.; Raghavachari, 
K.; Foresman, J. B.; Ortiz, J. V.; Cui, Q.; Baboul, A. G.; Clifford, S.; Cioslowski, J.; 
Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Martin, R. L.; Fox, D. J.; 
Keith, T.; Al-Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Challacombe, M.; Gill, P. M. W.; 
Johnson, B.; Chen, W.; Wong, M. W.; Gonzalez, C.; Pople, J. A.; B.05 ed.: Pittsburgh, PA, 
2003. 
22. Flack, H. D. Acta Crystallogr. 1983, A39, 876-881. 
23. Binkley, J. S.; Pople, J. A.; Hehre, W. J. J. Am. Chem. Soc. 1980, 102, 939-947. 
24. Gordon, M. S.; Binkley, J. S.; Pople, J. A.; Pietro, W. J.; Hehre, W. J. J. Am. Chem. Soc. 
1982, 104, 2797-2803. 
25. Pietro, W. J.; Francl, M. M.; Hehre, W. J.; DeFrees, D. J.; Pople, J. A.; Binkley, J. S. J. 
Am. Chem. Soc. 1982, 104, 5039-5048. 
26. Ditchfield, R.; Hehre, W. J.; Pople, J. A. J. Chem. Phys. 1971, 54, 724-728. 
27. Hehre, W. J.; Pople, J. A. J. Chem. Phys. 1972, 56, 4233-4234. 
28. Binkley, J. S.; Pople, J. A. J. Chem. Phys. 1977, 66, 879-880. 
29. Hariharan, P. C.; Pople, J. A. Theor. Chim. Acta 1973, 28, 213-222. 
30. Hehre, W. J.; Ditchfield, R.; Pople, J. A. J. Chem. Phys. 1972, 56, 2257-2261. 
31. Francl, M. M.; Pietro, W. J.; Hehre, W. J.; Binkley, J. S.; Gordon, M. S.; DeFrees, D. J.; 
Pople, J. A. J. Chem. Phys. 1982, 77, 3654-3665. 
 - 64 -
32. Clark, T.; Chandrasekhar, J.; Spitznagel, G. W.; Schleyer, P. V. J. Comput. Chem. 1983, 
4, 294-301. 
33. Frisch, M. J.; Pople, J. A.; Binkley, J. S. J. Chem. Phys. 1984, 80, 3265-3269. 
34. Krishnan, R.; Binkley, J. S.; Seeger, R.; Pople, J. A. J. Chem. Phys. 1980, 72, 650-654. 
35. McLean, A. D.; Chandler, G. S. J. Chem. Phys. 1980, 1980, 5639-5648. 
36. Kendall, R. A.; Dunning, T. H., Jr.; Harrison, R. J. J. Chem. Phys. 1992, 96, 6796-6806. 
37. Woon, D. E.; Dunning, T. H., Jr. J. Chem. Phys. 1993, 98, 1358-1371. 
38. Woon, D. E.; Dunning, T. H., Jr. J. Chem. Phys. 1994, 100, 2975-2988. 
39. Slater, J. C. Quantum Theory of Molecules and Solids, Vol. 4: The Self-Consistent Field 
for Molecules and Solids; McGraw-Hill: New York, 1974. 
40. Vosko, S. H.; Wilk, L.; Nusair, M. Can. J. Phys. 1980, 58, 1200-1211. 
41. Stephens, P. J.; Devlin, F. J.; Chabalowski, C. F.; Frisch, M. J. J. Phys. Chem. 1994, 98, 
11623-11627. 
42. Miehlich, B.; Savin, A.; Stoll, H.; Preuss, H. Chem. Phys. Lett. 1989, 157, 200-206. 
43. Perdew, J. P. In Electronic Structure Theory of Solids; P. Ziesche, H. Eschrig, Eds.; 
Akademie Verlag: Berlin, 1991. 
44. Perdew, J. P.; Chevary, J. A.; Vosko, S. H.; Jackson, K.; Perderson, M. R.; Singh, D., J.; 
Fiolhais, C. Phys. Rev. B 1992, 46, 6671-6687. 
45. Cancès, M. T.; Mennucci, B.; Tomasi, J. J. Chem. Phys. 1997, 107, 3032-3041. 
46. Mennucci, B.; Tomasi, J. J. Chem. Phys. 1997, 106, 5151-5158. 
47. Tomasi, J.; Mennucci, B.; Cancès, M. T. J. Mol. Struct. (THEOCHEM) 1999, 464, 211-
226. 
48. Blaudeau, J.-P.; McGrath, M. P.; Curtiss, L. A.; Radom, L. J. Chem. Phys. 1997, 107, 
5016-5021. 
49. Watchers, A. J. H. J. Chem. Phys 1980, 52, 1033-1036. 
50. Hay, P. J. J. Chem. Phys. 1977, 66, 4377-4384. 
51. Raghavachari, K.; Trucks, G. W. J. Chem. Phys. 1989, 91, 1062-1065. 
52. Binning, R. C., Jr.; Curtiss, L. A. J. Comput. Chem. 1990, 11, 1206-1216. 
53. Curtiss, L. A.; McGrath, M. P.; Blaudeau, J.-P.; Davis, N. E.; Binning, R. C., Jr. J. Chem. 
Phys. 1995, 103, 6104-6113. 
54. McGrath, M. P.; Radom, L. J. Chem. Phys 1991, 94, 511-516. 
55. Huang, M.-J. Int. J. Quantum Chem. 2004, 96, 374-379. 
56. Virovets, A. V.; Lider, E. V.; Elokhina, V. N.; Bushuev, M. B.; Lavrenova, L. G. J. 
Struct. Chem. 2005, 46, 358-362. 
57. Jadeja, R. N.; Shirsat, R. N.; Suresh, E. Struct. Chem. 2005, 16, 515-520. 
58. Bastos, B.; Mena, A.; Alcântara, A. F. d. C.; Beraldo, H. Tetrahedron 2005, 61, 7045-
7053. 
59. Papanikolaou, P. A.; Christidis, P. C.; Chaviara, A. T.; Bolos, C. A.; Tsipis, A. C. Eur. J. 
Inorg. Chem. 2006, 2006, 2083-2095. 
60. Sugihara, A.; Uemura, K.; Matsuura, Y.; Tanaka, N.; Ashida, T.; Kakudo, M. Acta 
Crystallogr. 1976, B32, 181-185. 
61. Motohashi, N.; Mori, I.; Sugiura, Y. Chem. Pharm. Bull. 1976, 27, 1737-1741. 
62. Holler, T. P.; Hopkins, P. B. J. Am. Chem. Soc. 1988, 110, 4837-4838. 
63. Zoete, V.; Bailly, F.; Vezin, H.; Teissier, E.; Duriez, P.; Fruchart, J.-C.; Catteau, J.-P.; 
Bernier, J.-L. Free Radic. Res. 2000, 32, 515-524. 
 - 65 -
64. Zoete, V.; Vezin, H.; Bailly, F.; Vergoten, G.; Catteau, J.-P.; Bernier, J.-L. Free Radic. 
Res. 2000, 32, 525-533. 
65. Jocelyn, P. C. The Biochemistry of the SH Group; Academic Press: New York, 1972. 
66. Scott, E. M.; Duncan, I. W.; Ekstrand, V. J. Biol. Chem. 1963, 238, 3928-3933. 
67. Voet, D.; Voet, J. G. Biochemistry; Second ed.; John Wiley and Sons: New York, 1995. 
68. Palumbo, A.; Misuraca, G.; D'ischia, M.; Donaudy, F.; Prota, G. Comp. Biochem. 
Physiol. 1984, 78B, 81-83. 
69. Rohl, I.; Scheider, B.; Schmidt, B.; Zeeck, E. Z. Naturforsch. 1999, 54C, 1145-1147. 
70. Turner, E.; Klevit, R.; Hager, L. J.; Shapiro, B. M. Biochemistry 1987, 26, 4028-4036. 
71. Shapiro, B. M. Science 1991, 252, 533-536. 
72. Acworth, I. N.; McCabe, D. R.; Maher, T. J. In Oxidants, Antioxidants and Free 
Radicals; H. Salem, Ed.; Taylor and Francis: Washington, D. C., 1997, pp 22-77. 
73. Sciuto, A. M. In Oxidants, Antioxidants, and Free Radicals; S. I. Baskin, H. Salem, Eds.; 
Taylor and Francis: Washington, D. C., 1997, pp 171-191. 
74. Brigelius-Flohe, R.; Traber, M. G. FASEB J. 1999, 13, 1145-1115. 
75. Burton, G. W.; Ingold, K. U. Acc. Chem. Res. 1986, 19, 194-201. 
76. Aruoma, O. I.; Spencer, J. P. E.; Mahmood, N. Food Chem. Toxicol. 1999, 37, 1043-
1053. 
77. Aruoma, O. I.; Whiteman, M.; England, T. G.; Halliwell, B. Biochem. Biophys. Res. 
Comm. 1997, 231, 389-391. 
78. Vogt, R. N.; Steenkamp, D. J.; Zheng, R.; Blanchard, J. S. Biochem. J. 2003, 374, 657-
666. 
79. Misiti, F.; Castagnola, M.; Zuppi, C.; Giardina, B.; Messana, I. Biochem. J. 2001, 356, 
799-804. 
 
 - 66 -
Chapter 3: Conformational Analyses of Mycothiol 
The novel thiol mycothiol (MSH, Figure 3.1, 3-1) is currently of intense interest due 
to its essential role in the cellular physiology of Mycobacteria,1-5 such as Mycobacterium 
tuberculosis, and its possible role in antimycobacterial drug resistance.6-8  Despite the 
medical importance of the organisms that use MSH as their major intracellular thiol, little is 
known concerning MSH biochemistry.†  In addition, there is very little information available 
regarding the chemical reactivity and conformational preferences of MSH, information that 
would be useful in the design of novel inhibitors of MSH-utilizing enzymes.  Based upon 
these considerations, a detailed conformational study of MSH was undertaken to determine if 
any conformational preferences exist in solution.  The findings of this study should not only 
contribute to our fundamental understanding of MSH, but should also aid in the design of 
MSH analogues, such as conformationally restricted derivatives, which may serve as 























Figure 3.1: Mycothiol (MSH, 3-1) 
3.1. Computational Chemistry 
As discussed in Chapter 2, the potential energy of a molecule is a function of the 
coordinates of its atoms. The way in which this energy changes with respect to geometry 
defines a potential energy surface, like the one seen in Figure 3.2.  The valleys of a potential 
energy surface correspond to minimum energy structures with the lowest overall energy point 
being the global minimum.  Most geometry optimization algorithms move down the potential 
energy surface and therefore can only locate the minimum energy which is closest to the 
starting structure (Figure 3.3).9  Consequently, the optimized structure obtained by a 
geometry optimization may not be a global minimum but rather a local minimum energy 
structure (Figure 3.3).  To ensure that a global minimum structure has been found, or to 
generate multiple local minimum energy structures and explore the conformational space of a 




                                                 
† A search of the PubMed database, a service of the National Library of Medicine and the National Institute of 
Health, for MSH returned 77 references, 8 of which are review articles while a search for glutathione, the main 
intracellular thiol of eukaryotes and most gram-negative bacteria, returned 73 334 references, 4 022 of which 
are review articles (accessed November 13, 2006). 
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Figure 3.2: Variation in the energy of pentane with the variation of the angles indicated.  Only the lowest 
energy regions are shown.9 
 
 
Figure 3.3:  A one dimensional representation of the energy of all possible conformers of a simple molecule10 
There are a variety of methods available for the generation of multiple starting 
structures and the exploration of a compound’s conformational space.  For example, the 
stochastic search algorithms, such as the Monte Carlo multiple minimization (MCMM) 
method,11 make random changes to a molecule’s structure to generate new geometries for 
optimization.10  Another popular method is the use of molecular dynamics (MDyn) 
simulations which apply Newton’s laws of motion and temperature to generate new starting 
geometries for optimization.  MDyn methods are not suitable for the study of all systems as 
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the forces applied to the individual atoms of the molecule may not be sufficient to overcome 
energy barriers between energy minima, resulting in inadequate sampling of the 
conformational space of the molecule.9  In addition, MDyn simulations can be very time 
consuming.10  The most thorough method available to explore the conformations of a 
molecule is dihedral angle driving, or adiabatic mapping, which rotates the torsional angles 
of a molecule by a predefined value to thoroughly cover the conformational space of the 
compound.  This method is not suited for larger molecules as the number of dihedral angle 
combinations sampled increases exponentially with the size of the molecule.9  For example, 
if a molecule had 10 dihedral angles and each one was rotated in 20° increments for a total of 
360°, one would generate 1810, or over 3.5 × 1012, structures.12 
The optimization of the numerous structures generated by conformational search 
algorithms is very demanding with respect to time and computational resources.  These 
demands often dictate the method chosen for the optimization of the resulting starting 
structures.  The Hartree-Fock (HF) and Density Functional Theory (DFT) methods are the 
most accurate; however, they are also the most demanding due to the large number of 
calculations involved.  Even the semi-empirical methods, which are less intensive than the 
HF and DFT techniques, can result in a prohibitively long study.  As an alternative, 
molecular mechanics methods are often used in conformational searches due to their speed 
and relatively low demand on computational resources.  With these factors in mind, we chose 
to use the MCMM method in combination with molecular mechanics methods to explore the 
conformational space of MSH.   
3.1.1. Monte Carlo Multiple Minimization Methods 
Monte Carlo (MC) simulations generate new conformations by applying random 
changes to the positions of the constituent atoms of a molecule.9  If enough random changes 
(or steps) are allowed, this method should give a statistically valid exploration of the 
conformational space of a molecule (Figure 3.4).10  An MCMM conformational search 
begins with the choice of a stable starting structure which then undergoes random variations 
in its dihedral angles, followed by geometry optimization and a comparison of the new 
conformer to any previously determined minima.  The optimized structure is either stored as 
new and unique or rejected as identical and the cycle is repeated.  If the molecule under study 
contains a ring, the ring is opened prior to dihedral angle variation and then closed before 
optimization.11  These methods are attractive as they require less computer time than MDyn 
simulations10 and can overcome energy barriers that may impede other methods such as 
MDyn simulations.9  
- 69 - 
 
Figure 3.4: Sampling the conformational space of a molecule using a Monte Carlo search with a small number 
of iterations10 
3.1.2. Molecular Mechanics Methods and Force Fields 
Molecular mechanics calculations are very useful for the study of systems which are 
too large for quantum mechanical techniques.  Quantum mechanical calculations focus on the 
electrons in a system, and even if some of these electrons are disregarded, as in semi-
empirical calculations, there are still a large number of particles to be considered and the 
calculations are very time consuming.9  Molecular mechanics methods are more feasible for 
large systems as they use the positions of the nuclei of a molecule to determine the overall 
energy of the system, with key energetic contributions from bond stretching, bond angle 
changes, rotations around single bonds and non-bonded interactions, such as electrostatic and 
van der Waals interactions.9 
The energy of the system is calculated using a collection of functions and parameters 
called a force field.13  These parameters are defined through the fitting of these functions to 
spectroscopic data or to the results of ab initio calculations for a given system.10  It is 
desirable to have a force field that can accurately describe a system other than the one used to 
develop its parameters.9  One method used to broaden the applicability of a force field is the 
use of atom types to describe the component atoms of a system.  For example, the MM2, 
MM3 and MM4 force fields distinguish between sp3, sp2, sp, carbonyl, cyclopropane, and 
cyclopropene carbon atoms, as well as carbon radicals, and carbonium ions.9,14-23  These 
atom types describe not only hybridization, but can also be used to describe functional 
groups, such as carbonyl versus carboxylic sp2 carbon atoms, as well as the local 
environment of the atom in question.9  Force fields designed for modeling specific classes of 
molecules, such as proteins and carbohydrates, often use more specific atom types than those  
force fields designed for general use.9,10  
The accuracy of molecular mechanics calculations is related to how well the 
parameters of the force field in use are suited to the system in question.  A force field 
parameterized for the study of hydrocarbons may not yield accurate results for the study of 
biological molecules.  For example, the rings in sugar molecules are known to pose a 
problem to general force fields, likely due to the unique properties of the anomeric position; 
therefore, these molecules should be modelled using force fields designed specifically for the 
study of carbohydrates.10  With the use of a well chosen force field, molecular mechanics 
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calculations can, in some cases, provide results with similar accuracy to higher level quantum 
mechanical calculations. 
3.1.3. Plan of Action 
Based upon the above factors, we performed a detailed search of the conformational 
space of MSH using MCMM and molecular mechanics methods.  We first evaluated the 
ability of the force fields available to us to model MSH, then performed a MCMM 
conformational search both in vacuo and with implicit solvation.  The resultant structures 
were subjected to cluster analysis to determine if any patterns existed with respect to specific 
dihedral angles within MSH.  The resultant global minimum and other low energy minima 
structures were compared to a recently published structure of an MSH-derivative found using 
NMR techniques.   
3.2. Materials and Methods 
All structures were drawn and visualized using Maestro (Schrödinger Inc., Portland). 
A conformational study of MSH was undertaken using MacroModel (versions 8.1 and 9.0, 
Schrödinger Inc., Portland).  The Generalized Born/Surface Area (GB/SA) continuum model 
was used to create the implicit water solvation model as implemented by MacroModel.  All 
calculations were performed on Violin or Flexor (see Chapter 2 for details of these systems). 
3.2.1. Geometry Optimizations of Mycothiol 
 All geometry optimizations were performed using the same protocol.  The 
electrostatic treatment was dependent upon the force field in use with a dielectric constant of 
1.0 and the charges were defined by the force field library.  Hydrogen-bonding interactions 
were cut off at 4 Å.  Van der Waals and charge-charge interactions were cut off at 7 and 12 Å 
respectively, in the gas phase, and at 8 and 20 Å respectively under implicit solvation.  A 
Polak-Ribiere Conjugate Gradient (PRCG) was used and each structure was allowed up to 
5000 iterations.  The minima converged on a gradient with a threshold of 0.05.   
3.2.2.   Survey of Force Fields Available 
An initial survey of the force fields available in MacroModel version 8.1 was 
undertaken to determine which force field was best suited to model MSH.  Minimizations of 
MSH were performed using each of the following force fields:‡ AMBER*,24 AMBER94,25 
MM2*,15 MM3*,16 MMFF,26 OPLS27 and OPLS-AA.28  Each returned information regarding 
the number and quality of the bend, stretch, and torsional parameters available in each force 
field for the atom types of MSH.  Of the force fields studied, OPLS-AA appeared best suited 
to model MSH (see Results and Discussion); therefore, OPLS-AA was used as the main 
force field in our conformational study of MSH. 
3.2.3. Monte Carlo Multiple Minimization Searches of the Mycothiol Conformational 
Space 
An X-ray structure of MSH is not currently available; therefore, the structure of MSH 
was drawn into Maestro and its geometry optimized both in the gas phase and with implicit 
                                                 
‡ As implemented by MacroModel v. 8.1. 
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water solvation (GB/SA)29 using the OPLS-AA force field.§  The minimized structures were 
then used as the starting structures for MCMM conformational searches in their respective 
phases (gas or implicit water).  Each subsequent step used the “least used” structure from the 
conformations thus far generated, based upon the number of times each conformer had been 
used as a starting conformer.  In this study the structures were allowed 500 000 MC steps and 
structures within 50 kJ/mol of the global minimum were retained.  For each starting structure, 
x number of degrees of freedom, or in this case torsional angles, were altered, where x is a 
randomly generated number between 2 and 5.  The bonds were rotated plus or minus a 
randomly generated number between 0 and 180°.  To adjust the torsional angles within the  
D-glucosamine and myo-inositol rings, the bonds between C3 and C4 and C2′ and C3′ (see 
Figure 3.1 for numbering) were temporarily broken to open each ring.  The dihedral angles 
were modified and the rings closed.  These newly formed bonds were constrained to between 
0.5 and 2.5 Å in length.  The absolute values of the torsion angles of the amide bonds were 
monitored and the structure was discarded if these values were outside of 0° - 90° for C2-N1″-
C2″-O (D-glucosamine) and 90° - 180° for H-N5″-C6″-O (N-acetyl-cysteine, see Figure 3.1 for 
numbering).   
The resultant conformation was then minimized using the OPLS-AA force field.  
After 1666 iterations, a preliminary energy test was performed and the minimization was 
aborted if the structure’s energy was more than 100 kJ/mol higher than that of the current 
minimum energy structure, speeding the overall conformational search.  The chiralities of the 
stereogenic atoms, the carbon atoms of the D-glucosamine and myo-inositol rings and the α-C 
of the N-acetyl-cysteine moiety, were monitored and any structure whose chirality was 
altered was rejected.  The structure was finally compared to the previously saved conformers 
for redundancy.  Structures whose least squares superimposition was less the 0.25 Å were 
considered identical and the higher energy conformer was then discarded.  Initially all heavy 
atoms and polar hydrogen atoms were used for comparison resulting in 13 074 and 137 764 
unique structures in the gas phase and with implicit water solvation, respectively.  These 
conformers were then subjected to the redundant conformation elimination module of 
MacroModel to eliminate conformers whose heavy atom placement differed by less than  
0.25 Å without consideration of the polar hydrogen atoms.    
A second search of the conformational space of MSH was performed using 
AMBER*** to account for any inadequacies of the OPLS-AA force field (see Results and 
Discussion).  MSH was minimized using AMBER* with implicit solvation (GB/SA) and this 
optimized structure was used as the starting point of the MCMM conformational search.  The 
MCMM conformational search was performed in a similar fashion to the OPLS-AA search 
except that the torsional angles within the myo-inositol and D-glucosamine rings were not 
modified nor were the rings opened.  The torsional angles between the rings were subjected 
to rotation (see Results and Discussion).  After the initial conformational search, 33 124 
conformers were found, which were then subjected to the redundant conformer elimination 
module.   
3.2.4. Resultant Conformer Analysis using XCluster 
The conformers modelled with implicit water solvation which were calculated to have 
energies within 3 kcal/mol of the global minimum (OPLS-AA: 198 conformers, AMBER*: 
                                                 
§ As implemented by MacroModel v. 8.1 
** As implemented by MacroModel v. 9.0 
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116 conformers) were further analyzed using the XCluster module of MacroModel v. 9.0.30  
The conformers were grouped into families based upon the φ (C1-O-C1′-H) and ψ (C1-O-C1′-
H) angles (see Figure 3.1 for numbering) of the disaccharide portion of MSH. Conformers 
containing five axial substituents on the myo-inositol ring were excluded from further 
analysis (OPLS-AA: 50 conformers, see Results and Discussion).    
3.2.5. MOE2004 Calculations 
 For comparison, a conformational search of MSH was also performed by Professor 
France-Isabelle Auzanneau of the University of Guelph Chemistry Department, using the 
Molecular Operating Environment program suite (MOE2004).  All MOE2004 calculations 
were performed on a PC Pentium 4, 2.40 GHz CPU.  Similar to the random incremental 
pulse search (RIPS)31 method, new MSH conformations were generated by the random 
rotation of all of the bonds in MSH, including the ring bonds, in addition to Cartesian 
coordinate perturbation.  Unfortunately, this method led to changes in the absolute 
configuration of the carbon atoms of the myo-inositol ring.  MSH was therefore minimized 
with the PEF95SAC force field32 and the heavy atoms of the myo-inositol ring were held 
fixed for all subsequent conformation searches.  All other dihedral angles were rotated 
randomly with a sum-of-Gaussians distribution with peaks at multiples of 30°.  To improve 
the efficiency of the search a simultaneous Cartesian perturbation of 0.4 Å was also applied.  
These random perturbations were repeated 250 000 times per conformational search and the 
resulting conformations were optimized using the PEF95SAC force field invoking the 
GB/SA implicit solvation model, both as implemented by MOE2004.  Initially each new 
conformation was checked against the previously determined conformations using a root-
mean-square (RMS) tolerance of 0.1 Å on all atoms, including the hydrogen atoms to 
account for possible hydrogen bonding.  A second search was performed using a more 
stringent RMS cut off of 0.01 Å, which was applied to the heavy atoms only.  Both searches 
were allowed 250 000 iterations with the limitation that the search would terminate if no new 
conformations were found after 10 000 iterations in a row.  This limitation was never reached 
in either search; therefore, both searches terminated after 250 000 iterations.  Structures that 
did not have the 4C1 conformation for D-glucosamine were eliminated (see Results and 
Discussion) and the results of the two searches were combined.  Conformations with energies 
of 10 kcal/mol above the global minimum were rejected yielding a total of 25 852 structures.   
 The combined database was re-minimized using the AMBER94 force field25 using 
the GB/SA implicit solvation model, both as implemented by MOE2004, yielding 10 656 
structures within 10 kcal/mol of the AMBER94 defined global minimum.  The structures 
within 3 kcal/mol of the global minimum for each force field (PEF95SAC: 1860 
conformations, AMBER94: 1067 conformations) were then grouped based upon their φ  and 
ψ angles. 
3.3.  Results and Discussion 
MSH is a clinically important glycothiol believed to be essential for the survival of 
Mycobacterium tuberculosis;33 however, there is very little known regarding its biochemistry 
and conformational preferences.4,12  Information regarding the conformational preferences of 
MSH may be useful for the design of novel inhibitors aimed at MSH-utilizing enzymes.  
MSH-S-conjugate amidase (MCA, Figure 3.5) for example, is an attractive target for the 
development of inhibitors as it is believed to be involved in the removal of electrophilic 
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species from Mycobacteria, and may be involved in the detoxification of thiol reactive 
antibiotics, such as rifamycin S and cerulenin.7  The design and synthesis of MSH-utilizing 
enzyme inhibitors is ongoing, with some of these being synthetic MSH analogues.34-37  The 
results of our modelling study may aid in the design of inhibitors by identifying key dihedral 































Figure 3.5: Hydrolysis of modified mycothiol by mycothiol-S-conjugate amidase (MCA). 
3.3.1. Choice of Conformational Search Method 
To accurately model the conformations of a molecule, multiple conformations must 
be generated that explore all, or at least a substantial portion of the conformational space of 
the molecule.  The MCMM methods sample a wide variety of conformations by making 
random changes to the torsional angles of a molecule, generating new geometries that do not 
necessarily resemble the starting structure.  If a sufficient number of conformers are 
generated, the MCMM methods should sample a large portion of the conformational space.  
An indication of a sufficient number of steps would be the repeated rejection of newly 
generated structures based upon their similarity to previously found conformations.  The 
MCMM methods are also not hindered by energy barriers between conformations as they can 
make “non-physical moves” which significantly enhance the ability of the MCMM method to 
explore the potential energy surface of the molecule.9  MCMM methods have been useful in 
many studies including the study of the coil-to-helix transition in polyalanine38 and the 
determination of the low energy conformations of synthesized carbohydrates.39  The ability 
of the MCMM method to overcome energy barriers to rotation makes it well suited for the 
study of MSH as it will not be hindered by the low mobility of the torsional angles between 
myo-inositol and D-glucosamine. This method was selected for our study of the 
conformations of MSH.   
Other known conformational search methods include torsional angle driving, also 
known as adiabatic mapping, and MDyn simulations (see Section 3.2.3).  Torsional angle 
driving, while one of the most thorough techniques, was rejected as a useful method for this 
study as the number of angles to be sampled in MSH would be prohibitively large.  If one 
ignored the dihedral angles in the disaccharide rings, there would still remain nine dihedral 
angles to evaluate, assuming only heavy atoms were considered.  If these dihedral angles 
were modified in 20° increments, 189 or over 198 billion possible starting conformations 
would be generated to examine; a major computational undertaking.  Dihedral angle driving 
is therefore not a feasible option for the study of MSH.  MDyn, another popular method, was 
also rejected for this study as these simulations can miss minimum energy structures if a 
large energy barrier exists between the starting structure and other minima on the potential 
energy surface.9  While the amino acid portion of MSH is relatively flexible, the torsional 
angles between the disaccharide rings have less mobility due to the steric bulk of myo-
inositol and D-glucosamine.  The energy barriers to rotation around these dihedral angles is 
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likely quite high and therefore an MDyn simulation would be unlikely to be able to fully 
sample the conformational space of MSH.  In addition, MDyn simulations are limited by the 
computational resources available and simulations of a few nanoseconds are standard; it is 
possible that carbohydrate molecules undergo dynamic events on longer time scales which 
could not be investigated by these methods.40 
3.3.2. Force Field Selection 
MSH is an unusual thiol in that it contains a disaccharide moiety coupled to cysteine.  
This results in a wide variety of atom and bond types within MSH, complicating force field 
selection; many force fields are not parameterized for all of the different MSH bond and 
atom types.  MacroModel returns information regarding the quality (high, medium, or low) 
of the parameters in use for a particular structure (Table 3.1).  The lower the quality of the 
parameter, the less experimental or ab initio data that has been used in fitting the force field 
equation.  A low quality rating indicates a general parameter whose use can lead to 
inaccurate conformational energy differences and geometries.  The use of low quality stretch 
parameters in particular, can give crude partial charges, which in turn, can cause computed 
charges and solvation energies to be inaccurate.41 
Table 3.1: Number of each quality of the various force field parameters available in MacroModel for bond 
stretching and angle bending and torsional angle rotation in MSH. 
Stretch Bend Torsion Force 
Fielda High Med Low High Med Low High Med Low 
AMBER* 37 0 0 111 1 0 152 11 0 
AMBER94b -- -- -- -- -- -- -- -- -- 
MM2 75 8 0 140 23 0 143 108 0 
MM3 35 14 14 58 73 137 82 20 1 
MMFF 63 0 0 113 0 0 173 0 6 
OPLS 63 0 0 112 0 1 170 9 0 
OPLS-AA 63 0 0 113 0 0 179 0 0 
aAs implemented by MacroModel v. 8.1; bInsufficient force field constants were available. 
. 
 Based upon the quality rating returned by Macromodel for the parameters of the 
various force fields, the OPLS-AA force field appeared best suited for modelling MSH and 
therefore, was used as the main force field in the MCMM conformational search.  The 
OPLS-AA force field has traditionally been used to model amino acids, but has also been 
parameterized,42 and successfully used to model carbohydrates including disaccharides43-45 
and cyclodextrin.46  In addition, as implemented by MacroModel, OPLS-AA has been 
parameterized for the sulfur atom of thiols.28   
 MSH was also modelled using MCMM methods with the AMBER* force field.  
While this force field returned a medium bend parameter for the bend of the Oring-C1-Olinkage 
angle and medium torsional angle parameters for the cysteine portion of MSH (Table 3.1), its 
use in the study of carbohydrates is well documented.47  This second conformational search 
was performed to detect any inadequacies in the OPLS-AA results. 
3.3.3. Ring Opening during the Conformational Search 
The initial MCMM conformational search using the OPLS-AA force field opened the 
myo-inositol and D-glucosamine rings for torsional angle variation followed by ring closure.  
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This ring opening allowed for an unbiased conformational search.  All of the conformers 
found to be within 3 kcal/mol of the implicitly solvated global minimum structure had a 4C1 
orientation for D-glucosamine.  This orientation is consistent with the known crystal48 and 
solution phase structures49 of N-acetyl-D-glucosamine (as seen in Figure 3.1).  The myo-
inositol ring, however, was found in two orientations with either one equatorial or five 
equatorial substituents.  It is known from solution phase NMR50 and X-ray crystallographic51 
data that myo-inositol prefers the five equatorial/one axial (5 eq/1ax) substituent 
conformation (as seen in Figure 3.1); therefore, all structures with the 1 eq/5 ax orientation 
were eliminated from further consideration (50 structures within 3 kcal of the global 
minimum). 
3.3.4. Gas Phase versus Solvation Phase Modelling 
MSH was modelled in the gas phase, as well as with implicit water solvation using 
the GB/SA implicit water solvation model.  The GB/SA model is a combination of the 
generalized Born and the solvent accessible surface area methods (SASA); the Born model is 
based on electrostatic interactions, dielectric permittivity and orbital overlaps while the 
SASA model assumes that the greatest interaction of the solvent with the solute is in the area 
very close to the solute molecule.10  This method has been shown to be effective in modelling 
carbohydrates47 and has been successfully applied to the conformational analyses of 
ganglioside head groups,52 and mannobiosides and triosides.53  The overlay of the global 
minima of MSH in the gas phase and with implicit water solvation demonstrates the effect of 
solvent shielding on the conformation of a polar compound.  In the gas phase the importance 
of hydrogen bonding and electrostatics can be exaggerated, and folded or collapsed structures 
become more probable.54  In a true aqueous environment, water molecules can provide 
competing hydrogen bonding interactions, which would also affect the structure of a 
molecule.  While implicit water solvation cannot mimic the effect of solute-solvent hydrogen 
bonding, it can provide electrostatic shielding, and lessen the effects of electrostatics to the 
overall structure of the molecule.  As can be seen in Table 3.2, the gas phase and implicitly 
solvated global minimum structures differ in hydrogen bond placement with the gas phase 
global minimum having a more closed structure with the amino acid portion of MSH 
hydrogen bonding to the disaccharide (Figure 3.6).  
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Table 3.2: Hydrogen-bonding interactions for the global minimum conformations of MSH found in vacuo and 
with implicit water solvation using the OPLS-AA force field. 
Phase Number of Intramolecular Hydrogen Bonds Atoms Involveda 
in vacuo 3 C6″=O···H-O-C2′ 
  C6″=O···H-N1″ 
  C2″=O···H-O-C6 
   
water 2 C2″=O···H-S 
  C6″=O···H-N1″ 
aSee Figure 3.1 for numbering 
 
 
Figure 3.6:  Stereoview overlay of the global minimum conformations of mycothiol found for the gas (coral) 
and implicit water (cyan) phases using the OPLS-AA force field. 
3.3.5. Energy Differences Relevant to Biological Systems 
The global minimum conformation is the most energetically favourable form of the 
molecule; however, it may not be the conformation required for protein binding.55  A study 
of 33 ligand-protein complexes found that for majority of the complexes, the protein bound 
ligand conformation was not the global minimum, but rather a conformation with an energy 
within 3 kcal/mol of the global minimum.54  In the case of highly flexible ligands, binding 
conformations with energies of 5 kcal/mol greater than the global minimum have been 
identified.56  It has been suggested that when performing a conformational study, a cut off of 
3 kcal/mol should be applied,55 except in the case of highly flexible ligands.56  While MSH 
has a high degree of flexibility in its cysteine component, there is much less flexibility 
around the disaccharide linkage of myo-inositol and D-glucosamine; hence a 3 kcal/mol cut 
off may be sufficient for the study of MSH.  Only those conformers within 3 kcal/mol of the 
implicitly solvated global minimum structure were studied further. 
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3.3.6. Analysis of the OPLS-AA Data using Clustering Techniques 
Clustering was performed using XCluster, which has been utilized to study a wide 
range of systems including the antibiotic mutacin 1140,57 thrombin inhibitors,58 agouti-
related peptides59 and peptide-tannin systems.60  Clustering of the implicit water OPLS-AA 
data, using the φ and ψ angles of interest, indicated the presence of three distinct clusters 
(Figure 3.7).  The conformation of disaccharides is largely dependent upon the orientation of 
around these two angles as the flexibility of a pyranose ring is rather limited and the 
substituents have little influence on the conformational space of the disaccharide.40  Cluster 1 
is the most highly populated group, with 131 members and contains the OPLS-AA implicitly 
solvated global minimum structure as well as the majority of the structures within 2 kcal/mol 
of the global minium (Figure 3.8). Clusters 2 and 3 contain 13 and 4 members, respectively 
(Figure 3.7 and Table 3.3). An overlay of the local minimum energy conformers from each 
cluster highlights the differences between these angles (Figure 3.9).   
 
Figure 3.7: Clustering of the φ and ψ angles of mycothiol conformers found to be within 3 kcal/mol of their 
respective global minima.  These conformers were generated using the OPLS-AA, AMBER*, AMBER94 and 
PEF95SAC force fields.  The purple box represents the φ and ψ angle ranges of MSH-S-bimane as determined 
by NMR data.12  There are two conformers found using AMBER*, which are not shown in this figure with 
(φ,ψ) = (-27°, -155°) and (-28°, -155°).   
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Figure 3.8: Comparison of the φ and ψ angles and energy (kcal/mol) determined for MSH using the OPLS-AA 
force field and implicit water solvation.  
 
 
Figure 3.9: Stereoview of the superimposition of the lowest energy conformers (C1-C3) of each of the cluster 
as determined by the OPLS-AA force field with implicit water solvation: cyan = Cluster 1 (C1), also the global 
minimum; coral = Cluster 2 (C2); green = Cluster 3 (C3). 
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Table 3.3: Comparison of the three clusters and global minima of the implicitly solvated MSH conformers 
generated in this study. 
 Cluster 1 Cluster 2 Cluster 3 GMa 
MacroModel     
OPLS-AAb     
φ Dihedral -55° to -26° -33° to -14° 19° to 32° -48° 
ψ Dihedral -49° to -10° 36° to 55° 17° to 24° -33° 
No. of members 131 13 4 -- 
     
AMBER*c,d     
φ Dihedral -52° to -22° -37° to -23° -- -25° 
ψ Dihedral -34° to 19° 46° to 54° -- -17° 
No. of members 101 13 -- -- 
     
MOE2004     
AMBER94e     
φ Dihedral -55° to -28° -44° to -8°f 8° to 30°g -31° 
ψ Dihedral -38° to -13° 22° to 51° 28° to 43°g 43° 
No. of members 391 390 285 -- 
     
PEF95SACe     
φ Dihedral -56° to -47° -39° to 27° 20° to 30° -36° 
ψ Dihedral -29° to -23° 42° to 58° 43° to 45° 52° 
No. of members 66 1782 12  




    
φ Dihedral -66° to -42°    
ψ Dihedral -22° to 18°    
aImplicitly solvated global minimum; bAs implemented by MacroModel v. 8.1; cAs implemented by 
MacroModel v. 9.0; dTwo outlying angle combinations were found with (φ, ψ) = (-27°, -155°) and (-28°, 155°), 
no angle combinations corresponding to Cluster 3 were found; eAs implemented by MOE2004; fOnly two 
conformers were found to have φ angles of -8°, all others in this cluster were below -17°; gOne outlying 
conformer was determined with (φ,ψ) = (54°, 61°); hAngle ranges suggested by NOE data reported for 
mycothiol-S-bimane. 
3.3.7. AMBER* Conformational Search and Comparison of Results to OPLS-AA 
The OPLS-AA force field was determined to be best suited to model the diverse atom 
types of MSH.  To ensure accurate modelling of the carbohydrate portion of MSH, 
AMBER*, a force field well-known for modelling carbohydrates,47  was used to detect any 
modelling inadequacies in the OPLS-AA results.  Within the 148 structures found by the 
OPLS-AA conformational search to be within 3 kcal/mol of the global minimum 
conformation with the correct orientation of myo-inositol and D-glucosamine, there was very 
little variation in the ring torsional angles.  Therefore, the AMBER* search froze the internal 
torsion angles of the two carbohydrate rings after an initial minimization with AMBER*.  
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This modification shortened the overall time of the conformational search by reducing the 
number of torsional angles available for random changes.   
Similar to the OPLS-AA results, the majority of the structures found to be within  
3 kcal/mol determined using AMBER*, including the global minimum, were found in 
Cluster 1 (101 conformers, Table 3.3).  There were some outlying structures found with the 
AMBER* force field that belonged to Cluster 1 with a φ angle of ~50° and ψ angles ranging 
from -20° to 20°.  These structures are not seen with any other force field used (OPLS-AA, 
PEF95SAC or AMBER94).  A medium quality parameter is present for the bond of the Oring-
C1-Olinkage bond angle.  Lower quality parameters can affect the relative energetics of 
optimized geometries.  It is possible that this medium quality parameter altered the calculated 
energetics, allowing for φ and ψ angle combinations within 3 kcal/mol of the global 
minimum which were found to be of higher energy with the other force fields (Table 3.3).   
This low quality parameter may also be responsible for the absence of any φ and ψ angle 
combinations consistent with Cluster 3 among the conformations found to be within  
3 kcal/mol of the global minimum (Figure 3.7) and the identification of two outlying low-
energy conformers with (φ,ψ) = (-27°, -155°) and (-28°, -155°). 
3.3.8. Comparison of the Monte Carlo Multiple Minimization and MOE Stochastic 
Search Results 
Initially the PEF95SAC conformational search performed by Professor France-
Isabelle Auzanneau did not hold the myo-inositol or D-glucosamine rings rigid which allowed 
for ring flipping.  In the case of myo-inositol, this flipping led to changes in the absolute 
configuration of the carbon atoms of the myo-inositol ring.  The myo-inositol ring was 
therefore held fixed after initial optimization for all further studies.  In addition, any resultant 
conformations of MSH found not to have the 4C1 orientation for D-glucosamine were 
eliminated from the database as N-acetyl-D-glucosamine has been shown to prefer 4C1 
orientation.48,49 
 The MOE stochastic search used random torsion angle changes combined with a 
Cartesian perturbation, as opposed to the MCMM method.  A comparison of the MOE results 
with those of the OPLS-AA force field were in good agreement with respect to the φ and ψ 
angle ranges found (Figure 3.7 and Table 3.3).  This agreement implies that both methods 
adequately covered the conformational space of MSH and it is unlikely that low energy 
conformations†† exist with φ and ψ angles outside of these ranges.   
 There was some variation in the cluster populations between the various force fields.  
The conformations found using the AMBER94 force field were almost evenly distributed 
between the clusters, with Clusters 1 and 2 being slightly favoured.  In contrast, over 95 % of 
the conformations found using the PEF95SAC force field belonged to Cluster 2 (1782 
conformations) while only 66 and 12 conformations belonged to Clusters 1 and 3.  Unlike the 
OPLS-AA and AMBER* results, the global minimum structures of the AMBER94 and 
PEF95SAC searches were found in Cluster 2.  While the relative energetics of the clusters 
differed between the various force fields, the overall φ and ψ angle ranges were in agreement, 
indicating that the conformations obtained are independent of force field (Figure 3.7 and 
Table 3.3).   
                                                 
††Those with energies within 3 kcal/mol of the global minimum. 
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 The determination of which basis set is best suited for the study of carbohydrates is a 
difficult process.  There is a lack of suitable experimental data available to act as benchmarks 
for the thorough testing of the force fields available for carbohydrate modelling.47  A 
comparison of 20 force fields commonly used for the modelling of carbohydrates, including 
PEF95SAC, AMBER94 and AMBER*, indicated that it is impossible to give an objective 
determination of the suitability and quality of the force fields available.47  A number of 
criteria were used to evaluate the force fields including their ability to model the geometry 
and energy of methyl glucopyranoside. Only the AMBER* force field was able to 
successfully predict energy differences between the α and β anomers.  AMBER94 gave a 
small preference for the β anomer while PEF95SAC returned unreasonably high preference 
for the α-anomer (~7 kcal/mol compared to the experimental value of 0.4 kcal/mol).  These 
energy discrepancies could account for the location of the global minimum energy structures 
determined by PEF95SAC and AMBER94 for MSH in Cluster 2, as opposed to in Cluster 1 
similar to OPLS-AA and AMBER*.  In addition, as implemented by MacroModel, 
AMBER94 was missing parameters for the atom types of MSH.  MOE does not return 
information regarding the quality or number of parameters available for the study of a 
particular molecule; but it is likely that the implementations of the force fields are similar 
between the two software packages.  Personal communications with MOE indicated that in 
the event of a missing parameter for a particular atom type, a generalized one is used in its 
place.  This generalized parameter could also contribute to the location of the global 
minimum in Cluster 2.  AMBER* was found to have some medium quality parameters for 
the atom types of MSH.  These parameters may account for the outlying φ and ψ angle 
combinations found by this force field to be within 3 kcal/mol of the global minimum.   
Based upon the above considerations, and the solely high quality rating for the 
parameters of the OPLS-AA force field, it was concluded that this force field was probably 
best suited for the study of MSH and the results obtained by this force field are the most 
reliable.  The dihedral angle ranges determined using OPLS-AA were in fairly good 
agreement with the other three force fields, indicating that likely these ranges are valid.  The 
energetic differences between the force fields may be related to variations in 
parameterization.  Based upon the energetics of the OPLS-AA results (Figure 3.8) MSH 
would most likely be found with the φ and ψ angle combinations consistent with Cluster 1, 
with some contributions from Clusters 2 and 3.   
3.3.9. Comparison to the Structure of a Bimane Derivative of Mycothiol Obtained 
Using NMR Methods. 
 A crystal structure of MSH is not yet available for comparison; however a solution 
phase structure of a bimane derivative of MSH (MSmB, 3-2, Figure 3.10) has been recently 
reported.12  This structure was determined by NMR using key inter-hydrogen atom distances 
obtained from NOE data.  MSmB is a substrate for MCA, the enzyme responsible for the 
cleavage of MSH-S-conjugates formed by the reaction of MSH with electrophiles.6-8  The 
structure of MSmB was therefore used as a comparison against the implicitly solvated MSH 
conformers found in this study.  The local minimum energy structures (C1-C3, Figure 3.9) of 
the three clusters, as found by the OPLS-AA force field, were used as representative 
structures of Clusters 1 to 3.  In the case of Cluster 1, the local minimum energy structure 
was also the global minimum conformation.  The structures were compared using important 
- 82 - 


























Figure 3.10: The bimane derivative of mycothiol (MSmB, 3-2), a substrate for mycothiol-S-conjugate amidase. 
The MSmB structure is in good agreement with C1 with respect to the select 
cysteinyl angles shown in Table 3.4.  A comparison of the key interatom distances used to 
determine the NMR structure of MSmB is shown in Table 3.5.  Among the three 
representative structures, C2 and C3 are more similar to each other than to C1, as can be 
seen in Figure 3.9.  This overlay demonstrates that the myo-inositol ring of C1 is oriented 
away from the myo-inositol rings of C2 and C3.  All three representative structures satisfy 
the interatom distance ranges determined from NOE data for H1-H1′, H1″-H3″, H5″-H3″, H5-H1′, 
and CH3-H5″ (Table 3.5, see Figure 3.10 for numbering).  Only C1 satisfies the distance 
ranges reported for H1-H6′, H5-H2′ and CH3-H6′ (Table 3.5).  C2 and C3 satisfy the range 
reported for H1-H2′, while C1 does not.  The orientation of the myo-inositol ring in C1 brings 
H6′ close to H1 and places H2′ away from H1, such that it cannot satisfy the H1-H2′ NOE 
predicted distance range.  The reverse is true for C2 and C3.  The inability of one local 
minima conformer to satisfy the criteria of the MSmB structure indicates that MSH does not 
exist as a static structure in solution, but is likely conformationally flexible.  This hypothesis 
is supported by a comparison of the φ and ψ angles calculated in this study and those 
determined for MSmB.  There is some overlap between the NOE predicted angle ranges and 
those found in Cluster 1, as seen in Table 3.3 and Figure 3.7.  MSmB is likely able to sample 
conformations of all three clusters on the time scale of the NMR experiment, leading to 
averaged values that do not correspond to one cluster alone.  Carbohydrates are fairly flexible 
molecules with respect to their glycosidic linkage and multiple conformations can exist in 
solution; therefore, any NMR data obtained will likely represent a time-averaged 
conformation.61  Care must be taken when using NOE data for structural determination as the 
measured value is an average which can lead to a single nonexistent conformation.61  It is 
therefore likely that the solution phase structure predicted for MSmB by NMR is a weighted 
average of the conformations found within each cluster.     
Table 3.4: Comparison of selected cysteinyl torsional angles from representative structures of the implicitly 
solvated MSH conformers found with the OPLS-AA force field to those of the bimane derivative of mycothiol 
found using NMR techniques.   
Torsion Angles NMR data C1b 
H-C3″-C2″-O Trans 125.3° 
O-C2″-N1″-H Trans 174.0° 
H-N5″-C3″-H -150° -140.1° 
aMahadevan et al. (2003);12  bC1 is also the global minimum. 
- 83 - 
Table 3.5: Comparison of key inter-hydrogen distances for representative structures of the implicitly solvated 
mycothiol conformers found with the OPLS-AA force field to those of the bimane derivative of mycothiol 
found using NMR techniques. 
Atomsa 
Structure 









NMRc Sd Md M Wd S S′d W′ W″d S″ 
C1e 2.6f 4.4 3.4 3.2 2.7 2.5 2.9 3.1 3.0 
C2 2.3 2.7 4.5 4.3 3.6 2.2 2.9 7.1 2.9 
C3 2.3 2.7 4.5 4.6 4.7 2.2 2.9 7.8 2.9 
aSee Figure 3.10 for numbering; bThe CH3 distance was obtained by averaging the distance from each H of the 
CH3 group to either H6′ or H5″; cMahadevan et al.;12 dS: strong (1.8 – 3.0 Å, M: medium (1.8 – 4.0 Å), W: weak 
(1.8 – 5.0 Å), S′: strong (1.8 – 3.2 Å), W′: (1.8 – 5.2 Å), S″: (1.8 – 3.5 Å), W″: (1.8 – 5.5 Å); eRepresentative 
structures from Clusters 1 (C1), 2 (C2) and 3 (C3).  These values are the implicitly solvated local minima from 
each cluster determined using the OPLS-AA force field; fValues in bold are in agreement with the NMR data. 
3.3.10. Applications to Drug Design 
Knowledge of the important angles or conformations of MSH could be of great 
assistance for the design of antimicrobials against Mycobacteria.  MSH is not found in 
eukaryotes and mutants of Mycobacteria deficient in the production of MSH have shown 
increased sensitivity to electrophiles, free radicals and antibitotics.62 The enzymes known to 
require MSH as an essential cofactor are therefore potential targets for the development of 
new therapeutics against Mycobacteria.  For example, a number of natural products and 
similar synthetic inhibitors have been identified for MCA,34,35,63 and there is intense interest 
in the development of substrate based inhibitors targeted at MCA and other MSH-utilizing 
enzymes.36,37,64  Substrate or transition state based inhibitors show some structural similarity 
to the substrate or mimic the properties of the transitions state of the reaction.  For example, 
enzymes that use trypanothione, the major thiol of the Leishmania and Trypanosoma65,66 are 
targets for development for antipathogetic therapeutics.67  A number of substrate based 
analogues have been developed which have inhibitory activity68,69 against trypanothione 
reductase, the enzyme responsible for maintaining trypanothione in its biologically useful 
reduced form.70-75  Select examples of these analogues can be seen in Figure 3.11.  The 
development of substrate-based inhibitors of MSH is ongoing64 and any information gained 
in this study regarding the preferred φ and ψ angles of MSH may aid in the design of 
inhibitors aimed at MSH-utilizing enzymes.  
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Figure 3.11: Trypanothione and select examples of substrate based inhibitors of trypanothione reductase. 
3.4. Conclusions and Future Work 
A detailed conformational investigation was performed on the novel intracellular 
glycothiol MSH, which is found solely in the Actinomycetales bacteria, including the 
medically important M. tuberculosis.  The OPLS-AA force field was used for MCMM 
calculations performed on MSH in vacuo and with implicit water solvation.  The global 
minimum energy structures of MSH in the two phases were found to be similar; however, 
intramolecular hydrogen-bonding played a greater role in the conformation of MSH in vacuo 
than when modelled with implicit water solvation.  This result is attributed to the lack of 
electrostatic shielding present in vacuo, as compared to solvated MSH. 
To detect any inadequacies in the OPLS-AA results, MSH was also modelled using 
AMBER* and the MCMM method, and using AMBER94 and PEF95SAC with a stochastic 
search method.  Conformers within 3 kcal/mol of the respective global minimum structure 
were compared and it was found that these conformations were independent of the force 
fields used.  All conformations clustered into three distinct families based upon the φ and ψ 
angles of the disaccharide.  Based upon the population of these clusters it is expected that 
MSH will be found predominantly with φ and ψ angles ranges of -55° to -26° and -49° to  
-10° or -44° to -14° and 22° to 58°.  This data compares favourably to a previously 
determined NMR structure of the bimane derivative of MSH.  Knowledge of the preferred 
conformations of MSH may aid in the design of substrate based inhibitors aimed at MSH-
utilizing enzymes. 
Future conformational studies of MSH could include the use of a higher level of 
theory to minimize the geometries generated by the MCMM algorithm.  In addition, the 
determination of a solution phase NMR or an X-ray crystal structure of MSH would provide 
greater insight into the behaviour and interactions of this critical glycothiol.  The 
determination of the structure of MSH bound to an enzyme would greatly enhance our 
understanding of the interactions which are essential to MSH binding and would aid in the 
design of MSH-based enzyme inhibitors.   
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Chapter 4: Efforts Towards the Identification of a Mycothiol-
Utilizing Glyoxalase System 
Mycobacteria are the causative agents of such diseases as tuberculosis 
(Mycobacterium tuberculosis),1 leprosy (Mycobacteria leprae)2 and Buruli ulcers 
(Mycobacterium ulcerans).3  Combined, these diseases affect over 9 million people 
worldwide.1-3  In the case of tuberculosis, over 1.69 million people succumbed to 
tuberculosis in 2004 alone.  Drug resistant strains of M. tuberculosis have been documented 
in every country surveyed and strains of M. tuberculosis resistant to all major anti-tuberculins 
have emerged, threatening the efforts to control tuberculosis outbreaks.1  The need for novel 
drug targets in Mycobacteria is essential for the future control of tuberculosis and other 
diseases caused by Mycobacteria.   
 Unlike humans and other eukaryotes, Mycobacteria and other Actinomycetales 
bacteria do not produce glutathione (GSH, 4-1), but rather use the novel glycothiol mycothiol 
(MSH, 4-2) as their major thiol.4  Mutants of M. tuberculosis deficient in the biosynthesis of 
MSH are not viable5,6 and MSH deficient mutants of Mycobacteria smegmatis are 
hypersensitive to toxic agents such as alkylating agents, free radicals, and antibiotics.7  The 
MSH biosynthetic and metabolic pathways are therefore attractive targets for the 
























Mycothiol (MSH, 4-2)  
Figure 4.1: Glutathione and mycothiol.  
The known MSH-dependent enzymes parallel GSH pathways in function; hence the 
biochemistry of GSH may serve as a template for the discovery of new roles for MSH.  Of 
particular interest to our laboratory is the possible existence of an MSH-dependent 
glyoxalase (Glx) system.  The two enzyme Glx system (Figure 4.2) is responsible for the 
removal of cytotoxic methylglyoxal (MG, 4-3) from the cell9 and our laboratory has 
extensive experience in the study of the first step (GlxI) of bacterial Glx systems.10-15  
Streptomcyes coelicolor, an organism known to produce MSH,4 was chosen for our studies 
due to its non-pathogenicity, ease of handling and its complete genome having been 
sequenced.16  The discovery of an MSH-dependent Glx system would provide a novel target 
for the development of anti-mycobacterial agents due to its essential role in the removal of 
cytotoxic MG. 


















































Figure 4.2: The two-enzyme glyoxalase (Glx) system composed of GlxI and GlxII. 
4.1. Introduction 
The use of GSH as a template for the discovery of new thiol functionalities is not 
novel.  The Trypanosomatidae, which include the causative agents of Chagas disease17 and 
African sleeping sickness,18 use trypanothione (TSH2, Figure 4.3, 4-7) as their major 
thiol.19,20  The enzymes thus far discovered as TSH2-dependent parallel GSH-dependent 
enzymes, including peroxidase,21,22 GlxI,23,24 GlxII,25 TSH2-S-transferase26,27 and TSH2 
disulfide reductase.28-31  It is expected that similar to TSH2, new MSH functions can be 






















Figure 4.3: Trypanothione (TSH2). 
4.1.1. Parallel Functions of Glutathione and Mycothiol Utilizing Enzymes 
The four enzymes that have been identified to date as requiring MSH are maleyl 
pyruvate isomerase,32 formaldehyde dehydrogenase,33-36 MSH-S-conjugate amidase37,38 and 
MSH disulfide (MSSM) reductase.39,40  As seen in Table 4.1, all of these enzymes have 
counterparts in GSH biochemistry.41-44  It is expected that many of the known GSH-
dependent enzymes, such as GSH-S-transferase and the Glx system have MSH counterparts 
in the Actinomycetales bacteria. 
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Table 4.1: Comparison of known glutathione and mycothiol biochemistry. 
GSH Utilizing Enzyme MSH-Utilizing Enzyme 
Formaldehyde dehydrogenase Formaldehyde dehydrogenase 
First step in the conversion of formaldehyde 
to formic acid45 and is involved in the 
metabolism of S-nitroso-GSH46,47 
First step in the conversion of formaldehyde 
to formic acid33-35 and is involved in the 
metabolism of S-nitroso-MSH36 
Found in animals, plants, certain bacteria45 Isolated from Amycolaptopsis methanolica, 
Rhodococcus erythropolis33-35 and                  
Mycobacterium smegmatis36 
  
GSH disulfide reductase MSH disulfide reductase 
Reduces GSH disulfide to the free thiol 
form44 
Reduces MSH disulfide to the free thiol 
form39,40,48 
Found in certain bacteria, fungi, plants 
protozoa and animals44 
Isolated from M. tuberculosis39,40,48 
  
GSH-S-conjugate metabolism MSH-S-conjugate amidase 
GSH-S-conjugates are converted to 
mercapturic acids, which are then excreted 
from the cell43 
Hydrolyzes MSH-S-conjugates to form 
mercapturic acids which are then excreted 
from the cell37,38 
Isolated from mammals, certain insects, 
plants, squid and bacteria49 
Isolated from M. smegmatis37,38 
  
Maleyl pyruvate isomerase Maleyl pyruvate isomerase 
Converts maleyl pyruvate to fumaryl 
pyruvate during the metabolism of aromatic 
species41 
Converts maleyl pyruvate to fumaryl 
pyruvate during the metabolism of aromatic 
species32 
Identified in Salmonella typhimurim,50 
Pseudomonas acidovorans,51 Klebsiella 
pneumoniae,52 Ralstonia sp. Strain U253 and 
Morexella OA354,55 
Isolated from Corynebacterium glutamicum32 
4.1.2. A Brief Review of the Glutathione-Dependent Glyoxalase System 
The two enzyme Glx system converts cytotoxic MG to D-lactate (4-6), using GSH as 
an essential cosubstrate (Figure 4.2).  MG is produced during glycolysis when the 
deprotonation of dihydroxyacetone phosphate (DHAP, 4-8) by triose phosphate isomerase 
(TIM) is followed by phosphate elimination rather than reprotonation (Figure 4.4).56,57  While 
reprotonation occurs 106 times more frequently than phosphate elimination, the high cellular 
concentration of TIM can result in the accumulation of large concentrations of MG.56,57  In 
microorganisms, MG is also produced directly from DHAP in a by-pass to phosphorylating 
glycolysis.58,59  When organisms have limited access to phosphate, DHAP can accumulate 
and MG synthase, in conjunction with the Glx system, may serve as a pathway for the 
formation of pyruvate with the release of phosphate.  The cellular concentration of MG must 
be tightly controlled as it can form adducts with proteins and nucleic acids, and can inhibit 
protein biosynthesis.60 












































Figure 4.4: The isomerization catalyzed by TIM: dihydroxyacetone phosphate (DHAP, 4-8) is converted to 
D-glyceraldehyde-3-phosphate (DGAP, 4-9) via a deprotonation and reprotonation mechanism.  When inorganic 
phosphate (Pi) is eliminated (pathway A) methylglyoxal (MG, 4-3) is formed56 
The true substrate of the first enzyme in the Glx pathway, GlxI, is the hemithioacetal 
(4-4) formed non-enzymatically by the reaction of MG with GSH (Figure 4.2).9 This 
hemithioacetal is deprotonated and reprotonated by GlxI to yield S-D-lactoylglutathione  
(4-5), which is then hydrolyzed by GlxII to yield D-lactate (4-6) and GSH (4-1, Figure 4.2).  
GlxI has been characterized or identified in humans,61-63 mice,64 yeasts,65,66 plants,67-74 
insects,9 protozoa,75 fungi76 and in at least 42 strains of bacteria,9,10 including Escherichia 
coli.14  GlxII, however, has not been as thoroughly characterized. It has been identified in 
humans,45,77 rats,78,79 yeasts,80,81 plants82-85 and Candida albicans86 and has been cloned from 
humans,87 Arabidopsis thaliana,88 Saccharomyces cerevisiae89 and Neisseria meningitidis.90  
In addition, a single enzyme, termed GlxIII, has been identified in E. coli, as catalyzing the 
conversion of MG to D-lactate without the need for a thiol cofactor.91  Due to its sensitivity to 
thiol blocking agents, it is believed that an active site thiol group may be involved in the 
reaction.91  The identification of the Glx system in such a diverse sampling of organisms 
makes it appear likely that such a system would exist in the Actinomycetales bacteria. 
4.1.3. The Trypanothione-Dependent Glyoxalase System 
The Glx system has also been identified in Leishmania24,25,92-94 and Trypanosoma23,95 
and is reliant upon TSH2 as an essential cosubstrate, in lieu of GSH.  The TSH2-dependent 
GlxI enzyme is specific for the hemithioacetal formed from TSH2 and MG24 and forms 
mono- and bis-S-D-lactoyltrypanothione,95  the substrates of TSH2-dependent GlxII.  The 
TSH2-dependent GlxI enzyme from Leishmania major demonstrates high substrate 
specificity for TSH2-based hemithioacetals and is insensitive to GSH based inhibitors.  It is 
thought that the structural differences between the human and L. major GlxI enzymes may be 
responsible for the specificity of the L. major enzyme.  This specificity makes TSH2-
dependent GlxI an attractive target for design of novel therapeutics against the pathogenic 
Trypanosoma.24  The identification of a non-GSH dependent Glx system reinforces our belief 
that an MSH-dependent system exists and its probable divergent substrate specificity from 
that of humans, would make it an excellent target for the development of novel anti-
microbial agents targeted against Mycobacteria.  In addition, a biochemical comparison of 
the identified enzyme to the previously characterized GSH, and TSH2 dependent Glx 
enzymes would be of interest as an example of convergent evolution. 
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4.1.4. Methods Used for the Detection of the Glyoxalase System 
The assays developed for the detection of GlxI and GlxII activity rely on 
spectrophotometric methods to monitor the formation and degradation of their respective 
products.  S-D-Lactoyl-glutathione96-98 and trypanothione,23,24 formed by GlxI, display a 
characteristic absorbance at 240 nm, which can easily be monitored to quantify GlxI 
activity.24,99  The formation of D-lactate, the product of GlxII, cannot be directly observed by 
absorbance; however, GlxII activity can still be monitored spectrophotometrically.  The 
simplest method to quantify GlxII activity is to monitor the decrease in absorbance seen at 
240 nm, which corresponds to the consumption of S-D-lactoylglutathione and  
S-D-lactoyltrypanothione.25,95,99,100  The free thiol released by GlxII with each turnover can 
also be trapped by a thiol reactive reagent such as Ellman’s reagent [5,5′-dithio-bis(2-
nitrobenzoic acid), DTNB], which upon reaction, releases a chromophore having a 
characteristic absorbance at 412 nm.95,101  Finally, the formation of D-lactate can be followed 
using D-lactate dehydrogenase (D-LDH).  D-LDH converts D-lactate to pyruvate with the 
simultaneous reduction of NAD+ to NADH (Eq. 4.1); the latter displays a characteristic 
absorbance at 340 nm.95,102  To quantitatively monitor GlxII activity, the pyruvate formed by 
D-LDH must be removed from the equilibrium; therefore trapping agents, such as hydrazine, 
are often used in conjugation with basic pH (i.e., pH 9).102  It is important to monitor for 
GlxII activity, as opposed to solely that of GlxI, when studying cell-free extracts as the 
activity of GlxII may be greater than that of GlxI, making the observation of a change at  
240 nm, and the formation of the S-D-lactoyl intermediate, difficult.  The use of an LDH 
assay would also be effective in the detection of a GlxIII enzyme, which converts MG 
directly to D-lactate without the need of GSH.91 
 
 D-Lactate + NAD+ + Hydrazine  Pyruvate Hydrazone + NADH + H3O+  Eq. 4.1 
  
 Glx activity can be successfully detected using the described methods; therefore if an 
MSH-dependent Glx system, or a GlxIII enzyme, exists in S. coelicolor, it should be 
detectable using these techniques. 
4.1.5. Introduction to Streptomyces Bacteria 
Unlike the Mycobacteria, the Streptomyces bacteria are of little clinical interest;* 
however, they are industrially important producers of a large number of antibiotics.103   
Approximately two-thirds of the known antibiotics produced by microorganisms are 
attributable to the Actinomycetales bacteria and nearly 80 % of these antibiotics are produced 
by Streptomcyes bacteria.  A sampling of these antibiotics is shown Table 4.2.  Similar to 
other Actinomycetales bacteria, Streptomyces have been shown to produce MSH as their 
major intracellular thiol (Table 4.3)4 and the biosynthetic enzymes responsible for MSH 
production in S. coelicolor have been identified and their activities confirmed 
experimentally.104  The complete genome of S. coelicolor has been sequenced16 and is 
available for data mining.†  S. coelicolor is an attractive target for our investigations into the 
presence of an MSH-dependent Glx system as it is known to produce MSH.  The availability 
of its complete genome sequence would also help in the development of an over-expression 
system for any Glx type enzymes identified.   
                                                 
* Streptomyces somaliensis is the only known human pathogen of this genus. 
† http://www.sanger.ac.uk/Projects/S_coelicolor/ 
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Table 4.2: Useful antibitoics produced by Streptomyces bacteria.103 
Antibiotic Producer Application Antibiotic Producer Application 
Actinomycin D S. spp. Antitumour Mitomycin C S. caespitosus 
S. verticillus 
Antitumour 
Avermectin S. avermitilis Antiparasitic Neomycin S. fradiae Antibacterial 
Bialaphos S. hygroscopicus Herbicidal Novobiocin S. niveus Antibacterial 
Bleomycin S. verticillus Antitumour Oleandomycin S.antibiticus Antibacterial 
Candicidin S. griseus Antifungal Oxytetracyclin S. rimosus Antibacterial 
Chloramphenicol S. venezuelae Antibacterial Phleomycin S. verticillus Antitumour 
Chlortetracycline S. aureofaciens Antibacterial Pristinamycin S. pristinaespiralis Antibacterial 
Cycloserine S. orchidaceus Antibacterial Spectinomycein S. spectabilis Antibacterial 
Daptomycin S.roseosporus Antibacterial Spiramycin S. ambofaciens Antibacterial 
Fosfomycin S. spp. Antibacterial Streptogramins S. graminofaciens Antibacterial 
Kanamycin S. kanamyceticus Antibacterial Streptomycin S. griseus Antibacterial 
Lincomycin S. lincolnensis Antibacterial Tetracycline S. aureofaciens Antibacterial 
Milbemycin S. hygroscopicus Antiparasitic Thienamycine S. cattleya Antibacterial 
Mithramycin S. argillaceus Antitumour Tobramycin S. tenebrarius Antibacteria 
 
   
Table 4.3: Thiols produced by Streptomyces bacteria.105 
Thiol (μmol/g [residual dry weight])a 
Strains MSH Cys GSH H2S CoA Other 
Streptomyces clavuligerus 5.40 0..78 <0.01 1.3 0.8 1.55b 
Streptomyces coelicolor 2.80 0.56 <0.02 0.75 0.5 <0.02c 
Streptomyces jumonjinensis 6.70 1.30 <0.09 0.83 1.9 1.1b 
Streptomyces lactamdurans 5.90 1.30 <0.08 1.3 1.1 23.05d 
Streptomyces lividans 6.60 0.58 <0.06 1.3 1.0 0.51b 
aMSH: mycothiol, Cys: cysteine, GSH: glutathione, H2S: hydrogen sulfide, CoA: coenzyme A, adapted from Newton et al. (1996);4 bδ-(L-α-amino-adipyl)-L-
cysteinyl-D-valine (ACV) and an unknown thiol; bACV; cACV and ergothioneine. 
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4.1.6. The Synthesis of Mycothiol 
MSH is not commercially available and the enzymes involved in its biosynthesis have 
not yet been fully characterized (Figure 4.5); hence, production of large quantities of MSH 
through the over-expression of its biosynthetic enzymes is not possible at this time.  The 
synthetic preparation of MSH is not a trivial matter.  The presence of the myo-inositol ring 
requires extensive protection and deprotection and the correct stereochemistry of the 
resulting product is essential for its use in enzymatic assays.106,107  This latter criterion is 
further complicated by the reversal of the numbering conventions for myo-inositol published 
during the 1970s: what was previously considered an L- configuration of the myo-inositol 
ring is now labeled as D108 (see Chapter 5 for a more detailed discussion of myo-inositol 
stereochemistry).  This reversal led to confusion in the initial structure determination of 
MSH: the solved structure was labeled as a D structure but was depicted as L.105,109  This error 
was perpetuated in papers detailing partial syntheses of MSH, as well as enzyme and 
substrate specificity.  This issue was resolved by the total synthesis of the bimane derivative 
of MSH (MSmB) and the characterization of MSH-S-conjugate amidase, an enzyme known 
to accept MSmB as a substrate.107  MSH was unambiguously determined to have the original 













































































Cys-GlcN-Ins (4-15)  
Figure 4.5: The biosynthesis of mycothiol. While the activity of the second enzyme in this pathway, MshA2, 
has been identified, the enzyme has not.   
The reported syntheses of MSH are inefficient modes for the production of MSH.  
The first published synthesis of MSH by Jardine et al. (Figure 4.6) had an overall yield of 
less than 2 % over 6 steps110  The key step, the coupling of cysteine to the disaccharide was 
accomplished using the cell-free extract of M. smegmatis111 to yield a mixture of MSH and 
des-acetyl-MSH.110  Unfortunately, this synthesis was published before the clarification of 
the stereochemistry of MSH, which casts doubt over the results of this method.  The 
published synthesis of MSmB,107 used to determine the stereochemistry of MSH (Figure 4.7), 
could be used as a basis for the synthesis of MSH.  The alkylation of the cysteine by 
monobromobimane could be replaced by the protection of the sulfur atom followed by 
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deprotection as the final step.  Unfortunately the reported overall yield of MSmB was less 
than 1 %.107  The first total synthesis of MSH and the MSH disulfide (MSSM) was reported 
by Lee and Rosazza in 2004 (Figure 4.8),112 and the resultant product was confirmed to be of 
the correct stereochemistry; however, the overall yield was, again, less than 1%.  These 
syntheses, though significant accomplishments, are not useful methods for the production of 
the quantities of MSH required for enzyme identification and characterization, i.e. the 
amounts needed for the monitoring of protein fractions from chromatographic steps or 
detailed kinetic studies.   
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Figure 4.6: The synthesis of MSH as reported by Jardine et al.110  Reagents: (i) 1-ethoxycyclohexene, p-
toluenesulphonic acid and DMF; (ii) NaH, BnBr and toluene; (iii) camphanic acid chloride and NEt3 in CH2Cl2; 
(iv) (a) KOH in ethanol; (b) 80 % acetic acid (v/v); (v) acetic anhydride and pyridine; (vi) H2 and Pd/C; (vii) 
AgOTf, 2,6-tert-dibutylpyridine and CH2Cl2; (viii) Amberlite IR400 (OH).  The addition of cysteine was 
achieved enzymatically through the addition of the boxed structure to crude cell-free extract of Mycobacterium 
smegmatis. 

















































iv: 4-31: R2 = Ac


















Figure 4.7:  Synthesis of the bimane derivative of mycothiol as described by Nicholas et al.107  Reagents: (i) 
2,4,6-tri-O-acetyl-2-azido-2-deoxy-α-D-glucopyranosyl chloride, AgOTf, 2,6-diisopropyl-4-methyl-pyridine, 
CH2Cl2; (ii) 1. ethyleneglycol, (+)-camphor sulfonic acid, CH3CN, 2. Ac2O, pyridine; (iii) Pd-C, H2, EtOAc; 
(iv) DEPC, iPr2EtN, DMF, N-Ac-Cys-R1 (shown in above figure); (v) Mg(OMe)2, MeOH (dry). 





































































































































Figure 4.8: Syntheis of mycothiol as reported by Lee and Rosazza.112  Reagents: (i) p-TsOH, CH2Cl2; (ii) BnBr, 
NaH, PhMe; (iii) DMAP, TEA, CH2Cl2; (iv) 1. KOH, EtOH; 2. AcOH, H2O sthen Ac2O, pyridine; (v) H2, Pd-C, 
EtOAc; (vi) TMSOTf, molecular sieves, CH2Cl2; (vii) H2, Pd-C, EtOAc, HCl; (viii) HATU, HOAt, collidine, 
DMF; (ix) Mg(OMe)2, MeOH; (x) H2O. 
4.1.7. The Use of Truncated Mycothiol as a Probe for Enzymatic Activity 
Interest in identifying MSH-dependent enzymes preceded the publication of synthetic 
methods for the production of MSH.  To avoid the complicated protection and deprotection 
strategies required by the inclusion of the myo-inositol moiety, an oxidized, truncated MSH 
analogue, des-myo-inositol mycothiol, was used to successfully identify MSSM reductase 
activity in M. tuberculosis.  The truncated disulfide substrate provided sufficient features of 
MSSM to act as an active analogue.  The synthesis of this truncated version reported an 
overall yield of ~ 9 % over four steps,113 making it an attractive tool for initial attempts to 
identify MSH-dependent enzyme activity. 
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Figure 4.9: Synthesis of des-myo-inositol mycothiol as reported by Patel and Blanchard.  Reagents: (i) HOBt, 
α-d-glucosamine, DMF; (ii). 5 % piperidine in DMF, (iii) acetic anhydride, K2CO3, H2O; (iv) Tl(CF3CO2)3, 
anisole, TFA.113 
4.1.8. Isolation of Mycothiol from Cell-Free Extracts 
While a truncated version of MSH would be useful for identification, the accurate 
determination of an enzyme’s kinetic parameters and full characterization requires the 
enzyme’s true substrates, i.e. MSH.  The synthetic methods for preparation of MSH are less 
than satisfactory for the production of sufficient quantities for enzyme characterization.  
MSH; therefore, MSH must be isolated from cell-free extracts.  In the first protocol published 
for the isolation of MSH, it was purified directly from cell-free extracts using HPLC 
techniques.114  This method is not necessarily useful for the isolation of large quantities of 
MSH, as the amount of cell-free extract to be processed would be prohibitively large for the 
average academic laboratory.115  In addition, thiols can be easily oxidized to symmetric and 
mixed disulfides or to sulfinic acids and can be modified through addition reactions to 
aldehydes and activated double bonds.  It is therefore desirable to remove the thiol from 
contaminants as soon as possible or to reversibly convert it to a more stable form, such as a 
disulfide of known composition.115   
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The second published protocol for the isolation of MSH addresses these issues by 
using a hydrophobic, thiol reactive agent, 2-S-(2′-thiopyridyl)-6-hydroxynaphthyldisulfide 
(Figure 4.10), to tag MSH for purification.115  This hydrophobic tag increases the solubility 
of MSH in organic solvents and allows for its retention on a hydrophobic solid support resin, 
which partially purifies and concentrates the tagged MSH for easier purification by HPLC 
using C18 reverse phase chromatography.115  The tag can then be easily removed to return the 




































Figure 4.10: The isolation of mycothiol using 2-S-(2′-thiopyridyl)-6-hydroxynaphthyldisulfide as described by 
Steenkamp and Vogt.115 
4.1.9. Plan of Action 
The MSH-dependent enzymes identified to date parallel GSH-dependent enzymes in 
function.  These enzymes can serve as targets for the development of novel therapeutics 
aimed at the pathogenic Mycobacteria.  The extensive experience of our laboratory in 
studying bacterial GlxI enzymes has led us to focus on the possibility of an MSH-dependent 
Glx system and S. coelicolor was selected as our organism of interest.  Initial assays were 
performed to determine if the endogenous levels of MSH would be sufficient to detect Glx-
type activity.  A control experiment using E. coli, an organism known to contain a GSH- 
dependent Glx system, was also performed to determine if Glx activity could be observed in 
this fashion.  It was determined that extraneous metabolites must be removed from the 
system, followed by the readdition of the pure substrates and cofactors of the enzyme system 
of interest.  The synthesis of des-myo-inositol mycothiol was undertaken, as was the isolation 
of MSH from cell-free extracts of S. jumonjinensis, with the aim of identifying Glx type 
activity in S. coelicolor. 
4.2. Materials and Methods 
All HPLC purifications were performed using either a Waters 600 gradient pump 
system with a 996 photodiode array detector or a Waters 625 LC system with a 994 
programmable photodiode array.  All HPLC purifications used Milli-Q water and HPLC 
grade methanol or acetonitrile.  All aqueous solvents were filtered through a 0.2 μm 
membrane filter (Pall Life Sciences, East Hills, NY) and all organic solvents were filtered 
through a 0.45 μm membrane filter (Millipore Corp., Billerica, MA) and all solvents were 
degassed before use.  Before injection, all samples were filtered through a syringe filter:  
0.2 μm PTFE membrane (Millipore) for organic solvents, 0.2 μm polyethersulfone membrane 
for aqueous samples (VWR International, Mississauga, ON). 
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All nuclear magnetic resonance (NMR) spectra were obtained using Bruker 300 MHz 
spectrometers using deuterated solvents manufactured by Cambridge Isotopes Laboratoties 
(Andover, MA).  Mass spectra were recorded using a Micromass Q-TOF Ultima Global 
instrument (electrospray ionization, ESI) using 1:1 water:acetonitrile with 0.2 % formic acid 
unless otherwise noted, or using a JEOL HX110 mass spectrometer (electron impact 
ionization, EI). 
N-(9-Fluorenylmethoxycarbonyl)-S-acetamidylmethyl-cysteine-pentafluorophenyl 
ester (FmocCys(Acm)-OPfP), and N-acetyl-S-triphenylmethyl-cysteine (AcCys(Trt)-OH) 
were purchased from Bachem Bioscience Inc. (King of Prussia, PA).  N-N′-Diacetyl cysteine 
was obtained from Toronto Research Chemicals (North York, ON).  O-Benzotriazole-
N,N,N′,N′-tetramethyl-uronium-hexafluoro-phosphate (HBTU) was obtained from Alfa Aesar 
(Ward Hill, MA) and ninhydrin was purchased from Pierce Chemicals (Rockford, IL). 
The following were obtained from Sigma-Aldrich Inc.: α-D-glucosamine 
hydrochloride (GlcN-HCl), 6-hydroxynapththyl disulfide, 2-thiopyridyl disulfide (trade 
name: 2-Aldrithiol), D- and L-LDH, MG, molybdophosphoric acid, NAD+, nickel chloride 
hexahydrate, piperidine, and reduced GSH. 
Ammonium chloride, cobalt chloride hexahydrate, cadmium chloride, dextrose, 
ethylenediaminetetraacetic acid (EDTA) disodium salt, hydrazine hydrochloride, manganous 
chloride tetrahydrate, sodium phosphate monobasic, and zinc chloride were purchased from  
J. T. Baker (Phillipsburgh, NJ). The Amberlyst A21 resin was supplied by Mallinckrodt Inc. 
(Phillipsburgh, NJ).     
Dimethylformamide (DMF) and trifluoroacetic acid (TFA) are from Caledon 
Laboratories Ltd. (Georgetown, ON).  DMF was dried over 4 Å molecular sieves overnight 
before use.  Acetic acid, acetic anhydride, HPLC grade ethanol, hydrochloric acid, perchloric 
acid, potassium phosphate, and sulfuric acid were purchased from Fisher Scientific Co. 
(Ottawa, ON).  Bacto™ peptone and malt extract were purchased from Becton, Dickinson 
and Company (Franklin Lakes, NJ).  Calcium chloride, iodine, potassium carbonate and 
vanillin were obtained from BDH Laboratories.  Glycine was supplied by Schwarz/Mann 
Biotech (Cleveland, OH).   
The following chemicals were purchased from EMD Chemicals Inc. (Gibbstown, 
NJ): agar, anhydrous magnesium sulfate, glucose, HPLC grade acetonitrile and methanol, 
magnesium chloride hexahydrate, potassium phosphate monobasic, sodium bicarbonate, 
sodium chloride, sucrose, triethyl amine (TEA), tryptone, and yeast extract. 
Hydroxybenzotriazole (HOBt) was purchased from NovaBiochem, a brand of EMD 
Biosciences, Inc.   
 The presence of hydroxyl groups was tested using a vanillin stain: 2.6 g of vanillin in 
a solution of 90 mL of ethanol, 2 mL of glacial acetic acid and 3.4 mL of sulfuric acid.  The 
presence of amines was tested using a ninhydrin stain: 0.2 % ninhydrin in ethanol.  TLC 
plates were also visualized using phosphomolybdic acid: 0.4 % in ethanol. 
 Cell-free extracts were obtained from suspended cells by sonication with a Sonicator 
cell disruptor model W225, converter model # 2 and a standard tapered microtip, with the 
output control set at 5, from Heat Systems-Ultrasonics, Inc. (Plainsview, NY).  
Centrifugation of cell cultures over 20 mL were performed using a Beckman Avanti J-25I 
centrifuge (Mississauga, ON).  Cell cultures were grown in either a Gyrotory Model G76 
water bath shaker or a Series 25 controlled environment incubator shaker, both of New 
Brunswick Scientific (Edison, NJ).   
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 Spectrophotometric assays were performed using a Varian (Mississauga, ON) Cary 3 
spectrophotomer and version 3.04 of the control and data collection software package. 
 NMR peak assignments were aided by the use of the ACD/HNMR DB and 
ACD/CNMR DB software, both version 2.51 (Advanced Chemical Development Inc. 
Toronto, ON) and Silverstein and Webster (1998).116 
4.2.1. Data Mining of the Streptomcyes coelicolor Genome 
The genome of S. coelicolor has been sequenced and is available for sequence 
searching.†  To investigate the presence of the known MSH-dependent enzymes in  
S. coelicolor, a series of sequence searches were completed using the amino acid sequences 
of MSH-dependent formaldehyde dehydrogenase, MSH-S-conjugate amidase, MSH-
dependent maleyl pyruvate isomerase and MSSM reductase.  Data mining using known 
GSH-dependent enzymes was also performed.  All sequence searches were performed using 
the BLAST server available through the Sanger Centre.‡   Multiple sequence alignments 
were performed using ClustalW available through the European Bioinformatics Institute §117.  
                                                
4.2.2. Media and Buffers Used 
Double Strength Germination Media 
1 % yeast extract 
1 % casamino acids 




0.05 M N-(tris(hydroxymethyl)methyl)-2-aminoethanesulfonic acid (TES) 
pH 8 
 
Yeast Extract-Malt Extract (YEME) Medium 
3 g yeast extract 
5 g bacto-peptone 
3 g oxoid malt extract 
10 g glucose 
340 g sucrose 
Distilled water to a final volume of 1 L 
After autoclaving the above solution add 2 mL of 2.5 M MgCl2•6 H2O to yield a final 
concentration of 5 mM. 
 
M9 Media 
12.8 g sodium phosphate dibasic heptahydrate 
3.0 g potassium phosphate dibasic 
0.5 g sodium chloride 
1.0 g ammonium chloride 




 - 103 -
Phosphate Buffered Saline (PBS) 
100 mM potassium phosphate 
0.8 % sodium chloride 
pH 7.2 
 
International Streptomyces Project (ISP) Medium 1 
5 g tryptone 
3 g yeast extract 
Distilled water to 1 L 
pH 7.0 to 7.2 
 
ISP Medium 2 
4 g yeast extract 
10 g malt extract 
4 g dextrose 
20 g agar 
Distilled water up to 1 L  
pH 7.3 – 7.5 
 
Lysis Buffer 1 
30 mM potassium phosphate 
0.1 mM EDTA disodium salt 
10 mM MgCl2 
pH 7.2 
 
Lysis Buffer 2 
0.25 M perchloric acid 
2 mM EDTA 
40 % acetonitrile in water 
 
Glx Assay Buffer 1 
27 mM MG 
50 mM potassium phosphate 
pH 6.6 
 
Glx Assay Buffer 2 
27 mM MG 
50 mM potassium phosphate 
1.8 mM GSH 
pH 6.6 
 
LDH Assay Solution 
0.17 M glycine 
0.17 M hydrazine hydrochloride 
pH 9.5 
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LDH  
The LDH enzymes were used as supplied in a pH 6, ammonium sulfate (L-: 2.1 M, D-: 3.2 M) 
stock solution solution 
Activities 
D-LDH: 1228 units/mL** 
L-LDH: 6000 units/mL 
 
NAD+ Stock Solution 
60 mg of β-NAD+ in 2 mL of milli-Q water 
4.2.3. Growth of Streptomyces coelicolor 
Spores of S. coelicolor A3(2) were a generous gift from Professor Sir David 
Hopwood of the Department of Molecular Microbiology at the John Innes Centre in Colney, 
Norwich, UK.  The spores were germinated as detailed by Kieser et al.103  The spores were 
pelletted on a bench-top centrifuge (3000 rpm for 2 min), re-suspended in 5 mL of TES 
buffer, transferred to a 125 mL erlenmeyer flask and heat shocked for 10 minutes at 50 °C 
and cooled under cold water.  To the flask was added 5 mL of autoclaved double strength 
Germination Medium and the resulting mixture was shaken at 37 °C at 300 rpm for 3 hr.  The 
suspension was decanted into a sterile Falcon tube and centrifuged at 5 800 rpm for 10 
minutes to pellet the cells.  The pellet was resuspended in autoclaved Milli-Q water and this 
was added to 200 mL of YEME media and shaken at 30 °C for approximately 49 hours.  The 
culture was centrifuged at 4 °C for 15 min at 8 000 rpm, the supernatant was decanted and 
the pellets were washed with 100 mL of M9 or PBS media and centrifuged for 15 min at  
10 000 rpm.  The resultant loose pellet was frozen in liquid nitrogen and the cells were stored 
at -80 °C. 
4.2.4. Initial Assay for Glyoxalase Activity in Streptomyces coelicolor 
Frozen S. coelicolor cells were thawed on ice with the addition of a small amount of 
Lysis Buffer 1 to cover the cells.  The cells were diluted up to 2 mL for 0.6 g of cells and  
3 mL for 1.2 g of cells (wet weight).  The cells were sonicated thirty times for 10 sec with a  
30 sec of wait time between each interval.  The cells were kept on ice at all times.  The cells 
were centrifuged in a small chemical tabletop centrifuge (speed setting 5) yielding a yellow 
supernatant and a fairly small pellet.  Half of the supernatant was then put through a 3 000 
molecular weight cut-off Centricon filter and the other half was used immediately.  Aliquots 
of both the unfiltered and filtered cell-free extract were incubated with MG (final MG 
concentration = 0.3 μM) for 30 min.  A cocktail of metal ions, copper chloride, cadmium 
chloride, manganous chloride and nickel chloride, each at a concentration of 500 mM, was 
prepared and used as noted below.   
To assay for GlxI activity the following combinations were placed in a 1 mL quartz 
cuvette and the change in absorbance at 240 and 340 nm was observed.  These assays were 
performed using unfiltered cell-free extract and unfiltered cell-free extract incubated with 
MG: 
 
                                                 
** 1 unit = the amount of enzyme that would reduce 1 μmole of pyruvate to lactate per minute at pH 7.0 and    
25 °C.   
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1. 950 μL of Glx Assay Buffer 1, 50 μL of cell-free extract 
2. 950 μL of Glx Assay Buffer 1, 50 μL of cell-free extract, 1 μL of metal cocktail 
3. 950 μL of Glx Assay Buffer 2, 50 μL of cell-free extract 
4. 950 μL of Glx Assay Buffer 2, 50 μL of cell-free extract, 1 μL of metal cocktail. 
 
To assay for GlxII and overall Glx system activity the following solutions were 
mixed in a 1 mL quartz cuvette and the change in absorbance at 340 nm observed.  These 
assays were performed using unfiltered cell-free extract and unfiltered cell-free extract 
incubated with MG:   
 
5. 895 μL of LDH assay buffer, 50 μL cell-free extract, 56 μL of NAD+ stock 
solution and 2 μL of either L- or D-LDH stock solution 
6. 895 μL of LDH assay buffer, 50 μL cell-free extract, 56 μL of NAD+ stock 
solution, 2 μL of either L or D-LDH stock solution and 1 μL of metal cocktail 
 
As a control, Assays 1 – 6 were repeated using filtered cell-free extract to monitor 
background activity.  In addition, Assays 5 and 6 were repeated without the addition of any 
LDH to monitor background activity. 
4.2.5. Control Assays for Glyoxalase Activity in Escherichia coli 
To determine if it is possible to monitor Glx activity using the assay described above, 
Assays 1 – 6 were repeated using cell-free extracts of E. coli MG1655, with the exception 
that a 500 μL nickel chloride solution was used in lieu of the metal cocktail.  Approximately 
1.6 g of cells were thawed and suspended in 4 mL of Lysis Buffer 1.  The cells were 
sonicated ten times for 10 sec with 30 sec between each interval and the mixture centrifuged.  
Approximately half of the supernatant was put through a 3 000 molecular weight cut off 
Centricon filter.   
























































Figure 4.11: Synthesis of N-α-Fmoc-S-acetamidomethyl-L-cysteinyl-2-amino-2-deoxy-α-D-glucopyranoside 
(Fmoc-Cys(Acm)GlcN).  (i) HOBt, DMF. 
This procedure is an adaptation of that published by Patel and Blanchard.113  GlcN-
HCl (3.72 g, 17 mmol) was dissolved in a 1 M solution of NaOH (17 mL, 17 mmol) and 
allowed to stir for 5 min at room temperature.  This solution was then frozen in liquid 
nitrogen and dried on the lyophilizer overnight.  Fmoc-Cys(Acm)-OPfP (4-44, 2 g,  
3.4 mmol) was dissolved in 10 mL of dry DMF and HOBt was added (0.930 g, 6.1 mmol).  
This was immediately transferred to the dried GlcN solid.  GlcN did not dissolve 
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immediately and vigorous stirring was required to break up the GlcN solid.  This mixture was 
allowed to stir for 3 hr at room temperature under argon.  The solvent was then removed by a 
rotary evaporator attached to a vacuum pump.  The product was precipitated with 100 mL of 
water and isolated by filtration followed by thorough rinsing with water to remove any 
residual DMF, GlcN, pentafluorophenol, NaCl, and HOBt.  The product was either collected 
from the filter manually or dissolved in MeOH and dried by rotary evaporation.  In both 
cases, the sample was also dried in vacuo overnight to remove any residual water.  Initial 
NMR data indicated the presence of unreacted Fmoc-Cys(Acm)-OH; therefore, the sample 
was dissolved in methanol and stirred with Amberlyst A21, a weakly basic macroreticular 
resin, for 30 minutes.  The resin was removed by filtration and the sample dried by rotary 
evaporation to give a 56 % yield of 4-46.  
 
1H NMR (300 MHz, MeOH-d4) δ 7.79 (d, 2H, H8″), 7.75 (d, 2H, H5″), 7.39 – 7.26 (m, 4H, 
H6″, H7″), 5.10 (d, 1H, H1), 4.47 – 4.22 (m, 6H, H2′, H4′, H2″, H3″), 3.79 – 3.61 (m, 6H, 
H2, H3, H4, H5, H6), 3.1 – 2.8 (m, 2H, H3′), 2.0 (s, 3 H, H6′).   
 
13C NMR (75 MHz, DMSO-d6) δ 172.0/171.5 (C1′/C5′), 156.5 (C1″), 144.1 (C9″), 141.0 
(C4″), 128.1 (C7″), 127.5 (C6″), 125.7 (C5″), 120.5 (C8″ ), 91.0 (C1), 73.1/72.0/71.5 
(C3/C4/C5), 66.2 (C2″), 61.0 (C6), 55.0 (C2), 54.5 (C2′), 46.9 (C3″), 32.5 (C3′), 23.5 (C6′), 
C4′ is expected to appear at ~ δ 39, which would be hidden by the DMSO-d6 solvent peak. 
 








































Figure 4.12: Synthesis of S-acetamidomethyl-L-cysteinyl-2-amino-2-deoxy-α,β-D-glucopyranoside               
(NH2-Cys(Acm)GlcN). (i) 5 % piperidine in DMF. 
The Fmoc-Cys(Acm)-GlcN (4-46, 0.55 g, 0.9 mmol) was dissolved in 5 mL of a 
solution of 5 % piperidine in DMF.  This was allowed to stir for 30 min and the solvent was 
removed with a rotary evaporator attached to a vacuum pump.  The cleaved dibenzofulvene 
was precipitated with 30 mL of water.  The precipitate was removed by filtration and the 
filtrate was dried in vacuo to give a 99 % yield of 4-47.   
 
1H NMR (300 MHz, D2O) δ 5.0 (d, 1H, H1), 4.2 (m, 2H, H4′), 3.8 – 3.3 (m, 7H, H2, H3, H4, 
H5, H6, H2′), 3.0 – 2.8 (m, 2H, H3′), 2.0 (s, 3H, H6′). 
 
13C NMR (75MHz, D2O) δ 174.2/172.3 (C1′/C5′), 90.9 (C1), 76.0/75.3/73.7 (C3/C4/C5), 
60.0 (C2), 63.6 (C6), 54.2 (C2′), 35.1 (C4′), 32.0 (C3′), 22.1 (C6′). 
 
ESI-MS (pos): m/z = 354 (MH)+, calculated (MH)+ = 354. 







































Figure 4.13: Synthesis of N-acetyl-S-acetamidomethyl-L-cysteinyl-2-amino-2-deoxy-α,β-D-glucopyranoside 
(AcCys(Acm)GlcN). (i) Ac2O, K2CO3. 
NH2-Cys(Acm)-GlcN (4-47, 0.17 g, 0.47 mmol) was dissolved in 1.2 mL of water, 
potassium carbonate (0.13 g, 0.94 mmol, 2 equiv.) was added and the mixture was stirred 
until the potassium carbonate was dissolved.  Acetic anhydride (56 μL, 0.06 g, 1.3 equiv.) 
was added dropwise over 30 min and the solution was allowed to stir at room temperature for 
45 minutes and then dried in vacuo.  The product was dissolved in 5 mL of ethanol to 
precipitate the potassium carbonate, which was removed by filtration, and the filtrate was 
dried to an oil.  The sample was purified by preparative HPLC using a Waters μBondapak 
C18 reverse phase radial compression column (25 × 100 mm) and the gradient shown in Table 
4.4.  The product eluted at ~ 10 min with a yield of 25 % of 4-48.   
Table 4.4: Solvent gradient used to purify N-acetyl-L-cysteinyl-2-amino-2-deoxy-α,β-D-glucopyranoside. 
Time Flow Rate % Water % Methanol 
0 5 mL/min 100 0 
14 5 mL/min 100 0 
17 5 mL/min 0 100 
30 5 mL/min 0 100 
35 5 mL/min 100 0 
 
1H NMR (300 MHz, D2O) δ 5.0 (d, 1H, H1), 4.5 (m, 1H, H2′), 4.3 (m, 2H, H4′), 3.9 – 3.2 (m, 
6 H, H2, H3, H4, H5, H6), 3.0 (d, 1H, H3′), 2.8 (d, 1H, H3′), 1.8 (s, 6H, H5′, H6′). 
 
ESI-MS (pos): m/z = 434 (MK)+, calculated (MK)+ = 434. 
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Figure 4.14:  Proposed synthesis of N-acetyl-L-cysteinyl-2-amino-2-deoxy-α,β-D-glucopyranoside disulfide.  
This procedure was adapted from that of Kamber et al.118 for the removal of the 
acetamidomethyl protecting group from thiols using iodine, with the simultaneous formation 
of a disulfide.  AcCys(Acm)-GlcN (4-48, 20 mg, 0.051 mmol) was dissolved in 7 mL of 
DMF and 3 mL of a 0.1 N solution of iodine (6 equiv.) was added.  This mixture was allowed 
to stir for 1 min at room temperature and was then diluted with 10 mL of chloroform and 10 
mL of water.  The water layer was washed repeatedly with chloroform until the chloroform 
layer was colourless.  The water layer was dried in vacuo and the residue was purified by 
HPLC using the conditions described above. The predicted product (4-49) was not visible by 
1H NMR nor ESI-MS. 
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Figure 4.15: Synthesis of N-acetyl-S-trityl-L-cysteinyl-2-amino-2-deoxy-α,β-D-glucopyranoside 
(AcCys(Trt)GlcN). 
N-acetyl-S-trityl-cysteine (4-52, 0.489 g, 1.21mmol) was dissolved in 10 mL of dry 
DMF followed by the addition of GlcN-HCl (0.290 g, 1.35 mmol, 1.12 equiv.), TEA (350 
μL, 2.5 mmol, 2.1 equiv.), and HBTU (0.504 g, 1.33 mmol, 1.10 equiv.).   The reaction was 
allowed to stir overnight under argon.  The mixture was diluted with 35 mL of saturated 
aqueous sodium chloride resulting in a large amount of precipitate.  The aqueous layer was 
neutralized (to pH ~7) using HCl, which eliminated most of the cloudiness.  The aqueous 
mixture was washed three times with 25 mL of dichloromethane and the organic layers were 
pooled, washed with 2 N HCl, water, 5 % sodium bicarbonate, and water, and then dried over 
anhydrous magnesium sulfate, which was later removed by filtration.  The product was dried 
on the rotary evaporator and then dried overnight with a vacuum pump to give an oil.  This 
oil was taken up in a minimum amount of 85:15 chloroform:methanol and purified by silica 
gel chromatography using the method described by Still et al.119 (85:15 
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chloroform:methanol) to give a yield of 53 % of 4-53.  The sample was contaminated with 
TEA and it was noted that racemization at the α-carbon had likely occurred, as the 1H NMR 
spectrum revealed multiple peaks for the acetyl group and the anomeric carbon, indicative of 
the formation of diastereomers.  The multiplets expected for the other protons in the 
molecule, GlcN etc, yielded a convoluted spectrum.  This synthesis was halted. 







4-54 4-55  
Figure 4.16: Reduction of 6-hydroxynaphthyl disulfide with sodium borohydride. 
This procedure was modified from that of Steenkamp and Vogt.115   
6-Hydroxynaphthyl disulfide (4-54, 0.198 g, 0.56 mmol) was added to 100 mL of a 1:1 
acetonitrile: 0.1 M NaHCO3 solution with a pH of 9, which had been degassed for 10 min.  
Sodium borohydride (0.6 g, 0.02 mol, 28 equiv.) was added, the system was flushed three 
times with argon and the mixture was allowed to stir at room temperature for 2 hr under 
argon.  As the disulfide was reduced, the solution became a clear yellow.  The reaction was 
quenched with glacial acetic acid (2 mL) and the pH was adjusted to approximately 4.55.  

























Figure 4.17: Synthesis of 2-S-(2′-thiopyridyl)-6-hydroxynaphthyldisulfide. 
 2-Thiopyridyl disulfide (4-56, 0.474 g, 2.06 mmol, 1.8 equiv) was dissolved in a 1:1 
acetonitrile:water solution that had been degassed for 10 min.  The 2-thio-6-hydroxynaphthol 
solution was added dropwise to 2-thiopyridyl disulfide over 20 minutes and allowed to stir at 
room temperature for 1.5 hours.  The mixture was diluted with 150 mL of 4 °C water and the 
precipitate isolated by filtration.  The very fine precipitate was dissolved from the filter paper 
using methanol and the solvent was removed by rotary evaporation.  It was essential to avoid 
heating the product to prevent isomerization of the disulfide.  The mixed disulfide was 
dissolved in a minimal amount of 95:5 chloroform:methanol, filtered and the filtrate was 
purified by silica gel chromatography using the method described by Still et al.119 (95:5 
chloroform: methanol, mixed disulfide Rf: 0.32, 6-hydroxynaphthyl disulfide Rf: 0.18,  
2-thiopyridyl disulfide Rf: 0.62).  The collected precipitate was redissolved in 95:5 
chloroform:methanol and purified by silica gel chromatography to give an overall yield of 25 
% of 4-50.  The product was most stable when stored dry.   
 
1H NMR (300 MHz, MeOH-d4) δ 8.4 (d, 1H, H1′), 7.9 (d, 1H, H7), 7.8 (d, 1H, H4′) 7.7 (dd, 
1H, H2′) 7.6 (t, 2H, H4, H9), 7.5 (dd, 1H, H2), 7.2 (m, 1H, H3′), 7.0 (m, 2H, H5, H10)  
 
 
 - 110 -
13C NMR (75 MHz, MeOH-d4) δ 157.5 (C5′), 150.4 (C1), 139.3 (C3′, C1′), 136.0 (C3), 130.5 
(C9), 130.2 (C6), 129.7 (C8), 128.9 (C10), 128.7 (C7), 127.6 (C5), 122.6 (C4), 121.5 (C2′), 
120.4 (C4′), 110.0 (C2). 
 
EI-MS (pos) m/z = 285, calculated (M)+ = 285.  
4.2.9. Growth of Streptomyces jumonjinensis, the Chosen Source of Mycothiol 
S. jumonjinensis was obtained from the American Tissue Culture Collection (ATCC, 
number 29864) as a freeze dried pellet.  The pellet was taken up in 1 mL of ISP medium 1.  
A few drops of this suspension were added to slants of ISP medium 2, which were then 
incubated at 27 °C and showed growth after three days.  The remainder of this suspension 
was divided between four flasks: two flasks with 50 mL of YEME media and two flasks 
containing 50 mL of ISP medium 1.  After three days of shaking at 26 °C the ISP medium 
cultures were very cloudy while the YEME cultures did not show a large amount of growth.  
The ISP medium 1 culture was centrifuged at 8 000 rpm for 10 min at 4 °C, and the pellet 
collected, frozen and stored at -80 °C. 
A second freeze dried pellet was rehydrated in the same fashion and after shaking for 
three days in ISP medium 1, the culture was evenly divided among six 4 L flasks each with 
500 mL of ISP medium 1.  These flasks were shaken at 26 °C for five days and the culture 
was centrifuged at 12 000 rpm for 20 minutes, the pellet collected, frozen and stored at  
-80 °C.   
















































Figure 4.18: Formation of 2-S-6-hydroxynaphthyl-mycothiol disulfide. 
This procedure was adapted from that of Steenkamp and Vogt which used  
M. smegmatis as the source of MSH.115  Frozen S. jumonjinensis cells (4.029 g of wet 
weight) were thawed and suspended in approximately 30 mL of Lysis Buffer 2 over three  
15 mL centrifuge tubes.  Each tube was sonicated with thirty 10 sec pulse sets with a 10 sec 
rest between each set.  These tubes were then centrifuged and the supernatant was distributed 
into two 15 mL centrifuge tubes as a thick yellow liquid.  The pH of the solutions was 
adjusted to approximately 4.7 using potassium carbonate and dilute hydrochloric acid.  The 
cell-free extract was then degassed for 10 min and added dropwise over 20 min to 3.65 mL of 
a degassed 4.4 mM (saturated) solution of 2-S-(2′-thiopyridyl)-6-hydroxynaphthyldisulfide in 
60 % (v/v) acetonitrile:water (0.016 mmoles).  The solution was allowed to stir under argon 
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at room temperature for 4.5 hours.  The reaction mixture was diluted with 56 mL of water 
and then filtered through a Waters classic Sep-pak, which had been conditioned with 
methanol and water.  The Sep-pak was rinsed with water followed by 1:1 acetonitrile:water, 
which gave a yellow product in approximately 1 mL.  This fraction was concentrated using 
rotary evaporation to remove the acetonitrile.  The sample was then purified by analytical 
HPLC using a Waters μBondapak C18 reverse-phase radial compression column (8 × 100 
mm) and the gradient shown in Table 4.5.  The elution was monitored at 220 and 280 nm and 
tagged MSH eluted at 28 min.  The 2-thiopyridyl disulfide eluted at 36 min, 2-S-(2′-
thiopyridyl)-6-hydroxynaphthyl disulfide at 41 min and 6-hydroxynaphthyl disulfide at  
44 min.  The use of ~ 4 g of wet weight cells yielded approximately 1.5 to 2 mg of tagged 
MSH. 
Table 4.5: Solvent gradient used to purify 2-S-6-hydroxynaphthyl-mycothiol disulfide. 
Time Flow Rate %  of 0.1 % TFAa in Water % of Acetonitrile 
0 1 mL/min 100 0 
10 1 mL/min 100 0 
50 1 mL/min 0 100 
aTFA = trifluoroacetic acid 
 
1H-NMR (500 MHz, D2O) δ 8.0 (s, 1H, H11), 7.8 (dd, 2H, H7, H10), 7.6 (d, 1H, H8), 7.2 (m, 
2H, H6, H9), 5.0 (s, 1H, H1′), 4.5 (m, 1H, H2), 4.1 (s, 1H, H2″), 3.9 – 3.7 (m, 7H, H2′, H3′, 
H5′, H6′ (2H), H4″, H6″), 3.6 (m, 4H, H4′, H1″, H3″, H5″), 3.2 (t, 1H, H3a), 2.9 (t, 1H, 
H3b), 2.1 (s, 3H, H5).††   
 
ESI-MS (pos): m/z (MH)+ = 661, (MLi)+ = 667, (MNa)+ = 683, (M + 2 Na+ + CF3COO-)+ = 
819, (M + 4 Na+ + 3 CF3COO-)+ = 1091, (M + 5 Na+ + 4 CF3COO-)+ = 1227, (M + 6 Na+ + 5 
CF3COO-)+ = 1363, (M + 7 Na+ + 6 CF3COO-)+ = 1499, calculated (MH)+ = 661.   








































Figure 4.19: Synthesis of a proposed mycothiol analogue.  Reagents: (i) HBTU, TEA, DMF. 
N-N′-Diacetyl-cystine (101 mg, 0.31 mmol) was dissolved in 0.6 mL of dry DMF.  
HBTU (260 mg, 0.69 mmol, 2.1 equiv.) was dissolved in 1.2 mL of dry DMF and added to 
the amino acid followed by cyclohexyl amine (74 μL, 0.65 mmol, 1.0 equiv.) and TEA  
                                                 
†† The pattern seen for the protons belonging to MSH is in full agreement with those found by Spies and 
Steenkamp (1994), Sakuda et al. (1994) and Newton et al. (1995) for the bimane derivative of MSH.   
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(180 μL, 1.29 mmol, 2.1 equiv.).  The mixture was allowed to stir at room temperature for  
1 hr.  The reaction mixture was diluted with 4 mL of water, which was washed three times 
with 3 mL of ethyl acetate.  The organic layer was then washed with 2 M HCl, water, 5 % 
sodium bicarbonate, and water and dried over magnesium sulfate.  The mixture was filtered 
and dried in vacuo.  The product was taken up in 1:1 water:methanol, loaded onto a 
preconditioned Sep-pak and eluted with 100 % methanol.  The product was then dried by 
rotary evaporation to give a 13 % overall yield of the N-N′-diacetyl-cystinyl-














1H-NMR (300 MHz MeOH-d4) δ 4.67 (m, 1H, H3), 3.62 (m, 1H, H5), 3.2 – 3.0 (m, 1H, 
H9a), 3.0 – 2.8 (m, 1H, H9b), 2.0 (s, 3H, H1), 1.8 – 1.5 (m, 5H, H6e, H6a, H7a), 1.3 – 1.0 
(m, 5H, H7e, H8a, H8e).   
 
13C-NMR (75 MHz, MeOH-d4) δ 171.7/171.5 (C2/C4), 52.4 (C3), 51.0 (C5), 32.0/31.9 
(C6/C9), 25.1 (C7), 24.6 (C8), 21.0 (C1)  
 
ESI-MS (pos): m/z (MH)+ = 487, calculated (MH)+ = 487 
4.3. Results and Discussion 
  MSH is the major thiol of the Actinomycetales bacteria and is essential for the 
viability of M. tuberculosis, the causative agent of tuberculosis.  The MSH-dependent 
enzymes identified to date parallel GSH biochemistry, implying that the functions of GSH 
may serve as a template for the discovery of new MSH functionalities.  GSH is an essential 
cofactor for the Glx system, which converts cytotoxic MG to D-lactate.  Our efforts towards 
the identification of an MSH-dependent Glx system in S. coelicolor have created a solid 
foundation for the possible future identification of this system in the Actinomycetales 
bacteria.  
4.3.1. Sequence Searching of the Streptomyces coelicolor Genome 
Sequence searches of the genome of S. coelicolor for homologous sequences to 
known MSH-dependent enzymes were performed using the sequences listed in Table 4.6.  
The sequences returned for MSH-dependent formaldehyde dehydrogenase and MSSM 
reductase are annotated as likely having these functions, indicating that these enzymes are 
likely present in S. coelicolor (Table 4.6 and Alignments 1 and 3).  The searches performed 
using the MSH-S-conjugate amidase and MSH-dependent maleyl pyruvate isomerase 
sequences returned sequences with identities of 49 %  and 30 %, respectively, indicating that 
these enzymes are likely present in S. coelicolor as well (Table 4.6 and Alignments 2 and 4).   
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Table 4.6: Results for the sequence searches of the Streptomyces coelicolor genome for homologous sequences 
to known mycothiol dependent enzymes. 
Query 
Organsism 























NP_215598 NP_629119 Noneb 49 % 62 % 5.7 × 
10-70 
 
Mycothiol disulfide reductase 
M. 
tuberculosis 
















Noneb 30 % 43 % 9.0 × 
10-17 
 
aThe same class to which the formaldehyde dehydrogenases belong; bThis peptide sequence, identified from the 
genome, has not yet been assigned a putative function. 
A similar search of the S. coelicolor genome was performed using a sampling of 
known GlxI and GlxII protein sequences (Table 4.7, Alignments 4 – 13).  The sequences 
returned by the search using GlxI returned three sequences including a putative lyase with 
similarity to S-D-lactoylglutatione lysases (GlxII) (NP_625147), as well as a hypothetical 
protein (NP_625386) and a putative dioxygenase (NP_626233), both of which may belong to 
the glyoxalase superfamily.  A comparison of the E. coli, L. major and S. coelicolor 
sequences (Alignment 9) demonstrated that three of the four ligands responsible for the 
binding of the catalytic metal in E. coli and L. major were not present in the S. coelicolor 
sequence (NP_625386).  This does not preclude the presence of a GlxI type enzyme in S. 
coelicolor, however, it does suggest that the enzyme may be structurally dissimilar to other 
known GlxI enzymes and may not be a metalloenzyme.   
The searches of the S. coelicolor genome using various GlxII enzyme sequences 
returned a hypothetical protein (NP_626224) and a hydrolase (NP_625789), both with 
similarity to the glyoxalases.  While the identity of the returned sequences was not high, this 
does not prohibit the presence of an MSH-dependent Glx system as the TSH2-dependent 
GlxII enzyme in L. donovani demonstrated only 35 % sequence identity with the human 
GlxII enzyme.25  The similarity between the L. major GlxI sequence and other eukaryotic 
GlxI sequences was only between 32.4 and 39.4 %.23  The structure of MSH, a pseudo-
disaccharide coupled to N-acetyl-cysteine, is very different from that of GSH, a linear 
tripeptide, and TSH2, which consists of two GSH molecules linked by spermidine; hence, it 
 - 114 -
is possible that sequences of the MSH-dependent Glx enzymes would differ dramatically 
from those of GSH and TSH2-dependent enzymes.  This idea is supported by the lack of 
homology between the MSH-dependent maleyl pyruvate isomerase sequence from  
C. glutamicum and the sequences from GSH-dependent maleyl pyruvate isomerase from  
K. pneumoniae or Ralstonia U2.32  
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Alignment 1: 
Alignment of the peptide sequence of MSH-dependent formaldehyde dehydrogenase from Amycolatopsis methanolica (Assession No. 
P80094) with the best matching sequence from S. coelicolor, a putative oxidoreductase predicted to be a zinc-dependent alcohol 
dehydrogenase (Accession No. NP_625045): 74 % identity and 83 % similarity (E value = 7.7 × 10-146). 
 
Query = P80094, Sbjct = NP_625045 
 
Query:     2 QTVRGVIARSKGAPVELTDIVIPDPGPSEVTALIATCAVCHTDLTYREGGINDEFPFLLG 61 
             Q VRGVIA  K  PV +  IV+PDPGP E    I  C VCHTDL Y++GGINDEFPFLLG 
Sbjct:     3 QEVRGVIAPGKDEPVRIETIVVPDPGPGEAVVKIQACGVCHTDLHYKQGGINDEFPFLLG 62 
 
Query:    62 HEAAGTVESVGEGVDSVQPGDYVVLNWRAVCGQCRACKRGRPQYCFSTFNATQKMTLTD- 120 
             HEAAG VESVG GV  V PGD+V+LNWRAVCG+CRAC+RGRP YCF T NA Q+MTL    
Sbjct:    63 HEAAGVVESVGAGVTDVAPGDFVILNWRAVCGKCRACRRGRPWYCFDTHNAEQRMTLAST 122 
 
Query:   121 GTELTPALGIGAFADKTLVHAGQCTKVDPAADPAVAGLLGCGVMAGLGAAVNTGAVSRGD 180 
             G EL+PALGIGAFA+KTLV AGQCTKVDPA    VAGLLGCGVMAG+GAA+NTG V RGD 
Sbjct:   123 GQELSPALGIGAFAEKTLVAAGQCTKVDPAVPAEVAGLLGCGVMAGIGAAINTGNVGRGD 182 
 
Query:   181 SVAVIGCGAVGDAVIAGARLAGANKIIAVDRDAKKLEWATELGATHTVNATETDVVEAVQ 240 
             +VAVIGCG VGDA IAG+ LAGA+K+IAVD D +KLE A  +GATHTVN+  TD VEA++ 
Sbjct:   183 TVAVIGCGGVGDAAIAGSYLAGASKVIAVDIDDRKLETARTMGATHTVNSRGTDPVEAIR 242 
 
Query:   241 ALTGGFGADVVIDAVGRPETWKQAFYARDLAGTVVLVGVPTPDMRLEMPLLDFFSRGGAL 300 
              LTGGFGADVVI+AVGRPET++QAFYARDLAGTVVLVGVPTP+M+LE+PLLD F RGG+L 
Sbjct:   243 ELTGGFGADVVIEAVGRPETYRQAFYARDLAGTVVLVGVPTPEMKLELPLLDVFGRGGSL 302 
 
Query:   301 KSSWYGDCLPERDFPVLIDLHLQGRLPLDKFVTERISLDDVEKAFHTMHAGEVLRSVVV 359 
             KSSWYGDCLP RDFP+L+DLHLQGRL L KFVTE I LD+VE+AF  MHAG+VLRSVVV 
Sbjct:   303 KSSWYGDCLPSRDFPMLVDLHLQGRLDLGKFVTETIRLDEVEQAFDRMHAGDVLRSVVV 361 
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Alignment 2: 
The alignment of the peptide sequence of MSH-S-conjugate amidase from M. tuberculosis (Accession No. NP_215598) and the best 
matching sequence from S. coelicolor, a conserved hypothetical protein (Accession No. NP_629119): 49 % identity and 62 % 
similarity (E value = 5.7 × 10-70). 
 
Query = NP_215598, Sbjct = NP_629119 
 
Query:     3 ELRLMAVHAHPDDESSKGAATLARYADEGHRVLVVTLTGGERGEILNPAMDLPD-VHGRI 61 
             +LRLMAVHAHPDDESSKGAAT+A+Y  EG  VLVVT TGGERG ILNP +     +   I 
Sbjct:     4 QLRLMAVHAHPDDESSKGAATMAKYVSEGVDVLVVTCTGGERGSILNPKLQGDAYIEENI 63 
 
Query:    62 AEIRRDEMTKAAEILGVEHTWLGFVDSXXXXXXXXXXXXXXCFARVPLEVSTEALVRVVR 121 
              E+RR EM +A EILGV   WLGFVDS              CFA   ++ +   LVR +R 
Sbjct:    64 HEVRRKEMDEAREILGVGQEWLGFVDSGLPEGDPLPPLPEGCFALEDVDKAAGELVRKIR 123 
 
Query:   122 EFRPHVMTTYDENGGYPHPDHIRCHQVSVAAYEAAGDFCRFPDA--GEPWTVSKLYYVHG 179 
              FRP V+TTYDENGGYPHPDHI  H++++ A+E A D  ++P++  G  +   K+YY  G 
Sbjct:   124 SFRPQVITTYDENGGYPHPDHIMTHKITMVAFEGAADTEKYPESEYGTAYQPLKVYYNQG 183 
 
Query:   180 FLRERMQMLQDEFARHGQRGPFEQWLAYWDPDHDFLTSRVTTRVECSKYFSQRDDALRAH 239 
             F R R + L       G   P+E WL  W  + +     +TT V C+ +F  RD AL AH 
Sbjct:   184 FNRPRTEALHHALLDRGLESPYEDWLKRWS-EFERKERTLTTHVPCADFFEIRDKALIAH 242 
 
Query:   240 ATQIDPNAEFFAAPLAWQERLWPTEEFELARSRIPARPPETELFAGI 286 
             ATQIDP   +F  P+  Q+ +WPTEE+ELA+S +    PE +LFAGI 
Sbjct:   243 ATQIDPEGGWFRVPMEIQKEVWPTEEYELAKSLVETSLPEDDLFAGI 289 
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Alignment 3: 
The alignment of the translated peptide sequence of MSSM reductase from M. tuberculosis (Accession No. AF002193) and the best 
matching sequence from S. coelicolor, a putative pyridine nucleotide-disulfide oxidoreductase (Accession No. NP_627648): 28 % 
identity and 43 % similarity (E value = 6.6 × 10-37). 
 
Query = AF002193; Sbjct = NP_627648 
 
Query:     1 METYDIAIIGTGSGNSILDERYASKRAAIC--EQGTFGGTCLNVGCIPTKMFVYAAEV-- 56 
             ++  D+ +IG G G   + ER A +   +   E    GG C    CIP+KM +    +   
Sbjct:     2 VQEIDVVVIGMGVGGEHVAERLAEEGLDVVGVEAELVGGECPYWVCIPSKMMIRGGNLLA 61 
 
Query:    57 -AKTIRG-ASRYGIDAHIXXXXXXXXXXXXFGRIDPIALSGEDYRRCAPNIDVYRTHTRF 114 
              A+ I G A +  +                    D +A+     R         R   R  
Sbjct:    62 EARRIPGMAGQAQVTPDFAPVASRIREEATDDWNDQVAVD----RFTGKGGQFVRGRARL 117 
 
Query:   115 -GP--VQADGRYLLRTDAGEEFTAEQ-VVIAAGSRPVIPPAILASGVDYHTSDTVMRIAE 170 
              GP  V+ DGR         EFTA + VVIA GSRP IPP      V Y T+   + + + 
Sbjct:   118 AGPKRVEIDGR---------EFTARRGVVIATGSRPQIPPVPGLDAVPYWTNREAIAVKD 168 
 
Query:   171 LPEHIVIVGSGFIAAEFAHVFSALGVRVTLVIRGSCLLRHCDDTICERFTRIASTKW-EL 229 
              P  ++++G G +  E A  F+  G  VT+V     LL   +         +   +   + 
Sbjct:   169 SPRSLMVLGGGAVGVELAQAFARFGTAVTVVEAAERLLPAEEPETSALLADVLGAEGITV 228 
 
Query:   230 RTHRNVVDGQQRGSGVALRLDDGCTINADLLLVATGRVSNADLLDAEQAGVDVEDGRVI- 288 
             RT       +  G    L L+ G  + A+ LLVATGR +    L     G+D  D R +  
Sbjct:   229 RTGAQANRARHDGDTFTLTLEGGEELTAERLLVATGRRAGLAGLGLGTVGLD-PDARALH 287 
 
Query:   289 VDEYQRTSARGVFALGDVSSPYLLKHVANHEARVVQHNLLCDWEDTQSMIVTDHRYVPAA 348 
             VDE  R +A G++ +GDV+      HVA ++A +    +L      Q     D+R +P   
Sbjct:   288 VDEQLR-AAPGLWGVGDVTGRGAFTHVAMYQAEIAVRAIL-----GQPGPGADYRALPRV 341 
 
Query:   349 VFTDPQIAAVGLTENQAVAKGLDISVKIQDYGDVAYGWAME-DTSGIVKLITERGSGRLL 407 
              FTDP++ +VGLTE +A  KGL +          A GW  +    G++KL+ +   G L+ 
Sbjct:   342 TFTDPEVGSVGLTEARAREKGLRVRTGTAQVPSSARGWIHKAGNEGLIKLVEDVDRGVLV 401 
 
Query:   408 GAHIMGYQASSLIQPLIQAMSFGLTAAEMARGQYWIHPALPEVVENALLGLR 459 
             GA   G     ++  L+ A+  G    +  R   + +P     VE+AL  LR 
Sbjct:   402 GATSAGPMGGEVLYGLVVAVQ-GEVPVDRLRHMMYAYPTFHRAVEDALRALR 452 
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Alignment 4: 
The alignment of the peptide sequence of MSH-dependent maleyl pyruvate isomerase from C. glutamicum (Accession No. 
NP_602215) with the best matching sequence from S. coelicolor, a hypothetic protein with no hypothesized function (Accession No. 
NP_626223): 30 % identity and 43 % similarity (9.0 × 10-17).  
 
Query = NP_602215; Sbjct: NP_626223 
 
Query:    13 LTLARLGTSHYSRQLSLVDNAEFGEHSLLEGWTRSHLIAHVAYNAIALCNLMHWANTGEE 72 
             L   R  T      +  +DNA   E S L GW+R H++AH+A NA AL N++      E  
Sbjct:     8 LASVRDATDRLLTAVGKLDNAFVTESSRLPGWSRGHVLAHLARNADALVNVL------EG 61 
 
Query:    73 TPMYVSPEARNEEIAYGSTLNPDA-LRNLHEHSVARLDVAWRETSEDAWSHEVLTAQGRT 131 
              PMYVS EAR+ +I   +    DA L ++ E S AR        ++  W+  V    G T 
Sbjct:    62 RPMYVSGEARDADIERDAPRPLDAQLADVRE-SAARFQDVGAAPAD--WTRTVELRNGVT 118 
 
Query:   132 VPASETLWMRSREVWIHAVDLGAVATFGDIPEVILRTLAAEITQKWTSQGAGEGLVLLDE 191 
               AS   + R  EV +H VDLGA     D+P          +  ++          L D  
Sbjct:   119 DSASRVPFRRWAEVELHHVDLGAGYELEDLPAEFTERETDFLAARFAGHPDVPPTRLTDG 178 
 
Query:   192 PSSTRYPAAPGQDEVVVSGSLAGIVRYAAGR-GSDGVTSSTGEVPE-PP 238 
               +          EV V+G  A ++ + AGR     +T   G +P  PP 




The alignment of the peptide sequence of GlxI from humans (Accession No. NP_006699) with the best matching sequence from  
S. coelicolor, a putative lyase (Accession No. NP_625147): 34 % identity and 57 % similarity  (E value = 1.6 × 10-5) to a portion of 
the human enzyme. 
 
Query = NP_006699; Sbjt = NP_625147 
 
Query:   128 IGIAVPDVYSACKRFEELGVKFVKKPDDGKMKGLAFIQDPDGYWIEI 174 
             + I V D+    + +  LG +F+  P D K +   +++DPDGY IE+ 
Sbjct:    87 LNIRVADIERCHREWSALGAEFLTPPIDRKAELRCYLRDPDGYLIEV 133 
 
 
 - 119 -
Alignment 6: 
The alignment of the peptide sequence of GlxI from yeast (S. cerevisiae, Accession No. CAC16163) with the best matching sequence 
from S. coelicolor, a putative dioxygenase believed to belong to the glyoxalase/bleomycin resistance protein/dioxygenase superfamily 
(Accession No. NP_626233): 23 % identity and 43 % similarity (E value = 0.12) to a portion of the S. cerevisiae enzyme. 
 
Query = CAC16163; Sbjct = NP_626233 
 
Query:   182 KFNHTMIRIKNPTRSLEFYQNVLGMKLLRTSEHESAKFTLYFLGYGVPKTDSVFSCESVL 241 
             + +H ++ +++P  +  FY+  LG++ LR +E+ +   T+ F    V   D     E++L 
Sbjct:    12 RLDHIVLWVRDPVAAAGFYEKNLGLEPLRITEYAAG--TVSFPS--VRLND-----ETIL 62 
 
Query:   242 ELTHNWGTENDPNFHYHNGNSEPQGY--GHICISCD--DAGALCKEIE---VKYGDKIQW 294 
             +L  +   +         G     G+   HIC+S    D  AL   +E   +   D + + 
Sbjct:    63 DLAPHAMADR---MRMVPGADASAGHPVNHICVSLSPHDFDALRTRLEEQSIPVSD-LSY 118 
 
Query:   295 SPKFNQGRMKNIAFLKDPDGYSIEVVPY 322 
                  +G  +   +  DPDG  IE   Y 
Sbjct:   119 DSYGARGMARRSFYFGDPDGNIIEARHY 146 
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Alignment 7: 
The alignment of the peptide sequence of GlxI from E. coli (Accession No. 1FA8A) with the best matching sequence from  
S. coelicolor, a conserved hypothetical protein believed to belong to the glyoxalase/bleomycin resistance protein/dioxygenase 
superfamily (Accession No. NP_625386): 29 % identity and 49 % similarity (E value = 0.00061) to a portion of the E. coli. 
 
Query = 1FA8A; Sbjct = NP_625386 
 
Query:     6 TMLRVGDLQRSIDFYTKVLGMKLLRT-SENPEYKYSLAFVGYGPETEEAVIELTYNWGVD 64 
             T+LR  D  RS  FY + LG+ + R     PE + ++ F+G G       +E++   G   
Sbjct:     9 TLLRPTDPDRSRAFYGEQLGLAVHREFGTGPE-RGTVYFLGNG------FLEVS---GRS 58 
 
Query:    65 KYELGTAYGHIALSVDNAAEACEKIRQNGGNVTREAGPVKGGTTVIA-FVEDPDGYKIEL 123 
                L      + + V++AA A E++   G  + R   PVK    ++  ++ DPDG +I L 
Sbjct:    59 DTPLTPGLA-LWIQVEDAAAAHEELGAKGVEIVRP--PVKEPWGLVEMWIADPDGTRIVL 115 
 
Query:   124 IE 125 
             +E 
Sbjct:   116 VE 117 
 
Alignment 8: 
The alignment of the peptide sequence of GlxI from L. major (Accession No. AAT98624) with the best matching sequence from  
S. coelicolor, a conserved hypothetical protein believed to belong to the glyoxalase/bleomycin resistance protein/dioxygenase 
superfamily (Accession No. NP_625386): 31 % identity and 50 % similarity (E value = 8.2 × 10-7) to a portion of the L. major 
enzyme. 
 
Query = AAT98624; Sbjct = NP_625386 
 
Query:     9 TMIRVGDLDRSIKFYTERLGMKVLRKWDVPEDKYTLVFLGYG-PEMSS-TVLELTYNYGV 66 
             T++R  D DRS  FY E+LG+ V R++    ++ T+ FLG G  E+S  +   LT    + 
Sbjct:     9 TLLRPTDPDRSRAFYGEQLGLAVHREFGTGPERGTVYFLGNGFLEVSGRSDTPLTPGLAL 68 
 
Query:    67 TSYKHDEAYGHIAIGVEDVKELVADMRKHDVPIDYEDESGFMA-FVVDPDGYYIELL 122 
                  D A  H  +G + V E+V        P+  ++  G +  ++ DPDG  I L+ 
Sbjct:    69 WIQVEDAAAAHEELGAKGV-EIVRP------PV--KEPWGLVEMWIADPDGTRIVLV 116 
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Alignment 9: 
Sequence alignment of the GlxI amino acid sequences from E. coli (Accession No. 1FA8A) and L. major (Accession No. AAT98624) 
with the best matching peptide sequence from S. coelicolor.‡‡  The residues in bold correspond to the ligands known to bind the 
catalytic metal in E. coli.   
 
EcoliGlxI        ---MRLLHTMLRVGDLQRSIDFYTKVLGMKLLRTSENPEYKYSLAFVGYGPETEEAVIEL 57 
LmajorGlxI       MPSRRMLHTMIRVGDLDRSIKFYTERLGMKVLRKWDVPEDKYTLVFLGYGPEMSSTVLEL 60 
Scoelicolor      MVHVLSSRTLLRPTDPDRSRAFYGEQLGLAVHREFGTGPERGTVYFLGNG------FLEV 54 
                        :*::*  * :**  ** : **: : *       : :: *:* *      .:*: 
 
EcoliGlxI        TYNWGVDKYELGTAYGHIALSVDNAAEACEKIRQNGGNVTREAGPVKGGTTVIAFVEDPD 117 
LmajorGlxI       TYNYGVTSYKHDEAYGHIAIGVEDVKELVADMRKHDVPIDYED-----ESGFMAFVVDPD 115 
Scoelicolor      S---GRSDTPLTPGL-ALWIQVEDAAAAHEELGAKGVEIVRPP-VKEPWGLVEMWIADPD 109 
                 :   *  .     .   : : *::.     .:  :.  :            .  :: *** 
 
EcoliGlxI        GYKIELIEEK----DAGRGLGN---- 135 
LmajorGlxI       GYYIELLNEKTMMEKAEADMKEQGTA 141 
Scoelicolor      GTRIVLVEVP-----AEHPLRYRPGI 130 
                 *  * *::       *   :       
 
Alignment 10: 
The alignment of the peptide sequence of GlxII from humans (Accession No.CAA62483) with the best matching sequence from  
S. coelicolor, a possible hydrolase (Accession No. NP_625789): 28 % identity and 45 % similarity (E value = 9.5 × 10-5) to a portion 
of the human protein. 
 
Query = CAA62483; Sbjct = NP_625789 
 
Query:    88 KITHLSTLQVGSLNVKCLATPCHTSGHICYFVSKPGGSEPPAVFTGDTLFVAGCGK--FY 145 
             ++T  + L +  L +     P HT G + + + +     PP +F+GD LF    G+  F  
Sbjct:   116 ELTDGARLALAGLELTVAHAPGHTKGSVTFGLPE-AADIPPVMFSGDLLFAGSIGRTDFP 174 
 
Query:   146 EGTADEMCKALLEVLGRLPPDTRVYCGH--EYTINNLK----FARHVEPGNAA 192 
              G+ D+M ++L  V   L   T V  GH  + TI   +    + R V  G  A 
Sbjct:   175 GGSMDDMLESLARVCLPLDDSTVVLSGHGPQTTIGQERATNPYLRQVAAGQGA 227 
                                                 
‡‡ The symbols below the alignment indicate the similarity of the sequences: “*” indicates that the residues in that column are identical; “:” indicates that 
conserved substitutions are observed and “.”  indicates a semi-conserved substitution. 
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Alignment 11:  
The alignment of the peptide sequence of GlxII from yeast (S. cerevisiae, Accession No. CAA58065) with the best matching sequence 
from S. coelicolor, a possible hydrolase (Accession No. NP_626224): 27 % identity and 40 % similarity (E value = 1.6 × 10-5) to a 
portion of the yeast enzyme. 
 
Query = CAA58065; Sbjct = NP_626224 
 
Query:    26 NYSYLLSTEDRRNSWLIDPAEPLEVSPKLSAEEKKSIDAIVNTHHHYDHSGGNLALYSIL 85 
             N +YLL         LID A   +    L       I ++V TH H DH      + +   
Sbjct:    33 NNAYLLRCRATDEQLLIDAAN--DAHTLLGTIGDDGIASVVTTHRHGDHWQALAEVVAAT 90 
 
Query:    86 -CQENSG-HDIKIIGGSKSSPGVTEVP-DNLQQYHLGNLRVTCIRTPCHTKDSICYYIKD 142 
               + ++G HD + I      P  T+V  D+     +G + +T      HT  S+     D 
Sbjct:    91 GARTHAGRHDAEGI------PVPTDVLIDDGDTIRVGQVELTARHIAGHTPGSVVLVYDD 144 
 
Query:   143 LETGEQCIFTGDTLFIAGCGRFFEGTGRDMDMALNQIMLRAVGETNWNKVKIYPGH 198 
                G   +FTGD LF  G G  F+    D   +L   +   V +T  ++  +YPGH 
Sbjct:   145 PH-GHPHVFTGDCLFPGGVGNTFKDP--DAFASLIHDVQTKVFDTLPDETWVYPGH 197 
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Alignment 12:  
The alignment of the peptide sequence of GlxII from T. brucei brucei (Accession No. CAD37800) with the best matching sequence 
from S. coelicolor, a possible hydrolase (Accession No. NP_626224): 27 % identity and 47 % similarity (E value = 1.2 × 10-5) to a 
portion of the T. brucei brucei enzyme. 
 
Query = CAD37800; Sbjct = NP_626224 
 
Query:    64 LRTILSTHKHHDHSGGNISLQKKLNAMGAFRIIGGAN--EPIPGVTEK-VREGDHFSIGE 120 
             + ++++TH+H DH     +L + + A GA R   G +  E IP  T+  + +GD   +G+ 
Sbjct:    67 IASVVTTHRHGDHWQ---ALAEVVAATGA-RTHAGRHDAEGIPVPTDVLIDDGDTIRVGQ 122 
 
Query:   121 LKVDVLDAPCHTSGHVLYKVYHPQKAENGIALFTGDTMFVGGIGAFFEGDAVLMCSALRK 180 
             +++       HT G V+  VY        +  FTGD +F GG+G  F+ D     S +   
Sbjct:   123 VELTARHIAGHTPGSVVL-VYDDPHGHPHV--FTGDCLFPGGVGNTFK-DPDAFASLIHD 178 
 
Query:   181 VYNLNGACESSACDATDVQKRDNHTYIFPGH 211 
             V       ++   D        + T+++PGH 
Sbjct:   179 V-------QTKVFDTLP-----DETWVYPGH 197 
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Alignment 13:  
The alignment of the peptide sequence of GlxII from L. infantum (Accession No. ABC41261) with the best matching sequence from 
S. coelicolor, a possible hydrolase (Accession No. NP_626224): 26 % identity and 47 % similarity (E value = 2.0 × 10-6) to a portion 
of the L. infantum enzyme. 
 
Query = ACB41261; Sbjct = NP_626224 
 
Query:    70 STILSTHKHWDHSGGNAKLKAELEAMNSTVPVVVVGGANDS--IPAVTKP-VREGDRVQV 126 
             +++++TH+H DH    A++ A   A           G +D+  IP  T   + +GD ++V 
Sbjct:    68 ASVVTTHRHGDHWQALAEVVAATGARTHA-------GRHDAEGIPVPTDVLIDDGDTIRV 120 
 
Query:   127 GDLSVEVIDAPCHTRGHVLYKVQHPQ-HPNDGVALFTGDTMFIAGIGAFFEGDEKDMCRA 185 
             G + +       HT G V+     P  HP+    +FTGD +F  G+G  F+  + D   + 
Sbjct:   121 GQVELTARHIAGHTPGSVVLVYDDPHGHPH----VFTGDCLFPGGVGNTFK--DPDAFAS 174 
 
Query:   186 MEKVYHIHKGNDYALDKVTFIFPGH 210 
             +  ++ +       L   T+++PGH 
Sbjct:   175 L--IHDVQTKVFDTLPDETWVYPGH 197 
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Alignment 14: 
Sequence alignment of the GlxII amino acid sequences from yeast (S. cerevisiae), T. brucei brucei and L. infantum (Accession Nos.. 
CAA68065, CAD37800, and ABC41261 respectively) with the best matching peptide sequence from S. coelicolor (Accession No. 
NP_626224).‡‡   
 
TbruceiGlxII        ----------MEVVVKSIGTAFTVAVIPVLKD---NYSYVIHDKATNTLAAVDVSVDIDP 47 
LinfantumGlxII      ---------MRNYCTKTFGSAFSVTVVPTLKD---NFSYLINDHTTHTLAAVDVNADYKP 48 
YeastGlxII          ----------MKFLLQQIRNMHVKPIKMRWLTGGVNYSYLLSTEDRRNSWLIDPAEPLEV 50 
Scoelicolor         MTYSGEVTVGGPADVHELKDLMITKVAVGPMN---NNAYLLRCRATDEQLLIDAANDAHT 57 
                                   : :       :        :* :*::  .       :*     .  
 
TbruceiGlxII        VIDYVRR----LGGVDRTTDLRTILSTHKHHDHSGGNISLQKKLNAMG---AFRIIGGAN 100 
LinfantumGlxII      ILTYIEEHLKQQGNADVTYTFSTILSTHKHWDHSGGNAKLKAELEAMNSTVPVVVVGGAN 108 
YeastGlxII          SPKLSAE---------EKKSIDAIVNTHHHYDHSGGNLALYSILCQENSGHDIKIIGGS- 100 
Scoelicolor         LLGTIGD-----------DGIASVVTTHRHGDH---WQALAEVVAATGARTHAGRHDAEG 103 
                                        : :::.**:* **      *   :   .        ..   
 
TbruceiGlxII        EPIPGVTEKVREGDHFSIGELKVDVLDAPCHTSGHVLYKVYHPQKAENGIALFTGDTMFV 160 
LinfantumGlxII      DSIPAVTKPVREGDRVQVGDLSVEVIDAPCHTRGHVLYKVQHPQHPNDGVALFTGDTMFI 168 
YeastGlxII          KSSPGVTEVPDNLQQYHLGNLRVTCIRTPCHTKDSICYYIKDLETGEQ--CIFTGDTLFI 158 
Scoelicolor         IPVP-TDVLIDDGDTIRVGQVELTARHIAGHTPGSVVLVYDDPHGHPH---VFTGDCLFP 159 
                     . * .     : :   :*:: :     . ** . :     . .   .   :**** :*  
 
TbruceiGlxII        GGIGAFFEGDAVLMCSALRKVYNLNGACESSACDATDVQKRDNHTYIFPGHEYTVNFLRF 220 
LinfantumGlxII      AGIGAFFEGDEKDMCRAMEKVYHIHKGND---------YALDKVTFIFPGHEYTSGFMTF 219 
YeastGlxII          AGCGRFFEGTGRDMDMALNQIMLRAVGETN-----------WNKVKIYPGHEYTKGNVSF 207 
Scoelicolor         GGVGNTFK-DPDAFASLIHDVQTKVFDTLP------------DETWVYPGHGNDT----- 201 
                    .* *  *:     :   :..:                     . . ::***      : : 
 
TbruceiGlxII        SRDALP-ASHPDVSFVEAQLRRYTESVAGNVPTVPSTLAEEKRQNLFLRTCDEAFVRVMN 279 
LinfantumGlxII      SEKTFPDRASDDLAFIQAQRAKYAAAVKTGDPSVPSSLAEEKRQNLFLRVADPAFVAKMN 279 
YeastGlxII          IRAKIYSDIGQNKEFDALEQYCKSNECTTG----HFTLRDELGYNPFMRLDDRAVRLAVG 263 
Scoelicolor         ------------------------------------TLGAERPHLPEWRARGW------- 218 
                        :         :                     :*  *       *  .  .   :  
 
TbruceiGlxII        KGETAVKLMDFLYNTCP----- 296 
LinfantumGlxII      QG-NAHALMMYLYNACD----- 295 
YeastGlxII          DTAGTYPRSVVMQELRKLKNAM 285 
Scoelicolor         ---------------------- 
                               :     :   :
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Table 4.7: Results for the sequence searches of the Streptomyces coelicolor genome for homologous sequences 
to known glyoxalase enzymes. 
Query 
Organism 
Accession #  S. coelicolor 
Sequence 






GlxI       
Human NP_006699 NP_625147 Lyase 34 % 57 % 1.6  
Yeast CAC16163 NP_626233 Dioxygenaseb 23 % 43 % 12000 
E. coli 1FA8A NP_625386 Nonec 29 % 49 % 61 
L. major AAT98624 NP_625386 Nonec 31 % 50 % 0.082 
 
GlxII 
      
Human CAA62483 NP_625789 Hydrolased 28 % 45 % 9.8 
Yeast CAA58065 NP_626224 Noneb.c 27 % 40 % 1.6 
T. brucei 
brucei 
CAD37800 NP_626224 Nonec 27 % 47 % 1.2 
L. infantum ABC41261 NP_626224 Nonec 26 % 47 % 0.2 
a% identity and similarity to portions of the query enzymes; bMay belong to the glyoxalase superfamily; cThis 
peptide sequence, identified from the genome, has not yet been assigned a putative function;  dSimilarity to the 
glyoxalases 
4.3.2. Choice of Organism 
S. coelicolor was chosen for our investigations into the presence of an MSH-
dependent Glx system, as it is known to produce MSH as its major thiol4 and the genes 
responsible for biosynthesis of MSH having been identified.104  The S. coelicolor genome has 
been sequenced16 and is available for homologous sequence searching,† which allows for the 
development of an over-expression system for a Glx enzyme should it be identified.  The 
isolation of an MSH-dependent Glx system would represent the first MSH-dependent 
enzyme identified in Streptomyces bacteria. 
4.3.3. Preliminary Assays for the Identification of a Mycothiol Dependent Glyoxalase 
System 
Cell-free extracts of S. coelicolor were prepared using sonication in Lysis Buffer 1.  
The thawed S. coelicolor cells were very clumpy and the initial five to ten sonication 
intervals distributed the cells more evenly in the buffer.  EDTA (0.1 mM), a chelating agent, 
was included in the lysis buffer to inhibit any metal dependent proteases present in the 
extract.  The inclusion of EDTA in the lysis buffer complicates the assays used to identify 
Glx type activity as all of the identified GlxI enzymes are metalloenzymes and are maximally 
activated by either nickel (most eukaryotes), or zinc (E. coli and L. major).  The GlxII 
enzymes are also metalloenzymes; however, the in vivo metal preferences of this enzyme 
have not yet been identified.  It is likely that, in addition to inhibiting metal dependent 
proteases, EDTA could remove the essential metal from the putative MSH-dependent Glx 
enzymes.  A cocktail of common metals was added to the various assay mixtures in hopes of 
reconstituting the metal in the putative MSH-dependent Glx metalloenzymes. 
To fully test for the presence of an MSH-dependent glyoxalase system, multiple 
possibilities must be explored.  With the exception of the GlxIII enzyme reported in E. coli, 
all reported Glx systems use two enzymes to convert cytotoxic MG to D-lactate.  The first 
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enzyme in this pathway, GlxI, converts the hemithioacetal of MG and GSH or TSH2 to  
S-D-lactoylglutathione or S-D-lactoyltrypanothione, both of which have a characteristic 
absorbance at 240 nm.  Assays to monitor GlxI activity, therefore, typically observe changes 
in absorption at this wavelength.  In addition, MG and the thiol of interest are usually 
incubated for at least 15 minutes before the assay to allow for the formation of the 
hemithioacetal.  It is likely that should an MSH-dependent GlxI enzyme exist, the resultant  
S-D-lactoylmycothiol would also have a characteristic absorbance at 240 nm; therefore, 
Assays 1 – 6 monitored the change in absorbance at this wavelength.  Assay Mixture 2 
included GSH, as well as MG, in hopes that an MSH-dependent Glx system would accept 
GSH in lieu of MSH, as MSH was unavailable at the time of this experiment. 
Unlike the product of GlxI, the product of GlxII, D-lactate, does not demonstrate 
absorbance at a unique wavelength.  Traditionally, GlxII activity is monitored by observing a 
decrease in absorbance at 240 nm, which corresponds to the conversion of the  
S-D-lactoylglutathione, or S-D-lactoyltrypanothione, to D-lactate.  The activity of GlxII can 
also be monitored using D-LDH which converts D-lactate to pyruvate, with the simultaneous 
reduction of NAD+ to NADH, the latter having a specific absorbance at 340 nm.  An increase 
at 340 nm would therefore correspond directly to the formation of D-lactate.  A pyruvate 
trapping agent, such as hydrazine, and a pH of ~9 is often used to force the equilibrium 
towards the formation of pyruvate.  It is possible that an MSH-dependent Glx system could 
convert MG to L-lactate, rather than D-lactate; therefore both possibilities were investigated 
in Assays 5 and 6.  
Unfortunately these assays were inconclusive.  Assays 1 – 4 did not show a 
significant change in absorption at 240 nm.  If S-D-lactoylmycothiol was formed, it is 
possible that it was consumed by MSH-dependent GlxII too quickly for an increase in 
absorbance to be noted.  Assays 5 – 6 were difficult to interpret due to the large amount of 
background absorbance in these assays.  The unfiltered lysate contained a large number of 
metabolites and other enzymes which could produce substrates for D and L-LDH.   
4.3.4. Comparative Assays Performed in Escherichia coli 
The assays aimed at the detection of Glx activity were repeated using cell-extracts 
from E. coli, an organism known to possess a Glx system.  Assays 1 – 4, which test for GlxI 
activity by observing a change in absorbance at 240 nm, performed using unfiltered cell-free 
extract did not show a change in absorbance at 240 nm.  This result is not surprising as GlxII 
would be present in the assay mixture and would very quickly convert any  
S-D-lactoylglutathione formed to D-lactate.  Assays 5 and 6, which used a coupled assay with 
D-LDH, did show a change in absorbance at 340 nm with the unfiltered cell-free extract. This 
result is consistent with the reduction of NAD+ to NADH, indicating the formation of  
D-lactate and GlxII activity; however, an increase in absorbance was also seen with L-LDH.  
The unfiltered cell-free extract would contain a variety of metabolites, including L-lactate, 
which could account for the increase in absorbance at 340 nm.   
Assays 1 – 4 were repeated using the filtered cell-free extract from E. coli and no 
increase in absorbance was noted at 240 nm; however, assays 5 and 6 did show an increase in 
absorbance at 340 nm when D-LDH was used.  In addition, no increase was seen with the use 
of L-LDH.  Combined, these results indicate the presence of a Glx system.  The lack of 
absorbance noted with Assays 1 – 4 is likely due to the fast consumption of  
S-D-lactoylglutathione to D-lactate.  The increase in absorbance at 340 nm in the absence of 
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GSH is attributed to the activity of GlxIII, which converts the MG directly to D-lactate 
without the need for GSH.   
Based upon the results of the E. coli assays, it is likely that the accurate detection of 
MSH-dependent Glx activity will require the removal of all small molecules from cell-free 
extracts followed by the readdition of MG and MSH.  We therefore turned our attention to 
the isolation of MSH and the synthesis of des-myo-inositol mycothiol, a truncated version of 
MSH shown to be useful in the identification of MSSM reductase activity. 
4.3.5. Synthesis of Des-myo-Inositol-Mycothiol 
The synthesis of des-myo-inositol mycothiol has been reported113 and was followed 
closely with the exceptions noted below.  The coupling of Fmoc-Cys(Acm)-OPfp (4-44) and 
D-glucosamine (4-45) did not go to completion, as some starting amino acid remained.  The 
activated ester of the remaining starting material would have been cleaved during the 
reaction to give Fmoc-Cys(Acm)-OH, which is also insoluble in water and would precipitate 
with the product during purification.  To separate the amino acid from the product, the 
precipitate was dissolved in methanol and stirred with a weakly basic anion exchange 
macroreticular resin to bind the amino acid.  The solution was then filtered to remove the 
resin affording Fmoc-Cys(Acm)-GlcN (4-46) in 56 % yield.   
As detailed by the original protocol, the Fmoc group was removed with 5 % 
piperidine in DMF (99 % yield of 4-47) and acetylation of the α-amino group was performed 
using acetic anhydride in water with a pH of ~ 9, maintained by potassium carbonate.  This 
method facilitated the selective acetylation of the α-amino group, as opposed to esterification 
of the hydroxyl groups of D-glucosamine, to yield AcCys(Acm)-GlcN (4-48).113 
In an attempt to avoid the use of highly toxic thallium trifluoroacetate, the oxidative 
deprotection of the thiol was attempted using iodine,118 one of the most simple, less 
expensive, less toxic oxidants.120  Iodine has been shown to be successful in the removal of 
S-acetamidomethyl and S-trityl groups from cysteine with the simultaneous formation of 
cystine.118  Unfortunately, the use of iodine in this instance did not appear to remove the  
S-acetamidomethyl group and the resultant 1H NMR spectrum was convoluted.  Catalytic 
amounts of iodine are known to catalyze the acetylation of D-glucose in the presence of 
acetic anhydride.120,121  By 1H NMR spectroscopy, it appeared that there was a small amount 
of residual acetic anhydride remaining after the purification of AcCys(Acm)-GlcN; therefore, 
it is possible that a mixture of products was formed with varying levels of acetylation.  The 
use of iodine as an alternative was rejected and future experiments will use thallium 
trifluoroacetate, as described by Patel and Blanchard,113 for the deprotection of cysteine with 
the simultaneous formation of the disulfide of des-myo-inositol mycothiol.   
4.3.6. Alternative Synthesis of Des-myo-Inositol Mycothiol 
AcCys(Trt)-OH (4-52) was used as a starting point in lieu of FmocCys(Acm)-OPfp in 
an attempt to simplify the production of des-myo-inositol mycothiol.  The use of a pre-
acetylated starting material eliminates two steps from the published protocol113 and removes 
the possibility of the esterification of the hydroxyl groups of D-glucosamine during the 
acetylation of the α-amino group.  The S-triphenylmethyl thioether protecting group was 
chosen to increase the organic solubility of the molecule.  Solely water soluble compounds 
cannot be purified with standard silica gel chromatography and even removing the solvent is 
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time consuming.  Increasing the product’s solubility in organic solvents opens more options 
for purification and makes it easier to handle.     
During the coupling of AcCys(Trt)-OH to D-glucosamine using HBTU racemization 
at the α-carbon occurred as expected.  Racemization can occur during the base catalyzed 
coupling of an N-acyl-protected, carboxyl-activated amino acid through the mechanism 
shown in Figure 4.20.  This racemization can be minimized with the use of nonpolar 
solvents, a minimum amount of base and low reaction temperatures.122  Due to the nature of 
the components involved in these reactions, such as D-glucosamine, nonpolar solvents are not 
an option.   In addition, the low solubility of D-glucosamine in DMF eliminates the use of 
low reaction temperatures.  Although it was known a racemic mixture was likely, this method 
was initially an attractive option as it was thought that the mixture could be easily prepared in 
large quantities and would be useful in testing for activity during the expected purification of 
MSH-dependent enzymes.  The racemic mixture was very difficult to purify, therefore this 
method was abandoned and all further efforts were focused on the published method for the 




















Figure 4.20: The mechanism for the racemization of amino acids that can occur during the base-catalyzed 
coupling reaction of an N-protected, carboxyl-activated amino acid.  Racemization takes place in the 
intermediate oxazolone that forms readily from an N-acyl-protected amino acid (R2 = alkyl, aryl).  Adapted 
from Greene and Wuts (1999)122 
4.3.7. Synthesis of 2-S-(2′-Thiopyridyl)-6-hydroxynaphthyl disulfide and Isolation of 
Mycothiol 
The synthesis of 2-S-(2′-thiopyridyl)-6-hydroxynaphthyl disulfide (4-50) was 
unsuccessful when the protocol detailed by Steenkamp and Vogt115 was followed exactly.  
The initial step, the reduction of 6-hydroxynaphthyl disulfide (4-55) by sodium borohydride 
in 1:1 acetonitrile:water, failed.  A review of the literature regarding the reactivity of sodium 
borohydride indicated that the optimum pH for this reagent is 9.123  The use of a 1:1 
acetonitrile:0.1 M sodium bicarbonate solution with a pH of 9 as the solvent resulted in the 
successful reduction of the 6-hydroxynaphthyl disulfide.  Also unlike the published protocol, 
all solvents were degassed before use and all reactions proceeded under argon to reduce the 
chance of oxidation of any free thiols in solution.115   
The published protocol used M. smegmatis as the source of MSH115 the largest known 
producer of this intracellular thiol.4  M. smegmatis is considered a class two biohazard, as it 
can cause tuberculosis-like symptoms in marine mammals.  The facilities available at the 
time of these experiments were not equipped to handle such an organism; therefore,  
S. jumonjinensis, a non-pathogenic organism was used as the source of MSH for this work, as   
S. jumonjinensis produces the largest amount of MSH of the non-pathogenic Streptomyces 
bacteria (Table 4.8).4  
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Table 4.8: A comparison of the amount of mycothiol produced by Streptomyces bacteria to that produced by 
Mycobacterium smegmatis. 
Organism MSH (μmol/g dry weight) 
Mycobacterium smegmatis 19.0 
Streptomyces clavuligerus 5.40 
Streptomyces coelicolor 2.80 
Streptomyces jumonjinensis 6.70 
Streptomyces lactamdurans 5.90 
Streptomyces lividans 6.60 
 
The isolation of MSH from S. jumonjinensis followed the protocol detailed by 
Steenkamp and Vogt fairly closely except that the reagent solution and the cell-free extract 
were degassed for 10 minutes before use and a different reverse-phase C18 column was used 
for HPLC purification due to availability.  There is a discrepancy in the published report of 
the purification of MSH.  The text of the paper states that tagged-MSH elutes at 35.5 min; 
however, the chromatogram included in the manuscript labels the peak at 35.5 minutes as 
excess reagent and the peak at 23 min as the tagged MSH.  The elution profile of this work is 
in better agreement with the chromatogram as tagged MSH eluted at 28 minutes, followed by 
excess reagents.  The amount of MSH isolated by this method varies, with a maximum yield 
of 1.5 mg of the tagged MSH being isolated from 4 g of wet weight S. jumonjinensis cells.  
4.3.8. Synthesis of Mycothiol Analogue 
The N,N′-diacetyl-cystinyl-cyclohexyl amide (4-59) was synthesized as a possible 
MSH analogue using HBTU as a coupling agent to give an overall yield of only 13 %.  The 
myo-inositol moiety is not essential for the detection of MSSM reductase activity,113 
indicating that it may not be essential for the binding of MSH to its cognate enzymes.  This 
analogue could be used to determine if the hydroxyl groups of the D-glucosamine of MSH 
are essential for binding or if the cyclohexyl scaffold is sufficient.   
4.4. Conclusions and Future Work 
Ground work towards the identification of a MSH-dependent Glx system in  
S. coelicolor was completed.  Preliminary assays for GlxI and GlxII activity in S. coelicolor 
were inconclusive.  Similar assays for Glx activity in E. coli, an organism known to contain 
the Glx system, indicated that, for accurate detection of Glx activity, all small molecules 
must be removed followed by the readdition of MG and the thiol cosubstrate.  Subsequent 
work therefore focused on the synthesis of des-myo-inositol mycothiol, a simplified MSH 
analogue used to detect MSSM reductase activity, as well as the synthesis of 2-S-(2′-
thiopyridyl)-6-hydroxynaphthyl disulfide and its use in isolating MSH from cell-free extracts 
of S. jumonjinensis.   
The obvious next steps of this project would be the removal of the acetamidomethyl 
group from AcCys(Acm)-GlcN to yield des-myo-inositol mycothiol disulfide, followed by 
reduction to the free thiol.  Once purified, this thiol would be used to assay cell-free extracts 
of S. coelicolor, which had been passed through a 3 000 molecular weight cut-off filter, for 
MSH-dependent Glx activity.  If activity was not detected, the assays would then be repeated 
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using MSH as an MSH-dependent Glx system might not accept the hemithioacetal of MG 
and des-myo-inositol mycothiol as a substrate.  If activity is detected, the enzymes 
responsible for this activity will be purified and the resulting enzymes characterized.  The 
identification of an MSH-dependent Glx system would be the first example of an MSH-
utilizing enzyme in S. coelicolor.  In addition, because the Glx system is an essential 
detoxification pathway, it would be a new target for the development of novel therapeutics 
aimed at Myocbacteria.   
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Chapter 5: Phosphorylation by Inositol Pyrophosphates 
 
Phosphorylation is a major component of molecular energy production and is 
essential for a diverse range of processes including the control of cellular pathways, hormone 
action and signal transduction.1  Adenosine and guanosine triphosphate (ATP and GTP) are 
the most commonly used phosphate donors in the cell; however, a number of other biological 
compounds are capable of phosphate donation.  Phosphoenol pyruvate and 1,3-
bisphosphoglycerate, for example, are known to be thermodynamically superior phosphate 
donors to ATP,1 and pyrophosphate alone has been shown to fulfill the role of ATP in some 
reactions in certain parasitic protozoa.2-5  In addition, inorganic polyphosphate has been 
shown to act as a phosphate donor through the polyphosphate kinase catalyzed conversion of 
polyphosphate and adenosine diphosphate (ADP) to ATP.6  The driving force for these 
reactions is the instability of the phosphoanhydride linkage caused by competing resonance 
and electrostatic effects, as well as solvation effects.1  
Recently, 5-diphosphoinositol pentakisphosphate (5-PP-InsP5, Figure 5.1, 5-1) has 
been shown to phosphorylate proteinaceous serine residues in mammalian and yeast cell 
extracts.7  Snyder and coworkers have shown that this novel activity proceeds without 
enzyme participation and is specific to eukaryotes, with no activity being observed in 
bacterial extracts.  The exact role that this process plays in these organisms is currently 
unknown, though 5-PP-InsP5 and bis-diphosphoinositol tetrakisphosphate (bis-PP-InsP4, 
Figure 5.1, 5-2) have been linked to cellular chemotaxis,8 apoptosis9,10 and endocytosis11 and 
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Figure 5.1: Representative structures of hexaphosphorylated myo-inositol (InsP6), 5-diphospho-myo-inositol 
pentakisphosphate (5-PP-InsP5), and 5,6-bis-diphospho-myo-inositol tetrakisphosphate (5,6-bis-PP-InsP4). 
5.1. Introduction to Inositol Phosphates and Pyrophosphates 
5.1.1. Numbering 
Inconsistencies in the literature and changes in nomenclature conventions have led to 
a large amount of confusion regarding the numbering of the inositol phosphates (InsPs).  
Myo-Inositol itself is a meso compound, with a plane of symmetry running from C2 to C5 
(see Figure 5.1 for numbering); once substituted outside of this plane, this derivative is chiral 
and can be classified as D or L depending on the direction in which the ring is numbered.  To 
clarify the numbering of myo-inositol derivatives, Agranoff developed a simple mnemonic 
for numbering myo-inositol derivatives: Agranoff likens myo-inositol to a turtle with the axial 
hydroxyl (C2) being its head, the opposite hydroxyl (C5) its tail, and all other hydroxyl 
groups are the flippers of the turtle (Figure 5.2).  Modern biochemical nomenclature uses the 
D numbering system, therefore the turtle is “right-flippered” and the “front-right flipper” is 
labelled C1 and the ring is labelled counter-clockwise.  If the L convention is in use, the 
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“front-left flipper” of the turtle is labelled C1 and the ring is numbered clockwise.  Biological 
journals tend to use the D numbering system exclusively, while chemical journals often use 
the L numbering system.  To further complicate matters, the official designation of the D and 
L numbering systems of the inositol rings were swapped in the 1970s; therefore, D labelled 
structur
ple the structures shown in Figure 5.1 are abbreviated as 5-PP-InsP5 
and 5,6-bis-PP-InsP4. 
es in earlier papers are actually L structures using today’s conventions.12   
In keeping with the current literature describing the inositol pyrophosphates (InsPPs) 
all structures and diagrams in this work will follow the D numbering system for myo-inositol 
derivatives.  Accepted naming conventions use the abbreviation “Ins” for myo-inositol and 
unless otherwise stated, it is assumed that the D numbering convention is used with this 
abbreviation.13  For example, D-myo-inositol-3-phosphate would be abbreviated as Ins(3)P1, 
while D-myo-inositol-3,4-bisphosphate would be abbreviated to Ins(3,4)P2.  A standard 
method for the abbreviation of the InsPPs has yet to be adopted.  Throughout this chapter, if 
the position of the pyrophosphate group is known, or relevant, it be included in the 
abbreviation, for exam
 
Figure 5.2: (a) A Haworth projection of myo-inositol; (b) The predicted thermodynamically preferred chair 
conformation of myo-inositol; (c) Agranoff’s turtle, which is used as an aid in determining the numbering of 
myo-inositol and its derivatives.  This model follows the D numbering convention, with the head of the turtle 
per” of the turtle corrcorresponding to C2 and the “right front flip esponding to C1.  This figure is credited to 
Irvine and Schell.12 
5.1.2. D
 P. palladum has been identified as 
1,5-bis-PP-InsP4, or its enantiomer, 3,5-bis-PP-InsP4.20   
istribution and Structure 
InsPPs have been detected in mammalian cells,14-16 Saccharomyces cerevisiae,17 
Dictyostelium discoideum,18 Entamoeba histolytica,19 Polysphondylium palladum20 and 
Phreatamoeba bamuthi.21  The structures of the InsPPs vary with species and have not been 
fully elucidated.  In mammals, the predominant PP-InsP5 has been identified as 5-PP-InsP5;22 
however, the identity of the major bis-PP-InsP4 is unknown.23  The structural identification of 
the InsPPs in mammals has been hampered by their low concentration which is in the μM 
range.  In contrast, the concentration of InsPPs in D. discoideum is almost 300 times that of 
mammals24 (0.05 – 0.25 mM),18 and the structures of both predominant InsPPs have been 
identified: 5-PP-InsP5 and 5,6-bis-PP-InsP4, with 10-25% of the pool of PP-InsP5 existing as 
6-PP-InsP5.22,25  In addition, the predominant PP-InsP5 in
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5.1.3. Biosynthesis 
The biosynthesis of the InsPs begins with the conversion of D-glucose-6-phosphate to 
Ins(3)P1,* catalyzed by L-myo-inositol-1-phosphate synthase,26,27 which is found in animals, 













Figure 5.3: The biosynthesis of L-myo-inositol-1-phosphate (D-myo-inositol-3-phosphate) catalyzed by L-myo-
inositol-1-phosphate synthase.  All components are shown using Haworth projections and Pi represents a 
phosphate group.28 
Ins(3)P1 is further phosphorylated to yield a wide variety of InsPs which differ in the 
number and placement of the phosphate groups.12  InsP6 was originally thought to be the end 
point of InsP biosynthesis, but is now known to be further phosphorylated to the InsPPs.  The 
biosynthetic pathway of InsP6 has not been elucidated with the biosynthetic intermediates 
being fully identified in only two organisms: Spirodela polyrhiza29 and D. discoideum.30  The 
latter is a known producer of InsPPs and its biosynthesis of InsP6 is as follows:30 
 
Ins(3)P1 → Ins(3,6)P2 → Ins(3,4,6)P3 → Ins(1,3,4,6)P4 → Ins(1,3,4,5,6)P5 → InsP6 
 
In addition, partial pathways for the biosynthesis of InsP6 have been identified in humans,  
S. cerevisiae, Drosophilia melanogaster and Arabidopsis thaliana, commencing with 
Ins(1,4,5)P3 31   
  
Human:31  
Ins(1,4,5)P3 → Ins(1,3,4,5)P4 → Ins(1,3,4)P3 → Ins(1,3,4,6)P4 → Ins(1,3,4,5,6)P5 → InsP6 
 
S. cerevisiae, D. melanogaster, and A. thaliana:31 
Ins(1,4,5)P3 → Ins(1,4,5,6)P4 → Ins(1,3,4,5,6)P5 → InsP6 
 
Once formed, InsP6 can be further phosphorylated to PP-InsP5 by the InsP6 kinases 
(InsP6Ks) using ATP as a source of phosphate.  InsP6Ks have been identified in  
mammals,32-34 Xenopus oocytes,35 and S. cerevesiae.32  Mammals have been shown to 
produce three unique isoforms of InsP6K which vary in cellular localization and expression 
level.32,34  InsP6K has a high specificity for InsP6 and does not further phosphorylate PP-
InsP5 to bis-PP-InsP4.32,33,35,36  A separate enzyme, PP-InsP5 kinase, has been identified 
which catalyzes the formation of bis-PP-InsP4 using PP-InsP5 as a substrate and ATP as a 
phosphate source.23 
                                                 
* Ins(3)P1 is equivalent to L-myo-inositol-1-phosphate 
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5.1.4. Biological Role 
The InsP6Ks and the InsPPs have been implicated in a number of biological 
processes; however, a definitive role has yet to be determined.  The InsP6Ks are believed to 
be involved in the regulation of apoptosis, cell death and cellular growth.9,10,37  
Unfortunately, the exact involvement of the InsPPs in these processes has yet to be 
determined. 
The InsP6 and PP-InsP5 kinases have been shown to transfer a phosphate group from 
their cognate InsPP to ADP, forming ATP.23,33  In vitro studies indicate that the rate of ATP 
formation by these kinases is similar to the rate of InsPP formation.  The in vivo direction of 
the enzymatic reaction will therefore likely be defined by the relative concentrations of ATP 
and the InsPPs.33  It has been suggested that the ability of the InsPPs to donate a phosphate 
group to ATP may indicate that they can act as energy sources for specific cellular 
functions.23  
Recently the ability of 5-PP-InsP5 to phosphorylate proteinaceous serine residues in 
eukaryotic cell extracts has been noted.7  Preliminary studies of the hydrolysis of the 
pyrophosphate moieties of the InsPPs have indicated that these compounds may have 
comparable or even greater energies of hydrolysis than ATP.18,38  To date, the exact role this 
phosphorylation plays in cellular physiology is unknown but it has been hypothesized that it 
may represent a novel signalling mechanism in these organisms.7  
5.2. Objectives 
The InsPPs have been linked to a number of important biological functions; however, 
the exact mechanism of action is unknown.  The ability of the InsPPs to non-enzymatically 
phosphorylate proteinaceous serine residues in eukaryotes may be crucial to their cellular 
role.  To better understand the driving forces behind these reactions, we performed a detailed 
theoretical study of the phosphorylation of methanol, as a model of serine, by the InsPPs.  
Our goal was to determine the effect of InsPP structure and overall charge on the 
thermodynamics of these reactions.  This information should contribute to our understanding 
of this novel cellular phosphorylation process. 
5.3. Computational Studies of Phosphate Transfer 
Phosphate transfer is an essential process in biological systems and hence, many 
studies have been performed on these reactions to further understand the behaviour of the 
compounds involved and the mechanisms of these reactions. 
5.3.1. The Modelling of Pyrophosphate  
Pyrophosphate has been thoroughly studied on its own and as a model compound for 
ATP.  These investigations have focused on the conformational properties, ionization states, 
solvation, and hydrolysis of pyrophosphate, as well as the effects of complexed metal ions on 
pyrophosphate behaviour.39-51  These studies have been performed using Hartree-Fock (HF) 
and Density Functional Theory (DFT) techniques in both the gas and aqueous  
phases.39,42-45,51  In addition, methyl pyrophosphate and its reactions have been studied to 
gain insight into phosphorylation.44,52  A major finding of these studies, through the 
comparison of theoretical and experimental results, is that the accurate modelling of 
phosphate transfer requires the consideration of solvation, as gas phase approaches do not 
 - 141 -
produce results in agreement with experimental data.39,42,46,49,53 Additionally the solvation 
energies of the substrates and products contribute substantially to the overall 
thermodynamics of these reactions.46,48-50   
At biologically relevant pH, phosphates are highly charged species with a large 
amount of intramolecular electrostatic repulsion.  In the aqueous phase, water molecules 
provide hydrogen bonding and electrostatic shielding, minimizing the electrostatic repulsions 
felt by the phosphate and pyrophosphate groups.  These interactions and shielding are not 
present in the gas phase, which can exaggerate the contribution of intramolecular interactions 
to the calculated thermodynamic stability of these compounds.54  The thorough study of 
pyrophosphates and phosphate donation is further complicated by the role that counter-ions 
are known to play in the stability of these compounds.46,48-52  The accurate placement and co-
ordination of these ions adds another layer of complexity to the design of theoretical studies 
of these systems. 
5.3.2. Modelling of the Inositol Phosphates 
 To date, extensive modelling studies of the InsPPs have not been conducted.  
Preliminary investigations into the bond energies of 1, 4-bis-PP-InsP4† using molecular 
mechanics indicate that these compounds may have a comparable or even greater energy of 
hydrolysis than ADP.18  Given the importance that serine phosphorylation by the InsPPs may 
play in cellular physiology, a more detailed study of the thermodynamics of these reactions 
appeared warranted. 
5.4. Computational Chemistry 
 There are multiple methods available to determine the thermodynamic properties of a 
system.  The higher level HF and DFT calculations were initially used for our studies of the 
InsPPs, followed by lower level molecular mechanics methods; however, in all cases, these 
techniques proved unsatisfactory.  An introduction to HF and DFT theory can be found in 
Chapter 2, while an introduction to molecular mechanics can be found in Chapter 3.  The 
semi-empirical methods were found to be better suited to this study and were used for all 
subsequent calculations.  
5.4.1. Semi-Empirical Theory 
Semi-empirical calculations were developed to model systems where the time and 
computational demands of an HF or DFT calculation would be prohibitive, but a level of 
theory higher than that of molecular mechanics was desired.  One of the most time-
consuming aspects of an HF calculation is the determination and manipulation of the 
integrals involved.  An obvious route to reduce the time required to complete these 
calculations would be to omit or approximate some of these integrals.  Semi-empirical 
techniques do this by explicitly including only the valence electrons in the calculation, while 
grouping the core electrons with the nucleus, as the core electrons have little effect on 
chemical bonding and other thermodynamic phenomena.55  The approximations made during 
semi-empirical calculations can lead to artificially large enthalpies; however, the relative 
magnitudes of the thermodynamic values are often realistic56 and these elevated effects often 
cancel in the determination of overall reaction enthalpies. 
                                                 
† 1,4-bis-PP-InsP4 or its enantiomer 3,6-bis-PP-InsP4 
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A semi-empirical calculation takes the same general form as an HF calculation in that 
they both have a Hamiltonian and a wavefunction;57 however, they are parameterized to 
reduce the amount of error inherent to the approximation of the integrals.  These parameters 
are obtained by fitting the equations to experimental data or the results of ab initio 
calculations.57  Semi-empirical methods are therefore a compromise between the speed of 
molecular mechanics and the accuracy of HF techniques.  Due to the inclusion of 
parameterization, the accuracy of a semi-empirical calculation is dependent upon the 
parameters in use; however, semi-empirical calculations are not as sensitive as molecular 
mechanics methods to parameterization and have been successful in the description of 
organic chemistry.57  If the molecule to be studied is similar to the compounds used to 
develop the parameter set, the results should be reasonable.57  A number of semi-empirical 
methods have been developed with the most popular methods in recent literature being AM1 
and PM3, which differ in their parameterization.58  The parameters of AM1 were developed 
using chemical knowledge and intuition and those of PM3 were derived from an automated 
parameterization procedure.58  While some of the parameters of AM1 and PM3 differ greatly, 
they predict various thermodynamic and structural properties to approximately the same level 
of accuracy.58  The results obtained do not require zero-point energy correction as it is 
implicit in the parameterization.57 
5.4.2. Plan of Action 
The ability of the InsPPs to phosphorylate proteinacious serine residues may be 
critical to cellular biochemistry.  To compare the thermodynamics of phosphate donation by 
the InsPPs to other model compounds, we performed geometry optimizations on 
pyrophosphate and a number of pyrophosphate derivatives, as well as ATP, triphosphate and 
methyl triphosphate to act as benchmarks for our study.  Geometry optimizations were 
performed on a variety of protonation states of InsP6, 5-PP-InsP5 and 5,6-PP-InsP4, and the 
ΔHf values for each structure were determined.  The overall thermodynamics (ΔHrxn) of 
phosphorylation of methanol by the various phosphate group donors was calculated to 
determine what trends, if any, exist, and if charge and InsPP structure have an effect on the 
thermodynamics of phosphorylation by the InsPPs. 
5.5. Materials and Methods 
5.5.1. Initial Hartree-Fock, Density Functional Theory and Molecular Mechanics 
Geometry Optimizations 
 All structures were drawn and visualized in Maestro (Schrödinger Inc., Portland, OR) 
and all calculations were performed on an SGI O2 workstation (Violin) or the University of 
Waterloo’s multi-CPU Origin 3800 system (Flexor).  For complete details of these systems, 
please see the Materials and Methods section of Chapter 2.     
 All HF and DFT geometry optimizations and vibrational frequency calculations were 
performed using the 6-31++G** basis set with and without implicit solvation, both as 
implemented by Jaguar version 6.0 (Schrödinger Inc.).  All DFT calculations used the 
B3LYP density functional, also as implemented by Jaguar.  If convergence was a problem, a 
similar tautomer whose geometry had been successfully optimized, was modified and used as 
a starting structure.  If a negative frequency was returned the conformation is not a minimum 
energy point on the potential energy surface.  The structure was then modified through bond 
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and/or torsion angle rotation to give a new starting structure or a similar optimized tautomer 
was modified and used as a new starting structure.   
 All molecular mechanics calculations were performed using the OPLS2003 force 
field and the GB/SA solvation model as implemented by MacroModel (Schrödinger Inc.).   
5.5.2. Semi-Empirical Geometry Optimizations 
All final geometry optimizations and vibrational frequency calculations were 
performed using the PM3 semi-empirical method59,60 with SM5.2 implicit water solvation as 
implemented by AMPAC 8 and the AMSOL module61 (Semichem Inc. Kansas City, KS).  
All structures were drawn and visualized using the AMPAC Gui 8.  All optimizations 
minimized the heat of formation of the molecule using the TRUST model62 and a restricted 
HF wavefunction.  Only those structures that returned non-negative frequencies were used 
for further analysis.  The starting structures for these calculations were drawn in the AMPAC 
Gui or were modified from previously optimized structures with a similar charge.  If a 
negative frequency was returned, the bond and/or torsional angles of the structure were 
modified to give a new starting structure.  If a negative frequency was returned despite these 
modifications, a minimum energy structure from a similar tautomer was modified and used 
as the new starting structure and the result was checked for negative frequencies.   
When a negative frequency could still not be obtained the structure’s geometry was 
optimized using molecular mechanics methods with the OPLS2003 force field and the 
GB/SA water solvation model as implemented by MacroModel.  All structures optimized by 
MacroModel were drawn and visualized using Maestro.  The resultant structure was then 
imported into the AMPAC Gui as a pdb file and its geometry optimized as detailed above. 
All AMPAC calculations were performed on an IBM Z Pro Intel Xeon two processor 
work station.  All Maestro and MacroModel operations were run on either Violin or Flexor. 
5.5.3. Geometry Optimizations of Model Phosphate Donors 
 Geometry optimizations were performed on the model compounds pyrophosphate 
(PPi), methyl pyrophosphate (MeOPPi), cyclohexyl pyrophosphate (cyclohex-PPi) and D-
myo-inositol-5-pyrophosphate (5-PP-Ins, Figure 5.4, (5-3 to 5-6)).  The pKa values of PPi are 
known (Table 5.1) and it is expected to have a charge of -2 or -3 at physiological pH.  The 
pKa values of the other model PPi compounds are unknown but are expected to be of a 
similar charged state under physiological conditions.  The model PPi derivatives were 
therefore modelled with charges of -2 and -3.  The starting conformations of cyclohex-PPi 
and 5-PP-Ins were such that the pyrophosphate group was in the equatorial position as shown 
in Figure 5.4.   
Geometry optimizations were also performed on the expected products of phosphate 
donation: phosphate (Pi), methyl phosphate (MeOPi), cylclohexyl phosphate (cylcohex-Pi), 
and Ins(5)P1 (Figure 5.4, (5-7 to 5-10)).  The pKa values of Pi and MeOPi are known and 
these compounds are expected to have a charge of -1 or -2 at physiological pH.  The pKa 
values of cyclohex-Pi and Ins(5)P1 are unknown, therefore based upon the Pi and MeOPi 
values, all of the model monophosphates were modelled with charges of -2 and -3 (Table 
5.1). 
   




































































Figure 5.4: Compounds used to model phosphate transfer. 
 
Table 5.1: The pKa values of pyrophosphate and its cleavage products phosphate and methyl phosphate1,63,64 
Structure pKa1 pKa2 pKa3 pKa4 Expec argea ted Ch
Pyrophosphate 0.  85 1.96 6  .68 9  .39 -2 / -3 




6.36 -- -- -1 / -2 
-1/ -2 6.82 12.38  
aat physiological pH 
5.5.4. Geometry Optimizations of the Inositol Pyrophosphates  
InsP6, 5-PP-InsP5 and 5,6-bis-PP-InsP4 were optimized with the 5 equatorial/ 1 axial 
(5 eq/1 ax) starting conformation as shown in Figure 5.5, Figure 5.6 and Figure 5.7  The pKa 
values of the InsPPs are unknown; therefore, the known pKa values of InsP6 (Table 5.2) were 
used to estimate the protonation states of the 5-PP-InsP5 and 5,6-bis-PP-InsP4 at 
physiological pH.  Additional charged states not expected to be present at physiological pH 
were also modelled to determine the effects of increased charge on the myo-inositol ring on 
the thermodynamics of phosphate donation.   
Table 5.2: The pKa values known for InsP665 
 Ca n Number rbo
pKa C1 3 /C C  2 C4 6 /C C  5
pKa1 1.5 1.1 2.1 1.7 
pKa2 5.7/12.0 6.9 10.0 7.6 






































































































Figure 5.5: InsP6 ionization states modelled in this study; where Pi represents a phosphate group. 




















































































































































































Figure 5.6: 5-PP-InsP5 ionization states modelled in this study; where Pi represents a phosphate group and PPi 
represents a pyrophosphate group. 
































































































































































































































Figure 5.7: 5,6-Bis-PP-InsP4 ionization states modelled in this study; where Pi represents a phosphate group 
5.5.5. Dihedral Angle Driving 
ated ΔHf values of the optimized geometries were not in 
agreem
and PPi represents a pyrophosphate group. 
In some cases, the calcul
ent with other structures with the same overall charge.  These structures were 
subjected to dihedral angle driving (0° to 360° in 10° increments) of the pyrophosphate group 
to overcome any energy barriers encountered during the initial minimization (see Figure 5.8 
for angles) in hopes of finding the global minimum or at the very least, a lower energy local 
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minimum structure.  The lowest energy structure was then minimized as detailed above.  In 
the case of 5,6-bis-PP-InsP4, the dihedral angle for the pyrophosphate group at position 5 on 
the inositol ring was first scanned, followed by the pyrophosphate group at position 6.  In 
most cases, these dihedral angle drives resulted in structures in better agreement with other 













































Figure 5.8: During dihedral angle scans, the angles marked by asterisks were altered systematically if require
5.5.6. Geometry Optimizations of Other Important Compounds 
pound of serine.  ATP, 
triphos
5.5.7. Calculation of the Thermodynamics of Phosphate Group Transfer 
d ΔHf values 
which w
5.6. Results and Discussion 
lity of 5-PP-InsP5 to phosphorylate proteinaceous serine 
residue
5.6.1. Selection of Modelling Technique 
5 and 5,6-bis-PP-InsP4 using HF and DFT 
techniq
                                                
d. 
Methanol was optimized in its neutral state as a model com
phate, and methyl triphosphate were modelled with the protonation state expected at 
physiological pH and therefore had overall charges of -2 and -3.  ADP was modelled with 
charges of -2 and -3 and AMP was modelled with overall charges of -1 and -2. 
The geometry optimizations of the various compounds studied returne
ere used to calculate the overall ΔHrxn values for the phosphorylation of methanol to 
form methyl phosphate. 
The newly discovered abi
s in eukaryotes has been hypothesized to be a novel signalling mechanism and may be 
critical for biological function.  Preliminary modelling studies of the InsPPs suggest that the 
phosphate donating ability of these compounds may be comparable to that of ATP.  Our 
theoretical study into the thermodynamics of these reactions gives insight into the effect of 
InsPP structure and overall charge on the ability of the InsPPs to donate a phosphate group 
and compares this ability to that of pyrophosphate, its derivatives and ATP.  
Initial attempts to model 5-PP-InsP
ues in vacuo and with implicit solvation did not yield satisfactory results.  These 
calculations were very lengthy, even when parallelized;‡ and the large number of negative 
charges present at physiological pH in 5,6-bis-PP-InsP4, combined with the inherent 
flexibility of the molecule, resulted in the inability of the geometry optimization algorithm to 
converge to a minimum energy structure for many tautomers.  In addition, the preliminary 
calculations performed using implicit water solvation gave results which were not in 
agreement with experimental data (Table 5.3).  Phosphorylation by pyrophosphate is known 
to be a favourable process; however, the results shown in Table 5.3 indicate that 
phosphorylation of methanol is unfavourable.  The inability of these methods to return results 
 
‡There were as many as 816 basis functions for InsP6, 902 for 5-PP-InsP5 and 940 for 5,6-bis-PP-InsP4 to be 
evaluated, depending on the protonation state of the molecule.   
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in agreement with experimental data, combined with the time constraints and the difficulty in 
finding a minimum energy structure for certain 5,6-bis-PP-InsP4 charged states, resulted in 
the abandonment of this method as a viable option for the modelling of phosphorylation by 
the InsPPs. 
Table 5.3: Calculated ΔHrxn values for phosphorylation of methanol by pyrophosphate. 
Calculated ΔHrxn Values (kcal/mol) 
HFb DFTc 
Pi Donora → Product Gas Water Gas Water 
ming M Pi(-1)dFor eO      
PPi(-2 Pi(-1) -5 2 41 -5 7 59  
-  
rming MeOPi(-2) 
)e → 5. .4 7. .7










11 2 ) → Pi(-1) 4 6 2 9.
aPi ate; HF rtree-Fo hods; cDFT ity functi e eOPi =  
 
s an alternative to the HF and DFT methods, the InsPPs were subsequently 
modell
orylation of methanol by pyrophosphate using molecular 
lated ΔHrxn Values (kcal/mol) 
= phosph b = Ha ck met  = dens onal theory m thods, dM  methyl
phosphate; ePPi = pyrophosphate. 
A
ed using molecular mechanics methods with the OPLS2003 force field.  OPLS2003 is 
an enhanced version of the OPLS-AA force field, which, though traditionally used to model 
amino acids, has been parameterized66 and successfully used for modelling  
carbohydrates.67-70  Previous studies had shown that AMBER*, another well-known force 
field used to model carbohydrates, could not predict the 5 eq / 1 ax conformation of InsP6, 
and hence was not used in this study.71  The OPLS2003 force field successfully predicted the 
5 eq/1 ax conformation of InsP6; however, the magnitude of the ΔHrxn values determined for 
the phosphorylation of methanol by pyrophosphate called these results into question (Table 
5.4, see Appendix 2 for detailed results).   
Table 5.4: Calculated ΔHrxn values for the phosph
mechanics methods. 
Calcu
Pi Donora → Product 
ming M Pi(-1)b
Gas Water 
For eO    
PPi(-2 Pi(-1) -262.4 -193.0 
rming M Pi(-2) 
PPi(-3 Pi(-1) -315.2 -200.7 
)c → 
PPi(-3) → Pi(-2) -330.8 -210.6 
Fo eO   
) → 
aPi = phosphate; bMeOPi = methyl ate; cPPi = pyrophosphat
 
s noted in Chapter 3, MacroModel returns information regarding the quality of the 
bend, s
accuracy of these results caused this method to be rejected as well.   
 phosph e 
A
tretch and torsion parameters of the force field used to model a particular structure.  
Of the force fields available, OPLS2003 seemed best suited for the study of the InsPPs: 
MacroModel returned only one type of low parameter the O-P-O-P torsional angle, and 
personal communications with Schrödinger Inc. indicated that despite the rating of this 
parameter, its value was reasonable.  The lower the quality of the parameter in use, the less 
experimental or ab initio data that has been utilized in fitting the force field equation, 
resulting in a generalized parameter, which can lead to inaccurate conformational energy 
differences and geometeries.72  Despite the assurances of Schrödinger Inc., concern over the 
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Finally, semi-empirical methods were attempted as they can provide greater accuracy 
over the molecular mechanics methods and greater speed and fewer computational demands 
than th
affect the thermodynamics of phosphate group transfer 
vatives.46,48-52  In addition, the transfer of a phosphate 
group 
xtracts, it is not anticipated that the omission of 
magnes
Methanol as a Model for Serine 
5 is specific to serine 
 observed.  Serine is a primary alcohol 
therefo
                                                
e HF and DFT methods.  The PM3 semi-empirical method was chosen as it has been 
used extensively to successfully model phosphorous41,73 and phosphate groups.40,74,75  In 
addition, the PM3 method accurately predicted the conformation of InsP6, while the AM1 
method did not.71  All further discussion of phosphate donation by the InsPPs focuses on the 
results obtained using semi-empirical methods. 
5.6.2. Exclusion of Counter-Ions 
Counter-ions are known to 
from pyrophosphates and their deri
from 5-PP-InsP5 to proteinaceous serine residues in eukaryotic cellular extracts is 
known to require the presence of magnesium (II) ions, though the exact role these ions play 
is unknown.  Studies of InsP6 indicate that in the cytosol, InsP6 likely exists in complex with 
five magnesium (II) ions and 22 water molecules; however, the exact location and 
coordination pattern of the magnesium (II) ions is unknown.  A search of the Cambridge 
Crystallographic Database for crystal structures of InsP6 in coordination with biologically 
relevant ions, such as sodium (I) and magnesium (II), returned structures involving  
sodium (I) ions and hydrogen bonded water molecules.§76-79  The use of these structures as a 
starting point in an implicitly solvated study would likely require the removal of the 
explicitly defined water molecules, invalidating the use of the structure as a starting point. 
The water molecules contribute hydrogen bonding and possibly electrostatic interactions 
integral to the conformation of the molecule.  In addition, there is no data available regarding 
the coordination of counter-ions and water molecules by the InsPPs; therefore, any inclusion 
of counter-ions or water molecules in our calculations would be arbitrary with a large amount 
of uncertainty in their placement.  This uncertainty would add a prohibitive layer of 
complexity to this preliminary study and therefore all counter-ions and water molecules were 
omitted from our geometry optimization.   
While magnesium (II) is required for phosphorylation of proteinaceous serine 
residues by 5-PP-InsP5 in eukaryotic cell e
ium (II) ions from these calculations would dramatically alter the relative ΔHrxn 
values for phosphate transfer as experimental studies of ATP hydrolysis in the presence of 
magnesium (II) ions have indicated that the ΔG°obs of hydrolysis ranges from ~31 to  
~ 35 kJ/mol, a change of only 1 kcal/mol, depending on the concentration of magnesium 
(II)80 and therefore any trends that we observe in our data should be valid for this preliminary 
investigation. 
5.6.3. Use of 
The phosphorylation of eukaryotic proteins by 5-PP-InsP
residues, with no phosphorylation of threonine
re methanol was used as a model.  Serine itself was not used as the inclusion of  
α-amino and carboxyl groups would add extra electrostatic interactions which may affect the 
overall thermodynamics of phosphorylation. 
 
§ A search conducted November 4, 2006 returned five structures for InsP6 with CCDC Deposition Codes 
NAMIHP01, NAMIHP02, NAMIHP10, QQQCQV and QQQCQS. 
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5.6.4. Geometry Optimizations of Inositol Pyrophosphates using Semi-Empirical 
Techniques 
The non-enzymatic phosphorylation of serine residues in eukaryotic cells specifically 
required 5-PP-InsP5 as a phosphate donor;7 therefore, this regioisomer was chosen for these 
studies.  The phosphorylation of protein residues by bis-PP-InsP  has not been observed; 
howeve
rial substituents, with the pyrophosphate 
groups 
ge.  During geometry optimization, energy barriers 
ions focused on the phosphorylation of methanol by the model 
5-6) to serve as comparison 
 important for the accurate 
4
r, it is expected that the increased electrostatic and steric repulsion caused by the 
additional pyrophosphate group would make phosphate donation by bis-PP-InsP4 even more 
thermodynamically favourable.  Because the structure of bis-PP-InsP4 in mammals and  
S. cerevisiae is unknown, 5,6-bis-PP-InsP4, the predominant bis-PP-InsP4 in the eukaryote  
D. discoideum,22,81 was used in this investigation. 
To date, the conformational preferences of the InsPPs have not been determined.  It is 
likely that, similar to InsP6,71,82,83 the most stable conformation of the InsPPs at physiological 
pH would have the maximum number of equato
in particular being equatorial.  5-PP-InsP5 and 5,6-PP-InsP4 were therefore modelled 
using a 5 eq / 1 ax starting conformation. 
 When the calculated ΔHf values for optimized InsPP structures with identical charges 
were compared, it was apparent that certain structures had a ΔHf value unexpectedly higher 
than other conformations of the same char
can be encountered which funnel geometry optimizations towards local minima of higher 
energy (see Chapter 2 for an introduction to geometry optimization).  To overcome these 
potential energy barriers, a dihedral angle drive of the pyrophosphate groups was performed 
on these anomalous structures and the geometries of the lowest energy conformations 
optimized.  In almost all cases, these drives resulted in lower energy conformations whose 
ΔHf values were in better agreement with other tautomers of similar charge.  The average 
change in the ΔHf values of these structures was 7.7 kcal/mol, with the greatest change being 
18.1 kcal/mol and the lowest being 0.1 kcal/mol.  The best estimate in the error present in our 
calculated ΔHf values would therefore be ± 7.7 kcal/mol.  All final energy values can be 
found in Appendix 2.  
5.6.5. Phosphorylation of Methanol by Model Compounds 
 Initial calculat
compounds PPi, MeOPPi, Cyclohex-PPi and 5-PP-Ins (5-3 to 
points and to indicate any trends or factors which may be
modeling of phosphorylation by the InsPPs.  5-PP-Ins was used as a model for the myo-
inositol framework, omitting the steric and electrostatic contributions of the multiple 
phosphate moieties to the overall thermodynamics of phosphorylation.  The ΔHrxn values 
determined for these preliminary calculations (Table 5.5) indicate that the thermodynamics of 
phosphorylation may be affected by the overall charge of the molecules involved.  
Phosphorylation is predicted to be thermodynamically more favourable when the starting 
structure has a higher charge.  For example, phosphorylation of methanol by PPi(-3) to form 
MeOPi(-1) was calculated to be more favourable than phosphorylation by PPi(-2).  In 
addition, the formation of MeOPi(-2) was predicted to be favoured over the formation of 
MeOPi(-1), when the same starting ionization states are involved.  These results indicate that 
the overall thermodynamics of phosphorylation may be affected by the ionization states of 
both the reactants and products of these reactions.  
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Table 5.5: ΔHrxn values determined for the phosphorylation of methanol to form methyl phosphate. 
Pi Donora → Product  Pi Donor → Product  
Forming MeOPi(-1)b ΔHrxnc Forming MeOPi(-2) ΔHrxn 
PPi(-2)d → Pi(-1) -8.9 PPi(-3) → Pi(-1) -13.9 
PPi(-3) → Pi(-2) -12.9     
MeOPPi(-2)e → MeOPi(-1) -7.2 MeOPi(-3) → MeOPi(-1) -15.2 
Cyclohex-PPi(-2)f → Cyclohex-Pi(-1)g -7.3 Cyclohex-PPi(-2) → Cyclohex-Pi(-1) -14.8 
Cyclohex-PPi(-3) → Cyclohex-Pi(-2) -14.3     
InsPPi(-2)h → InsPi(-1)i -2.0 InsPPi(-3) → InsPi(-2) -6.2 
InsPPi(-3) → InsPi(-2) -14.8     
aPi = phosphate; bMeOPi = methyl phosphate; cΔHf in kcal/mol; dPPi = pyrophosphate; eMeOPPi = methyl 
pyrophosphate; fCyclohex-PPi = cyclohexyl pyrophosphate; gCyclohex-Pi = cycohexyl phosphate; hInsPPi = 
myo-inositol-5-pyrophosphate; iInsPi = myo-inositol-5-phosphate (Ins(5)P1). 
5.6.6. Phosphorylation of Methanol by the Inositol Pyrophosphates 
The effects of reactant and product ionization state on the thermodynamics of 
phosphorylation by pyrophosphate and the model compounds discussed above indicate that 
protonation state may also play a role in the thermodynamics of phosphorylation of serine by 
the InsPPs.  A variety of ionization states were therefore modelled, in hopes of obtaining a 
complete picture of the factors affecting the thermodynamics of phosphorylation.  Because 
the pKa values of the InsPPs are unknown, the pKa values of InsP6 were used to estimate the 
protonation states of the InsPPs likely to be present at physiological pH.   
Selected calculations producing protonation states of InsP6 consistent with those 
found at physiological pH are shown in Table 5.6.  In all cases, the transfer of a phosphate 
group from 5-PP-InsP5 was calculated to be thermodynamically favourable.  Similar to the 
results found for PPi, the charge of the products formed affects the overall thermodynamics 
of these reactions.  For example, the formation of MeOPi(-2) was predicated to be favoured 
over the formation of MeOPi(-1) when comparing the same starting protonation states.  In 
general, increasing the negative charge around the myo-inositol ring also increased the 
predicted thermodynamic favourability of phosphorylation.  This result is likely due to the 
increased electrostatic repulsion felt by the pyrophosphate group of 5-PP-InsP5.  In addition, 
under physiological conditions, the phosphorylation of methanol, and by extension serine, by 
5-PP-InsP5 was predicted to be thermodynamically favoured over phosphorylation by PPi.  
There are subtle variations between the predicted ΔHrxn values for tautomers of 5-PP-InsP5 
with the same charge; however, this observation may be due to conformational variations 
caused by the differences in charge placement around the ring, as well as differences in 
hydrogen bonding patterns.  A more encompassing set of calculations can be found in 
Appendix 2. 
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Table ected 
at phy ological p
5-PP-In P6 5-PP-Ins sP6 
 5.6: ΔHrxn values calculated for the phosphorylation of methanol by 5-PP-InsP5 ionization states exp
si H. 
sP5 → Ins P5 → In
Forming MeOPi(-1) ΔH ing M Pi(-2) Δ
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-19.9 ND    
ain kcal/mol; bNot determined as further deprotonation is improbable due to the increasing negative charge on 
InsP6. 
 Results for the phosphorylation of methanol by 5,6-bis-PP-InsP4 to yield 5-PP-InsP5 
with protonation states consistent with the known pKa values of InsP6 are shown in Table 5.7 
and Table 5.8.  Consistent with the pyrophosphate model compounds and 5-PP-InsP5, the 
charge states of the product affects the overall thermodynamics of the phosphorylation: the 
formation of MeOPi(-2) was predicted to be favoured over MeOPi(-1) for the same 
phosphorylating agent.  Similar to 5-PP-InP5, an increase in the charge around the myo-
inositol ring increase the calculated thermodynamic favourability of the phosphorylation of 
methanol by 5,6-bis-PP-InsP4.  A comparison of the ΔHrxn values determined for the 
phosphorylation of methanol at physiological pH indicates that when forming the same 
ionization state of MeOPi, 5,6-bis-PP-InsP4 was calculated to be a thermodynamically 
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superior phosphorylating agent to 5-PP-InsP5 and the pyrophosphate model compounds.  
Steric and electrostatic repulsions caused by the adjacent pyrophosphate groups are likely the 
cause of this increased favourability.  Similar to the results for 5-PP 5, there are 
va n ues o t ers ssed f P
InsP5, this result m tional variations caused by the different charge 
placements around the ring, as well as changes to the hydrogen bonding patterns.  A m re 
encomp Appendix 2.  The highly charged and 
sterically congested structure of 5,6-bis-PP-InsP4 in an overall charged state of -8 can be 
appreciated in Figure 5.1, where the electrostatic potential is pped onto the electron 
density of this compound. 
Table 5.7: ΔHrxn values calculated for the phosphorylation of methanol by 5,6-bis-PP-InsP4 ionization states 
expected at pH 5.7. 
5,6-PP-Ins  → 5-PP-InsP 5,6-PP-InsP4 → 5-PP-InsP5 
-InsP
discuriations between the ΔHrx
ay be due to confor
 val f tau om
ma
 of the same charge.  As or P -
o
assing set of calculations can be found in 
ma
P4 5 
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Table 5.8: ΔHrxn values calculated for the phosphorylation of methanol by 5,6-bis-PP-InsP4 ionization states 
expected at pH 6.8 – 7.6. 
5,6-bis-PP-InsP4 → 5-PP-InsP5 5,6-bisPP-InsP4 → 5-PP-InsP5 











































































































































































































Figure 5.9: Electrostatic potential (using a range of -0.8 (red) to -0.5 (blue) kcal/mol) mapped onto the electron 
density isosurface (0.0004 electrons/au3) for 5,6-bis-PP-InsP4 with a charge of -8. 
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5
Compounds 
r lcu e ΔHrxn valu y n o  by ATP, 
ADP, AM mpounds triphosphate and m were perfor  
Comparisons of these results to those of the InsPPs indicate that, in some cases, 
phosphorylation of methanol by the 5-PP-InsP5 and 5,6-bis-PP-InsP  is more favourable than 
phosphorylation by ATP and ADP.   
Table 5. : ΔHrxn values calculated r the phosphorylation of met  by ATP, ADP and model com ounds. 
Pi Donora → Product  Pi Donor → Product  
.6.7. Phosphorylation of Methanol by Adenosine Triphosphate and Other Model 
Prelimina y ca lations of th es for phosphor latio f methanol
P and the model co ethyl triphosphate med.  
4
9 fo hanol p
Forming MeOPi(-1)b g MeOPi(-2) Δ
ATP(-3)d → ADP(-2)e -2.2 ATP(-4) → ADP(-2) -10.7 
ΔHrxnc Formin Hrxn 
ATP(-4) → ADP(-3) -11.8     
ADP -2) → AMP )f -5.4 AD -3) → AMP ) -4.3 
ADP(-3) → AMP(-2) -7.4     
MeOPPPi(-3)g MeOPPi(-2)h MeOPPPi(-4) MeOPPi(-2) -
MeOPPPi(-4) → MeOPPi(-3) -14.3     
PPPi(-3)i → PPi(-2)j -7.2 PPPi(-4) → PPi(-2) -18.1 
PPPi(-4) → PPi( 3) -13.0    
( (-1 P( (-1
→ -10.0 → 22.3 
-  
aPi = phosphate; bMeOPi = thyl phosphate; cΔHrxn is in kc dATP = adenosine triphosphate; e hosphate; f
= adenosine monoph ate; gMeOPPPi = methyl triph ; hMeOPPi = methyl pyrophos iPPPi = triphosphate; jPPi 
pyrophosphate. 
5.7. Conclusions and Future Work 
It is evident from this study that increasing the overall charge of the phosphate d
as well as the steric bulk near the pyrophosphate group, tends to increase the predicted 
thermodynamic favourability of phosphorylation.  A specific value for the transfer potential 
of a phosphate group to methanol by 5-PP-InsP5 and 5,6-PP-InsP4 cannot be easily 
determined due to the ensemble of tau ic and charged states that would exist under 
physiological conditions.  It is clear that phosphorylation would be a thermodynamically 
favourable process and biological systems may be able to control the phosphate transfer 
potential of the InsPPs by tuning th nd electrostatic environments of the 
pyrophosphate moiety.   
It is tempting to comment on the effect of the position of the negative charges on the 
overall ΔHrxn values of phosphate transfer; however, the limitations of the methods used 
precludes the drawing of certain conclusions.  The use of implicit solvation simplifies the 
calculation but it eliminates any thermodynamic contribution of hydrogen bonding which 
may occur between the surrounding water molecules and compound in question.  Further 
analysis is warranted to determine the thermodynamic contribution of each phosphate on the 
inositol ring to the overall thermodynamics of each 5-PP-InsP5 and 5,6-bis-PP-InsP4 
structure.  The inclusion of at least one solvation sphere of explicitly defined water molecules 
should be a future approach to account for the effects of hydrogen bonding with the solvation 
sphere.  The contribution of counter-ions to the overall thermodynamics of these reactions 
would be an obvious route towards a more quantitative comparison of the thermodynamics of 
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Appendix 1: Modelling of Ergothioneine and Ovothiol  
Supplementary Information 
  
Please see Chapter 2 for a full description of the methods used as well as a discussion of 
these results.   

















































































Figure A1.1: Structures of 2-thiol-4-methyl-imidazole (TMI) and ergothioneine (ESH) 
A1.1.1: Crystal Structure Data 
ESH was recrystallized from water/ethanol and its crystal structure was determined 
by Dr. Nicholas J. Taylor.  The coordinates were deposited in the Cambridge 
Crystallographic Database, deposition FOLRII. 
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Table A1.1: Bond lengths of ergothioneine determined using X-ray crystallography in this work.a 
Bond Length in Å Bond Length in Å 
S-C2 1.6931(11) C7-C8 1.5524(16) 
N1-C2 1.3518(15) C7-N11 1.5365(14) 
N1-C5 1.3807(15) C8-O9 1.2522(15) 
N3-C2 1.3541(14) C9-O10 1.2512(15) 
N3-C4 1.3870(15) N11-C12 1.5004(16) 
C4-C5 1.3524(17) N11-C13 1.5049(15) 
C4-C6 1.4952(16) N11-C14 1.5107(15) 
C6-C7 1.5238(16)   
aSee Figure A1.1 for numbering. 
Table A1.2: Bond angles of ergothioneine as determined by X-ray crystallography in this work.a 
Bonds Angle (in degrees) Bonds Angle (in degrees) 
N1-C2-N3 105.55(10) C6-C7-C8 111.39(10) 
N1-C2-S 126.55(9) C6-C7-N11 110.79(8) 
N1-C5-C4 107.22(11) C7-C8-O9 115.52(11) 
C2-N1-C5 110.34(10) C7-C8-O10 116.25(9) 
C2-N3-C4 110.41(10) C7-N11-O12 109.65(9) 
N3-C2-S 127.89(9) C7-N11-O13 108.62(8) 
N3-C4-C5 106.48(10) C7-N11-O14 113.39(9) 
N3-C4-C6 123.71(11) C12-N11-C13 108.68(10) 
C4-C6-C7 112.37(9) C12-N11-C14 108.35(9) 
C5-C4-C6 129.75(12) C13-N11-C14 108.04(9) 
aSee Figure A1.1 for numbering 
A1.1.2: Geometry Optimizations of the Ergothioneine Crystal Structure 
A series of geometry optimizations of the ESH crystal structure were performed using 
Jaguar (Schrödinger Inc.) and Hartree-Fock (HF) and Density Functional Theory (DFT) 
methods with a variety of basis sets in the presence and absence of diffuse functions.  The 
DFT calculations used the B3LYP functional as implemented by Jaguar unless otherwise 
stated.  Full procedural details can be found in Chapter 2.   
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Table A1.3: Bond distances (in Å) returned by geometry optimizations of the crystal structure of ergothioneinea 
using density functional theory methods in the gas phase.b 
Basis set ** ++ C2-S N1-C2 C2-N3 N1-C5 N3-C4 C4-C5 C4-C6 
B3LYP          
6-31G ** ++ 1.68 1.37 1.37 1.39 1.40 1.36 1.50 
 ** None 1.68 1.37 1.37 1.39 1.40 1.36 1.50 
 none None 1.73 1.38 1.38 1.40 1.41 1.36 1.50 
6-311g ** ++ 1.67 1.37 1.37 1.39 1.40 1.35 1.50 
 ** None 1.68 1.37 1.37 1.39 1.40 1.36 1.50 
 None none 1.72 1.37 1.38 1.40 1.41 1.36 1.50 
cc-pVDZ Incl.c ++ d 1.68 1.37 1.37 1.39 1.40 1.36 1.50 
 Incl. None 1.67 1.37 1.37 1.38 1.40 1.36 1.50 
cc-pVTZ(-f) Incl. ++ NDe ND ND ND ND ND ND 
 Incl. None 1.67 1.37 1.37 1.39 1.40 1.35 1.49 
B3PW91          
cc-pVTZ(-f) ** ++ 1.67 1.36 1.36 1.38 1.39 1.35 1.49 
Crystala -- -- 1.69 1.35 1.35 1.38 1.39 1.35 1.50 
aObtained in this work; bSee Figure A1.1 for numbering; cPolarization functions are included in this basis set; 
dConvergence required the use of the GVB-DIIS convergence scheme; fNot determined 
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Table A1.4: Bond angles (in degrees) returned by a geometry optimization of the ergothioneine crystal structurea using density function theory methods in the 
gas phas.b 
Basis set ** ++ S-C2-N1 S-C2-N3 C2-N3-C4 C2-N1-C5 N1-C2-N3 N3-C4-C5 N1-C5-C4 N3-C4-C6 
B3LYP           
6-31G ** ++ 128.80 127.95 111.91 111.78 103.24 106.01 107.06 123.29 
 ** None 128.89 128.05 112.02 112.00 103.06 105.97 106.94 122.43 
 None None 128.73 127.91 111.75 111.88 103.36 106.93 106.93 122.23 
6-311g ** ++ 128.56 128.14 111.78 111.75 103.30 106.06 107.11 123.42 
 ** None 128.60 128.08 111.84 111.84 103.32 106.05 106.96 123.08 
 None None 128.52 127.93 111.64 111.66 103.55 106.09 107.07 123.55 
cc-pVDZ Incl.c ++d 128.69 127.97 111.86 111.73 103.33 106.05 107.02 123.17 
 Incl. None 128.75 128.06 112.01 111.84 103.24 106.01 107.06 123.29 
cc-pVTZ(-f) Incl. None 128.76 127.99 111.85 111.64 103.25 106.04 107.18 123.02 
 Incl. ++ NDe ND ND ND ND ND ND ND 
B3PW91           
cc-pVTZ(-f) Incl. None 128.81 127.97 111.92 111.71 105.23 105.93 107.21 123.37 
Crystala -- -- 126.55 127.89 110.41 110.34 105.55 106.48 107.22 123.71 
aObtained in this work; bSee Figure A1.1 for numbering; cPolarization functions are included in this basis set; dConvergence required the use of the GVB-DIIS 
convergence scheme; eNot determined 
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Table A1.5: Bond lengths (in Å) returned after geometry optimizations of the ergothioneine crystal structurea 
using density functional theory methods with implicit water solvation.b 
Basis set ** ++ C2-S N1-C2 C2-N3 N1-C5 N3-C4 C4-C5 C4-C6 
B3LYP          
6-31G ** ++ 1.71 1.36 1.36 1.39 1.39 1.36 1.50 
 ** None 1.71 1.36 1.36 1.39 1.39 1.36 1.50 
 None None 1.75 1.36 1.36 1.40 1.40 1.37 1.50 
6-311G ** ++c 1.70 1.35 1.35 1.38 1.39 1.36 1.50 
 ** Noned 1.71 1.35 1.35 1.40 1.40 1.37 1.50 
 None None 1.75 1.36 1.36 1.39 1.40 1.36 1.50 
cc-pVDZ Incl. ++ N/D N/D N/D N/D N/D N/D N/D 
 Incl. None 1.70 1.35 1.36 1.38 1.39 1.36 1.49 
cc-pVTZ(-f) Incl. ++ 1.70 1.35 1.35 1.38 1.39 1.35 1.49 
 Incl None 1.71 1.35 1.35 1.38 1.40 1.36 1.49 
B3PW91          
cc-pVTZ(-f)   1.70 1.35 1.35 1.38 1.39 1.35 1.49 
Crystala -- -- 1.69 1.35 1.35 1.38 1.39 1.35 1.50 
aObtained in this work; bSee Figure A1.1 for numbering; cThe starting structure for this optimization was the 
conformation obtained from the optimization of the crystal structure using HF/6-311++G** methods and 
implicit water solvation; dThe starting structure for this optimization was the conformation obtained from the 
optimization of the crystal structure using HF/6-311G** methods and implicit water solvation; 
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Table A1.6: Bond angles (in degrees) returned by geometry optimizations of the ergothioneine crystal structurea using density functional theory methods with 
implicit water solvationb 
Basis set ** ++ S-C2-N1 S-C2-N3 C2-N3-C4 C2-N1-C5 N1-C2-N3 N3-C4-C5 N1-C5-C4 N3-C4-C6 
B3LYP           
6-31G ** ++ 127.57 127.18 111.06 110.61 105.24 105.88 107.20 123.14 
 ** None 127.68 127.30 111.24 110.77 105.02 105.80 107.18 122.50 
 None None 127.42 127.33 110.98 110.68 105.25 105..88 107.21 122.81 
6-311G ** ++c 127.15 127.46 110.96 110.57 105.36 105.86 107.23 123.04 
 ** Noned 127.22 127.38 110.95 110.58 105.39 105.93 107.14 122.76 
 None None 127.22 127.29 110.77 110.55 105.49 106.02 107.17 123.13 
cc-pVDZ Incl. ++ N/D N/D N/D N/D N/D N/D N/D N/D 
 Incl. None 127.62 127.39 111.21 110.76 104.99 105.74 107.30 122.87 
cc-pVTZ(-f) Incl. ++ 127.67 126.98 110.89 110.48 105.36 106.00 107.27 123.12 
 Incl. None 127.68 127.15 111.02 110.67 105.17 105.93 107.22 122.56 
B3PW91           
cc-pVTZ(-f) Incl. None 128.81 127.97 111.92 111.71 103.21 105.94 107.21 123.25 
Crystala -- -- 126.55 127.89 110.41 110.34 105.55 106.48 107.22 123.71 
aObtained in this work; bSee Figure A1.1 for numbering; cThe starting structure for this optimization was the conformation obtained from the optimization of the 
crystal structure using HF/6-311++G** methods and implicit water solvation; dThe starting structure for this optimization was the conformation obtained from 
the optimization of the crystal structure using HF/6-311G** methods and implicit water solvation; 
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Table A1.7: Bond lengths (in Å) returned by geometry optimizations of the ergothioneine crystal structurea 
using Hartree-Fock methods in the gas phase.b 
Basis set ** ++ C2-S N1-C2 C2-N3 N1-C5 N3-C4 C4-C5 C4-C6 
B3LYP          
3-21G * ++ 1.68 1.36 1.36 1.40 1.41 1.33 1.50 
 * None 1.68 1.34 1.35 1.40 1.41 1.33 1.50 
 None None 1.74 1.34 1.35 1.40 1.41 1.34 1.50 
6-31G ** ++ 1.69 1.34 1.34 1.39 1.39 1.33 1.50 
 ** None 1.69 1.34 1.34 1.39 1.40 1.33 1.50 
 None None 1.74 1.35 1.35 1.40 1.40 1.34 1.50 
6-311G ** ++ 1.68 1.34 1.34 1.39 1.39 1.33 1.50 
 ** None 1.68 1.34 1.34 1.39 1.39 1.33 1.50 
 None None 1.73 1.34 1.34 1.39 1.40 1.34 1.50 
cc-pVDz Incl ++ 1.69 1.34 1.34 1.39 1.40 1.34 1.50 
  none 1.68 1.34 1.34 1.38 1.39 1.33 1.49 
cc-pVTZ(-f) Incl ++ 1.68 1.34 1.34 1.39 1.40 1.32 1.50 
 Incl none 1.68 1.34 1.34 1.39 1.39 1.33 1.49 
Crystala -- -- 1.69 1.35 1.35 1.38 1.39 1.35 1.50 
aObtained in this work; bSee Figure A1.1 for numbering 
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Table A1.8: Bond angles (in degrees) returned by the geometry optimizations of the ergothioneine crystal structurea using Hartree-Fock methods in the gas 
phase.b 
Basis set ** ++ S-C2-N1 S-C2-N3 C2-N3-C4 C2-N1-C5 N1-C2-N3 N3-C4-C5 N1-C5-C4 N3-C4-C6 
B3LYP           
3-21G * ++ 128.47 127.53 111.34 111.34 103.99 106.29 107.04 122.90 
 * None 128.42 127.49 111.37 111.41 104.09 106.19 106.94 123.10 
 None None 128.21 127.09 111.20 111.22 104.70 106.06 106.82 123.15 
6-31G ** ++ 128.31 127.18 111.32 111.18 104.51 106.02 106.97 122.64 
 ** None 128.24 127.37 111.39 111.30 104.40 105.97 106.94 122.67 
 None None 128.20 127.28 111.34 111.31 104.52 105.95 106.88 122.71 
6-311G ** ++ 128.04 127.35 111.20 111.12 104.61 106.05 107.02 122.84 
 ** None 128.16 127.28 111.30 111.21 104.56 106.00 106.93 122.67 
 None None 128.13 127.26 111.25 111.19 104.61 105.97 106.98 122.81 
cc-pVDZ Incl. ++ 128.15 127.23 111.26 111.12 104.62 106.02 106.98 122.83 
 Incl. None 128.24 127.26 111.36 111.20 104.50 105.94 106.99 122.39 
cc-pVTZ(-f) Incl. ++ 128.23 127.23 111.35 111.01 104.53 105.87 107.22 122.70 
 Incl. None 128.26 127.14 111.25 111.00 104.60 106.02 107.11 122.55 
Crystala -- -- 126.55 127.89 110.41 110.34 105.55 106.48 107.22 123.71 
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Table A1.9: Bond lengths (in Å) returned by geometry optimizations of the ergothioneine crystal structurea 
using Hartree-Fock methods with implicit water solvation.b 
Basis set ** ++ C2-S N1-C2 C2-N3 N1-C5 N3-C4 C4-C5 C4-C6 
6-31G ** ++ 1.72 1.33 1.33 1.38 1.39 1.34 1.50 
 ** None 1.71 1.33 1.33 1.38 1.39 1.34 1.50 
 none None 1.76 1.33 1.34 1.39 1.40 1.34 1.50 
6-311G ** ++ 1.71 1.32 1.33 1.38 1.39 1.34 1.50 
 ** None 1.71 1.32 1.33 1.38 1.39 1.34 1.50 
 None None 1.75 1.33 1.33 1.39 1.40 1.34 1.49 
cc-pVDZ Incl. ++ 1.72 1.33 1.33 1.38 1.39 1.34 1.50 
 Incl. None 1.71 1.32 1.33 1.38 1.38 1.34 1.49 
cc-pVTZ(-f) Incl. ++ 1.71 1.32 1.32 1.38 1.39 1.33 1.49 
 Incl. None 1.71 1.32 1.33 1.38 1.39 1.33 1.49 
Crystala -- -- 1.69 1.35 1.35 1.38 1.39 1.35 1.50 
aObtained in this work; bSee Figure A1.1 for numbering 
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Table A1.10: Bond angles (in degrees) returned after the geometry optimization of the ergothioneine crystal structurea using Hartree-Fock methods with implicit 
water solvationb 
Basis set ** ++ S-C2-N1 S-C2-N3 C2-N3-C4 C2-N1-C5 N1-C2-N3 N3-C4-C5 N1-C5-C4 N3-C4-C6 
B3LYP           
6-31G ** ++ 126.95 126.55 110.39 110.06 106.50 105.97 107.07 123.07 
 ** None 126.93 126.70 110.44 110.13 106.67 105.94 107.12 123.17 
 None None 127.06 126.74 110.59 110.30 106.20 105.92 106.98 123.12 
6-311G ** ++ 126.87 126.53 110.33 110.04 106.59 105.96 107.08 123.00 
 ** None 126.94 126.50 110.33 110.06 106.56 106.02 107.04 123.06 
 None None 127.07 126.56 110.47 110.22 106.37 105.96 106.98 122.63 
cc-pVDZ Incl. ++ 126.92 126.50 110.38 110.03 106.58 105.93 107.08 123.24 
 Incl. None 127.06 126.61 110.51 110.13 106.33 105.94 107.08 122.95 
cc-pVTZ(-f) Incl. ++ 126.91 126.55 110.36 109.97 106.54 105.99 107.15 122.79 
 Incl. None 127.02 126.45 110.34 110.01 106.54 106.02 107.09 122.55 
Crystala -- -- 126.55 127.89 110.41 110.34 105.55 106.48 107.22 123.71 
aObtained in this work; bSee Figure A1.1 for numbering 
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A1.1.3: Geometry Optimizations of 2-Thiol-4-Methyl-Imidazole 
All structures were optimized using Gaussian 03 both in vacuo and with implicit 
solvation.  The B3LYP functional was used for all calculations with the 6-311G basis set 
with the addition of polarization and diffuse functions.  Full details of these calculations can 
be found in Chapter 2.  
Table A1.11: Energies, bond lengths and angles of 2-thiol-4-methylimidazole, its tautomers and ergothioneine 
determined by geometry optimization.a,b 
Tautomer Phase Energy (kcal/mol) N1-C2-N3 N1-C2 C2-N3 C2-S 
2-3 Gas -416525.75 103.2 1.37 1.37 1.67 
 Water -416545.39 104.7 1.35 1.36 1.71 
2-4 Gas -416518.04 111.9 1.36 1.31 1.77 
 Water -416532.12 111.8 1.36 1.32 1.77 
2-5 Gas -416517.20 111.2 1.31 1.37 1.77 
 Water -416531.86 110.0 1.32 1.37 1.77 
2-6 Gas -416525.76 103.2 1.37 1.37 1.67 
 Water -416545.41 104.7 1.35 1.36 1.71 
ESHxrayc Gas -668215.49 103.2 1.37 1.37 1.68 
 Water -668261.72 104.7 1.36 1.40 1.68 
aAngles in degrees, bond lengths in Å; bSee Figure A1.1 for numbering  cX-ray structure, this work1 optimized 
using 6-311++G(d,p). 
 
Table A1.12: Energies, bond lengths and angles of the thiolate and thiyl radicals of 2-thiol-4-methylimidazole 
determined by geometry optimization.a,b 
Species Phase Energy (kcal/mol) N1-C2-N3 N1-C2 C2-N3 C2-S 
2-7 Gas -416184.52 108.4 1.38 1.34 1.73 
 Water -416251.60 109.5 1.37 1.34 1.75 
2-8 Gas -416183.10 108.5 1.34 1.39 1.73 
 Water -416251.37 109.4 1.33 1.38 1.75 
2-9 Gas -416134.63 108.6 1.40 1.35 1.68 
 Water -416148.87 108.7 1.39 1.36 1.68 
2-10 Gas -416134.52 108.5 1.35 1.40 1.68 
 Water -416149.09 108.7 1.36 1.39 1.68 
aAngles in degrees, bond lengths in Å; bSee Figure A1.1 for numbering 
 
- 171 - 
Table A1.13: Energies and selected bond lengths and angles of the various tautomers of the disulfide of 2-thiol-4-methylimidazole determined by geometry 
optimization.a,b 
Ring A/Ring B 
Form Phase Energy N1-C2-N3 N1-C2 C2-N3 C-S S-S 
CA2-SA- 
SB-CB2 
2-11 Gas -832280.12 110.8/110.8 1.37/1.37 1.32/1.32 1.76/1.76 2.16 -80.7 
 Water -832299.34 111.8/110.9 1.36/1.36 1.32/1.76 1.77/1.76 2.15 83.8 
2-12 Gas -832280.36 110.9/110.9 1.32/1.32 1.38/1.38 1.75/1.75 2.18 -73.3 
 Water NDc ND ND ND ND ND ND 
2-13 Gas -832283.43 112.1/110.5 1.36/1.37 1.32/1.32 1.76/1.76 2.14 -84.1 
 Water -832299.29 111.7/110.9 1.36/1.33 1.32/1.36 1.77/1.76 2.15 -84.0 
aEnergy in kcal/mol, angles in degrees, bond lengths in Å; bSee Figure A1.1 for numbering; cND = not determined 
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Figure A1.2: Ovothiol A (OSHA) and 4-thiol-N1-methyl-5-methylimidazole (TMMI), used to model OSH and its forms. 
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A1.2.1: Geometry Optimizations of 4-Thiol-N1-Methyl-5-Methyl-Imidazole 
All structures were optimized using Gaussian 03 both in vacuo and with implicit 
solvation.  The B3LYP functional was used for all calculations with the 6-311G bases set 
with the addition of polarization and diffuse functions.  Full details of these calculations can 
be found in Chapter 2. 
Table A1.14: Energies and selected bond lengths and angles for ovothiol A and 4-thiol-N1-methyl-5-
methylimidazole, its thiolate, thiyl radical and zwitterion determined by geometry optimization.a,b 
Species Phase Energy (kcal/mol) N1-C2-N3 N1-C2 C2-N3 C4-S 
2-14 Gas -441174.55 112.3 1.37 1.31 1.78 
 Water -441185.67 111.9 1.36 1.32 1.78 
2-15 Gas -440829.10 112.6 1.37 1.31 1.75 
 Water -440899.53 111.9 1.36 1.32 1.77 
2-16 Gas -440789.69 112.9 1.39 1.30 1.70 
 Water -440801.20 112.6 1.38 1.30 1.65 
2-17 Gas -441166.64 107.0 1.34 1.34 1.67 
 Water -441189.96 107.7 1.33 1.34 1.74 
OSHA thiolate Gas -618596.11 112.8 1.36 1.31 1.75 
 Water ND ND ND ND ND 
aAngles in °, bond lengths in Å; bSee Figure A1.3 
A1.3: Studies of Methyl Mercaptan and Other Biologically Relevant 
Compounds 
All structures were optimized using Gaussian 03 both in vacuo and with implicit 
solvation.  The B3LYP functional was used for all calculations with the 6-311G bases set 
with the addition of polarization and diffuse functions.  Full details of these calculations can 
be found in Chapter 2. 
A1.3.1: Geometry Optimizations of Methyl Mercaptan and its Derivatives 
SHH3C SH3C SH3C S CH3SH3C
2-19            2-20             2-21                  2-22  
Figure A1.3: Methylmercaptan structures used to model glutathione and its various forms. 
Table A1.15: Energies and C-S bond lengths for methylmercaptan, its thiolate, thiyl radical and disulfide 
determined by geometry optimization.a,b 
Species Phase Energy (kcal/mol) C-S (Å) S-S (Å) 
2-19 Gas -275302.12 1.84 -- 
 Water -275306.64 1.84 -- 
2-20 Gas -274946.62 1.85 -- 
 Water -275014.20 1.86 -- 
2-21 Gas -274946.52 1.81 -- 
 Water -274907.33 1.81 -- 
2-22 Gas -549849.30 1.83 2.09 
 Water -549852.16 1.83 2.10 
aBond lengths in Å, bSee Figure A1.3 
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A1.3.2:  Geometry Optimizations of the Ascorbate Model Compound 
OO
HO O




Figure A1.4: The compounds used to model ascorbic acid and its radical. 
Table A1.16: Energies of the model compounds of ascorbate and its radical determined by geometry 
optimization.a 
Species Phase Energy (kcal/mol) 
2-23 Gas -285696.31 
 Water -285759.82 
2-24 Gas -285319.30 
 Water -285379.69 
aSee Figure A1.4 
A1.3.3: Geometry Optimizations of Thiophenol and Diphenyldisulfide 
 
SH S S
2-25                          2-26  
Figure A1.5: Thiophenol and diphenyldisulfide are used as models for aromatic thiols. 
 
Table A1.17: Energies and bond lengths of thiophenol and diphenyldisulfide determined by geometry 
optimization.a,b 
Species Phase Energy (kcal/mol) C-S S-S 
2-25 Gas -395618.20 1.81 -- 
 Water -395626.00 1.79 -- 
2-26 Gas -790479.64 1.80/1.79 2.13 
 Water -790487.28 1.81 2.08 
aBond lengths in Å; bSee Figure A1.5 
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A1.3.4: Geometry Optimizations of other Biologically Relevant Molecules 
Table A1.18: Energies of other biologically relevant molecules determined by geometry optimization. 
Species Phase Energy (kcal/mol) 
HO• Gas -47546.95 
 Water -47555.28 
HO- Gas -47587.29 
 Water -47679.52 
H2O2 Gas -95128.80 
 Water -95143.20 
H2O Gas -47976.17 
 Water -47985.63 
H3O+ Gas -48140.08 
 Water -48230.14 
A1.4: Reaction Enthalpy Calculations 
To determine the thermodynamics of a number of biologically relevant oxidation and 
reduction reactions, the sum of the thermal and electronic energies (ZPE corrected) were 
taken as ΔG° for each compound.  
Table A1.19: RSSR + 2 CH3SH  2 RSH + H3CSSCH3 
Reactant Product Phase ΔG° (kcal/mol) 
2-11 2 2-3 Gas -16.43 
  Water -30.32 
 2 2-4 Gas -1.00 
  Water -3.78 
2-12 2 2-3 Gas -16.19 
  Water NDa 
 2 2-5 Gas -0.32 
  Water ND 
2-13 2 2-3 Gas -13.12 
  Water -30.37 
 2-4 + 2-5 Gas 3.15 
  Water 3.47 
2-18 2 2-14 Gas 0.03 
  Water 2.18 
 2 2-15b Gas 363.11 
  Water 85.46 
 2 2-17 Gas 15.84 
  Water -6.40 
aND = not determined; bBalanced equation becomes (TMMI-S)2 +2CH3SH + 2H2O → 2 TMMI- + H3CSSCH3 + 
2 H3O+ 
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Table A1.20: 2 TMIthiol → 2 TMIthione 
Reactant Product Phase ΔG° (kcal/mol) 
2 2-4 2 2-3 Gas -15.43 
  Water -26.53 
2 2-5 2 2-3 Gas -16.27 
  Water -27.06 
2-4 + 2-5 2 2-3 Gas -17.11 
  Water -26.80 
 
Table A1.21: 2 TMMI → 2 TMMIzwitterion 
Reactant Product Phase ΔG° (kcal/mol) 
2 2-14 2 2-17 Gas 15.81 
  Water -8.58 
2 2-15a 2 2-17 Gas -347.27 
  Water -91.85 
aBalanced equation becomes 2 OS- + 2 H3O+ → 2 OSHzwitterion + 2 H2O 
 
Table A1.22: TMMIzwitterion + OH- → TMMI- + H2O 
Reactant Product Phase ΔG° (kcal/mol) 
2-17 2-15 Gas -51.33 
  Water -21.68 
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Table A1.23: 2 RSH + H2O2 → RSSR + 2 H2O 
Reactant Product Phase ΔG° (kcal/mol) 
2 2-4 2-11 Gas -67.58 
  Water -63.17 
2 2-5 2-12 Gas -69.49 
  Water NDa 
2-4 + 2-5 2-13 Gas -71.73 
  Water -63.38 
2 2-3 2-11 Gas -52.15 
  Water -36.63 
 2-12 Gas -52.39 
  Water ND 
 2-13 Gas -55.46 
  Water -36.58 
2 2-14 2-18 Gas -68.61 
  Water -69.13 
2 2-15b 2-18 Gas -431.69 
  Water -152.41 
2 2-17 2-18 Gas -84.42 
  Water -60.55 
2 2-19 2-22 Gas -68.58 
  Water -75.97 
aND = not determined; bBalanced equation becomes 2 TMMI- + 2 H3O+ + H2O2 → (TMMI-S)2 + 4 H2O. 
 
Table A1.24: RSH + HO• → RS• + H2O 
Reactant Product Phase ΔG° (kcal/mol) 
2-4 2-9 Gas -45.80 
  Water -47.10 
2-5 2-10 Gas -46.53 
  Water -47.58 
2-14 2-16 Gas -44.35 
  Water -45.88 
2-19 2-21 Gas -35.35 
  Water -31.04 
 
- 177 - 
Table A1.25: RS- + HO• + H3O+ → RS• + 2 H2O 
Reactant Product Phase ΔG° (kcal/mol) 
2-7 2-9 Gas -215.40 
  Water -83.12 
2-8 2-10 Gas -216.71 
  Water -83.57 
2-15 2-16 Gas -225.89 
  Water -87.52 
2-20 2-21 Gas -224.04 
  Water -78.97 
 
Table A1.26: 2 RSH + 2 HO• → RSSR + 2 H2O 
Reactant Product Phase ΔG° (kcal/mol) 
2 2-3 2-11 Gas -87.04 
  Water -69.27 
 2-12 Gas -87.28 
  Water NDa 
 2-13 Gas -90.35 
  Water -69.21 
2 2-4 2-11 Gas -102.48 
  Water -95.80 
2 2-5 2-12 Gas -104.39 
  Water ND 
2-5 + 2-4 2-13 Gas -106.62 
  Water -72.85 
2-14 2-18 Gas -103.50 
  Water -101.77 
2-15b 2-18 Gas -466.58 
  Water -185.04 
2-17 2-18 Gas -119.32 
  Water -93.19 
2-19 2-22 Gas -103.47 
  Water -99.58 
aND = not determined; aBalanced equation becomes 2 TMMI- + 2 HO• +2 H3O+ → (TMMI-S)2 + 4 H2O 
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Table A1.27: RS• + 2-23 → RSH + 2-24 
Reactant Product Phase ΔG° (kcal/mol) 
2-9 2-3 Gas -14.11 
  Water -16.39 
 2-4 Gas -6.40 
  Water -3.12 
2-10 2-3 Gas -14.22 
  Water -16.17 
 2-5 Gas -5.67 
  Water -2.64 
2-16 2-14 Gas -7.85 
  Water -4.34 
 2-15a Gas 173.69 
  Water 37.3 
 2-17 Gas -163.86 
  Water -8.63 
2-21 2-20 Gas -19.85 
  Water -19.18 
aBalanced equation modified to TMMI• + 2-23 + H2O → TMMI- + 2-24 + H3O+ 
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A1.5: Electron Density Determination 
Table A1.28: Mullikan charges and spin densities for 2-thiol-4-methyl-imidazole and 4-thiol-N1-methyl-5-
methylimidazole. 
Gas Phase Water Phase 
Compound Atom Charge Spin Density Charge Spin Density 
2-9 N1 -0.127 0.031 -0.118 0.021 
 N1-H 0.329 -0.001 0.423 -0.001 
 C2 0.170 0.003 0.219 0.052 
 N3 0.010 0.111 -0.119 0.069 
 C4 0.068 0.001 0.050 0.072 
 C5 -0.033 0.297 0.032 0.313 
 C5-H 0.175 -0.019 0.269 -0.018 
 C6 -0.572 -0.001 -0.651 -0.007 
 C6-H 0.174 0.005 0.178 0.008 
 C6-H 0.174 0.005 0.178 0.008 
 C6-H(in plane) 0.136 -0.001 0.165 -0.001 
 S -0.503 0.571 -0.627 0.483 
2-10 N1 -0.042 0.137 -0.178 0.097 
 C2 0.126 0.003 0.182 0.053 
 N3 -0.064 0.012 -0.048 -0.001 
 N3-H 0.329 -0.001 0.426 0.000 
 C4 0.019 0.247 0.031 0.268 
 C5 0.169 0.023 0.134 0.090 
 C5-H 0.184 -0.005 0.261 -0.009 
 C6 -0.754 -0.017 -0.775 -0.015 
 C6-H 0.169 0.014 0.188 0.016 
 C6-H 0.169 0.014 0.188 0.016 
 C6-H(in plane) 0.168 0.000 0.183 0.000 
 S -0.472 0.571 -0.592 0.486 
2-16 N1 0.022 0.015 0.053 0.006 
 C2 0.176 0.058 0.157 0.114 
 C2-H 0.187 -0.006 0.284 -0.009 
 N3 -0.022 0.000 -0.177 -0.029 
 C4 0.029 0.064 0.072 0.105 
 C5 0.275 0.182 0.325 0.204 
 C6 -0.767 -0.018 -0.812 -0.018 
 C6-H 0.153 0.012 0.184 0.014 
 C6-H 0.154 0.012 0.185 0.014 
 C6-H(in plane) 0.164 -0.008 0.160 -0.006 
 C7 -0.299 -0.002 -0.320 -0.002 
 C7-H 0.181 0.003 0.203 0.003 
 C7-H 0.182 0.004 0.204 0.003 
 C7-H(in plane) 0.137 -0.001 0.164 -0.001 
 S -0.572 0.684 -0.681 0.602 
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Appendix 2: Phosphorylation by Inositol Pyrophosphates 
Please see Chapter 5 for a full introduction and discussion of this topic. 
A2.1: Hartree-Fock and Density Functional Techniques 
All HF and DFT geometry optimizations and vibrational frequency calculations were 
performed using the 6-31++G** basis set with and without implicit solvation, both as 
implemented by Jaguar version 6.0 (Schrödinger Inc.).  All DFT calculations used the 
B3LYP density functional, also as implemented by Jaguar.  Full procedural details can be 
found in Chapter 5.   
Table A2.1: ΔG°f values calculated using HF and DFT techniques 
ΔG°f (kcal/mol) 
HF DFT 
Structure Gas Phase 
Implicit 
Solvation Gas Phase 
Implicit 
Solvation 
MeOH -72176.1 -72195.6 -72604.7 -72623.6 
MeOPi(0) -427350.9 -427403.6 -428855.7 -428902.2 
MeOPi(-1) -427015.8 -427189.0 -428531.9 -428695.0 
MeOPi(-2) -426556.5 -427076.7 -428080.1 -428585.2 
PPi(0) -758049.1 -758138.2 -760456.9 -760531.5 
PPi(-2) -757333.1 -757760.4 -759755.9 -760194.5 
PPi(-3) -756804.1 -757722.7 -759239.4 -760134.3 
PPi(-4) -756177.8 -757773.6 -758621.3 -760185.7 
Pi(0) -402880.6 -402934.5 -404209.6 -404265.5 
Pi(-1) -402548.6 -402725.6 -403886.5 -404053.4 
Pi(-2) -402085.5 -402615.1 -403434.6 -403949.8 


















































-3266223.3 ND ND ND 
aND = not determined 
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Table A2.2: ΔG°rxn values for the phosphorylation of methanol by pyrophosphate as calculated using HF and 
DFT methods. 
Pi Donora → Product  Pi Donor → Product  
Forming MeOPi(-1)b ΔG°rxnc Forming MeOPi(-2) ΔG°rxn 
HF HF 
Gas Phase Gas Phase 
PPi(-2)e → Pi(-1) -55.2 PPi(-3) → Pi(-1) -124.9 





PPi(-2)e → Pi(-1) 41.4 PPi(-3) → Pi(-1) 116.1 
PPi(-3) → Pi(-2) 114.2  →   
DFT DFT 
Gas Phase Gas Phase 
PPi(-2)e → Pi(-1) -57.7 PPi(-3) → Pi(-1) -122.4 





PPi(-2)e → Pi(-1) 59.7 PPi(-3) → Pi(-1) 119.2 
PPi(-3) → Pi(-2) 113.0     
aPi = phosphate; bMeOPi = methyl phosphate; cin kcal/mol 
 
Table A2.3: Calculated ΔG°rxn values determined for the phosphorylation of methanol by InsPPs using HF and 
DFT techniques. 
   ΔG°rxn a(kcal/mol) 
Pi Donorb → Product HF DFT 


























































-298.1 NDa ND ND 
ain kcal/mol; bPi = phosphate; cMeOPi = methyl phosphate; dND = Not determined 
A2.2:  Molecular Mechanics Methods 
All molecular mechanics calculations were performed using the OPLS2003 force field 
and the GB/SA solvation model as implemented by MacroModel (Schrödinger Inc.).  Full 
details can be found in Chapter 5.  
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Table A2.4: The quality ratings of the parameters of the force fields available in MacroModel. 
Stretch Bend Torsion 
Force Field High Med Low High Med Low High Med Low 
MM2* 50 28 0 114 0 42 106 36 92 
MM3* --a -- -- -- -- -- -- -- - 
MMFF 24 28 0 36 54 1 54 42 18 
MMFFs 24 28 0 36 54 1 52 42 18 
AMBER* 46 6 0 90 0 1 114 0 0 
OPLS -- -- -- -- -- -- -- -- -- 
AMBER94 -- -- -- -- -- -- -- -- -- 
OPLS2001 52 0 0 91 0 0 90 0 0 
OPLS2003 52 0 0 91 0 0 90 0 6b 
aMissing force field constants; bPersonal communications with Schrödinger Inc. indicated that these parameters, 
though rated low, were reasonable values. 
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Table A2.5: Calculated ΔHf values determined using molecular mechanics methods. 
ΔHf (kcal/mol) 
Structure Gas Implicit Solvation 
MeOHa 3.4 -2.2 
MeOPi(0)b -66.3 -82.5 
MeOPi(-1) -79.8 -169.2 
MeOPi(-2) -40.0 -320.9 
PPi(0)c -63.8 -92.1 
PPi(-2) 74.8 -168.4 
PPi(-3) 167.4 -312.4 
PPi(-4) 302.7 -539.9 
Pi(0)d -72.3 -91.4 
Pi(-1) -104.4 -194.3 
Pi(-2) -80.2 -355.9 



















































aMeOH = methanol; bMeOPi = methyl phosphate; cPPi = pyrophosphate; dPi = phosphate. 
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Table A2.6: Calculated ΔHrxn values for the phosphorylation of methanol by pyrophosphate using molecular 
mechanics methods 
ΔHrxn Values (kcal/mol) 
Pi Donora → Product Gas Phase Implicit Solvation 
Forming MeOPi(-1)b   
PPi(-2)c → Pi(-1) -262.4 -193.0 
PPi(-3) → Pi(-2) -330.8 -210.6 
Forming MeOPi(-2)   
PPi(-3) → Pi(-1) -315.2 -200.7 
aPi = phosphate; bMeOPi = methyl phosphate; cPPi = pyrophosphate 
 
Table A2.7: Calculated ΔHrxn values for the phosphorylation of methanol by the InsPPs as determined by 
molecular mechanics methods 
Pi Donora → Product ΔHrxn Values (kcal/mol) 





















































aPi = phosphate; bMeOPi = methyl phosphate; 
A2.3: Results from Semi-Empirical Methods 
All final geometry optimizations and vibrational frequency calculations were 
performed using the PM3 semi-empirical method58, 59 with SM5.2 implicit water solvation as 
implemented by AMPAC 8 and the AMSOL module60 (Semichem Inc. Kansas City).  Full 
details can be found in Chapter 5.   
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Table A2.8: Calculated ΔHf values determined using semi-empirical techniques for the various InsP6 charged 
states studied. 








































































































-2118.8   
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Table A2.9: ΔHf values calculated for the various 5-PP-InsP5 charged states studied. 
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Table A2.10: ΔHf values calculated for the various 5, 6-bis-PP-InsP4 charged states studied. 
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Table A2.11: ΔHrxn values determined for the phosphorylation of methanol by various pyrophosphates. 
Pi Donora → Product  Pi Donor → Product  
Forming MeOPi(-1)b ΔHfc Forming MeOPi(-2) ΔHf 
PPi(-2)d → Pi(-1) -8.9 PPi(-3) → Pi(-1) -13.9 
PPi(-3) → Pi(-2) -12.9     
MeOPPi(-2)e → MeOPi(-1) -7.2 MeOPi(-3) → MeOPi(-1) -15.2 
Cyclohex-PPi(-2)f → Cyclohex-Pi(-1)g -7.3 Cyclohex-PPi(-2) → Cyclohex-Pi(-1) -14.8 
Cyclohex-PPi(-3) → Cyclohex-Pi(-2) -14.3     
InsPPi(-2)h → InsPi(-1)i -2.0 InsPPi(-3) → InsPi(-2) -6.2 
InsPPi(-3) → InsPi(-2) -14.8     
aPi = phosphate; bMeOPi = methyl phosphate; cΔHf in kcal/mol; dPPi = pyrophosphate; eMeOPPi = methyl 
pyrophosphate; fCyclohex-PPi = cyclohexyl pyrophosphate; gCyclohex-Pi = cycohexyl phosphate; hInsPPi = 
myo-inositol-5-pyrophosphate; iInsPi = myo-inositol-5-phosphate (Ins(5)P1). 
 
Table A2.12: ΔHrxn values calculated for the phosphorylation of methanol by 5-PP-InsP5. 
Pia Donor → Product Pi Donor → Product 
Forming MeOPi(-1)b 

























































































































-20.4  ND   
aPi = phosphate, bMeOPi = methyl phosphate, cin kcal/mol, dNot determined as inappropriate charge states 
would  result 
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Table A2.13: ΔHrxn values calculated for the phosphorylation of methanol by 5-PP-InsP5. 
Pia Donor → Product Pi Donor → Product 
Forming MeOPi(-1)b 





















































































































































































































aPi = phosphate, bMeOPi = methyl phosphate, cin kcal/mol 
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Table A2.14: ΔHrxn values calculated for the phosphorylation of methanol by 5, 6-bis-PP-InsP5 (Part A). 
Pia Donor → Product Pi Donor → Product 
Forming MeOPi(-1)b 

























































































































-30.6  ND   
aPi = phosphate, bMeOPi = methyl phosphate, cin kcal/mol, dNot determined as inappropriate charges states 
would result. 
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Table A2.15: ΔHrxn values calculated for the phosphorylation of methanol by 5, 6-bis-PP-InsP5 (Part B). 
Pia Donor → Product Pi Donor → Product 
Forming MeOPi(-1)b 







































































































































































































































































































































aPi = phosphate, bMeOPi = methyl phosphate, cin kcal/mol. 
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Table A2.16: ΔHrxn values calculated for the phosphorylation of methanol by 5, 6-bis-PP-InsP5 (Part C). 
Pia Donor → Product Pi Donor → Product 
Forming MeOPi(-1)b 























































































































































































































































-21.1     
aPi = phosphate, bMeOPi = methyl phosphate, cin kcal/mol 
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TableA2.17: ΔHrxn values calculated for the phosphorylation of methanol by 5, 6-bis-PP-InsP5 (Part D). 
Pia Donor → Product Pi Donor → Product 
Forming MeOPi(-1)b 


















































































































































































































































aPi = phosphate, bMeOPi = methyl phosphate, cin kcal/mol. 
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Table A2.18: ΔHrxn values calculated for the phosphorylation of methanol by ATP, ADP and model 
compounds. 
Pia Donor → Product Pi Donor → Product 
Forming MeOPi(-1)b ΔHrxnc Forming MeOPi(-2) ΔHrxn
ATP(-3)c → ADP(-2)d -2.2 ATP(-4) → ADP(-2) -10.7 
ATP(-4) → ADP(-3) -11.8     
ADP(-2) → AMP(-1)e -5.4 ADP(-3) → AMP(-1) -4.3 
ADP(-3) → AMP(-2) -7.4     
MeOPPPi(-3)f → MeOPPi(-2)g -10.0 MeOPPPi(-4) → MeOPPi(-2) -22.3 
MeOPPPi(-4) → MeOPPi(-3) -14.3     
PPPi(-3)h → PPi(-2)i -7.2 PPPi(-4) → PPi(-2) -18.1 
PPPi(-4) → PPi(-3) -13.0     
aPi = phosphate; bMeOPi = methyl phosphate; cin kcal/mol 
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